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Background: Antiretroviral therapy (ART), notably lopinavir and nevirapine substantially 
reduces Human immune-deficiency virus (HIV) associated morbidity and mortality in HIV-
infected children. Low concentrations of nevirapine and lopinavir have been linked to inferior 
virological outcomes; it is recommended that lopinavir and nevirapine concentrations are 
maintained above 1 mg/L and 3 mg/L, respectively, in order to maintain viral suppression.  
Adherence to both lopinavir and nevirapine ART, respectively has long known to be a crucial 
contributor to HIV treatment success. Lopinavir and nevirapine pharmacokinetics 
demonstrate considerable inter-individual variability, which may affect treatment outcomes. 
At least part of this variability may be explained by host genetic factors. Associations between 
human genetic variants and exposure to lopinavir and nevirapine are incompletely 
understood, and have not been studied in a South African paediatric population. Data in this 
thesis were from a clinical trial conducted at Rahima Moosa Mother and Child Hospital in 
Johannesburg to assess whether NVP can be re-used (Post-randomization Phase) among 323 
children exposed to NVP for PMTCT if they are first suppressed on ritonavir-boosted lopinavir 
based regimen (Pre-randomization Phase). This thesis assessed the relationship between 
serial clinic visits lopinavir (Pre-and-Post-randomization) and nevirapine (Post-
randomization) concentrations and/or percentage adherence(Pre-and-Post-randomization) 
and virological outcomes in children. Moreover, population pharmacokinetics models were 
used to characterise lopinavir and nevirapine parameters. From the final models parameters 
were derived and were used to assess the relationship between lopinavir and nevirapine 
pharmacokinetics and genetic polymorphism relevant to both drugs  
Methods: Cox proportional hazard regression modelling for multiple failure events was used 
to estimate the crude and adjusted hazard effect of lopinavir (Pre-and Post-randomization) 
and nevirapine(Post-randomization) concentrations and/or percent adherence(Pre-and 
Post-randomization) of viral load>400 copies/mL (Pre-randomization) and >50 copies/mL 
(Post-randomization), respectively. The population means and variances of lopinavir and 
nevirapine pharmacokinetic parameters at steady state were estimated using non-linear 
mixed-effects regression. The final models of lopinavir and nevirapine were used to derive 
individual clearances (CL/F), minimum concentrations (Cmin) and area under the 




parameters and genotypes in selected genes relevant to lopinavir or nevirapine were 
explored.  
 
Results: In 237 children pre-randomization with viral loads and lopinavir concentrations, the 
crude and adjusted Cox models revealed significant associations between virologic failure 
(viral load>400 copies/mL) and both lopinavir plasma concentrations (<1/mg/L) and pre-
treatment height-for-age z-scores but not percent adherence. In 99 children post-
randomization, lopinavir concentrations >1 mg/L reduced the risk of viremia (viral load >50 
copies/mL) with about 40%, compared to children with LPV <1 mg/L. No association was 
found with percent adherence in this group. In 95 children on nevirapine post-randomization, 
nevirapine concentrations were not significantly associated with increased hazard of viremia 
(viral load >50 copies/mL). Similarly, there was no significant association with percent 
adherence in this group.  Lopinavir and nevirapine pharmacokinetics were both separately 
best described with a one compartment models with absorption lag time and transit 
compartment absorption models, respectively. There was an age driven effect on lopinavir 
and nevirapine relative bioavailability, respectively. After adjusting for multiple testing, there 
was no significant association between lopinavir CL/F, Cmin and AUC and genetic 
polymorphisms in the ABCB1, CYP3A4, CYP3A5 and SLCO1B1. CYP2B6 516G→T and CYP2B6 
983T→C were associated with NVP CL/F.  CYP2B6 983T→C was associated with NVP Cmin and 
AUC. Additionally, polymorphisms in the ABCB1 and CYP3A5 were independently associated 
with NVP CL/F, Cmin and AUC. 
Conclusions: Lopinavir concentrations <1mg/L were associated with the increased hazard of 
viremia (viral load >400 copies/mL or >50 copies/mL). The results suggest that lopinavir 
plasma concentration monitoring at a routine clinic visit may be a useful tool in identifying 
sub-therapeutic antiretroviral concentrations in children, and this could be used as a guide to 
therapeutic drug monitoring in children.  There was no statistically significant association 
between polymorphisms in the ABCB1, CYP3A4, CYP3A5 and SLCO1B1 and lopinavir 
pharmacokinetics. Polymorphisms in the ABCB1, CYP2B6 CYP3A4 and CYP3A5 predicted 
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There are only few clinical trials of strategies to optimally utilize currently-approved 
antiretroviral drugs for the long-term treatment of human immunodeficiency virus infected 
children in low resource settings.  Treatment is complicated by selection of drug resistance in 
many children whose mothers receive nevirapine (NVP) for prevention of mother to child HIV 
transmission (PMTCT).The NEVEREST2 (clinicaltrials.gov Identifier: NCT00117728) study was 
an open-labelled clinical trial conducted at Rahima Hospital Johannesburg, South Africa 
assessing  the re-use of nevirapine amongst children exposed to NVP for PMTCT if children 
were first suppressed on a Lopinavir/ritonavir (LPV/r)-based regimen. As part of this trial 323 
HIV-infected children (less than 24 months of age) exposed to nevirapine for PMTCT that met 
immunologic and clinical criteria requiring antiretroviral therapy were started on a LPV/r-
based regimen. Data collected included age initiating LPV/r, sex, pre-treatment viral load, pre-
treatment CD4+ T lymphocyte percent, WHO stage, pre-treatment weight-for-age z-scores 
and pre-treatment height-for-age z-scores.   During the pre-randomization phase, post LPV/r 
initiation treatment, children achieving and maintaining viral load <400 copies/ml for at least 
3 months were eligible for randomization.  Once criteria were met, 195 children entered the 
post-randomization phase where they either remained on the LPV/r-based regimen (LPV 
group) or nevirapine (NVP group) was substituted for LPV/r in their regimen.  All children were 
followed to 76 weeks post-randomization. Data collected included age at randomization, viral 
load (dichotomized to viral <50 copies/mL or viral load>51-400 copies/mL), weight-for-age z-
scores and height-for-age z-scores and concomitant tuberculosis therapy. Regular 
ultrasensitive viral loads assays were conducted to determine if virologic control was 
sustained in both the pre-and-post randomization phases.  
Current World Health Organization guidelines recommend LPV/r as the first-line antiretroviral 




transcriptase inhibitors is the preferred antiretroviral regimen for young children (< 2 years 
old) previously exposed to non-nucleoside reverse transcriptase inhibitors.  NVP is an 
inexpensive non-nucleoside reverse transcriptase inhibitor widely used in resource-limited 
settings for treating HIV in children. Despite its high potency, NVP has low genetic barrier for 
developing resistance and sub-therapeutic concentrations increase the risk of developing 
treatment failure and drug resistance. LPV/r has a high barrier for resistance but has poor oral 
palatability which might lead poor treatment adherence. Both LPV/r and NVP 
pharmacokinetics display considerable inter-individual variability, which may affect 
treatment outcomes. At least part of this variability may be explained by host genetic factors. 
Associations between human genetic variants and exposure to LPV and NVP are incompletely 
understood, and have not been studied in a South African paediatric population. 
 Firstly in this thesis, relationships between LPV and NVP plasma concentrations at serial clinic 
visit and virological outcomes were characterised using Cox proportional hazards multiple 
failure event models. Secondly, population pharmacokinetic models for LPV and NVP were 
developed using a non-linear mixed modelling approach. From the final models, individual 
clearances (CL/F), minimum concentrations (Cmin), area under curves (AUC) were derived and 
were used to assess their relationship with genetic polymorphisms in preselected genes 
respective for both drugs.   
During the pre-randomization phase, a total of 237 children aged 4-42 months on LPV/r oral 
solution were followed up for 52 weeks. LPV concentrations and viral load were measured at 
clinic visits 12, 24, 36 and 52 weeks. Cox proportional hazards multiple failure events models 
were used to estimate the crude and adjusted hazard of viral load>400 copies/mL for lopinavir 




copies/mL was increased with LPV concentrations <1mg/L compared to >1 mg/L and lower 
height-for-age z-scores.  
During the post-randomization 99 children were randomized to remain on LPV/r regimen 
whereas 95 children were switched to NVP regimen. Viral load and LPV or NVP concentrations 
were measured at clinic visits 4, 8, 12, 16, 20, 24, 36, 52, 64 and 76 weeks post randomization. 
Cox proportional hazards multiple failure events models were used to estimate the crude and 
adjusted hazard of viral load>50 copies/mL for LPV or NVP concentrations and pre-selected 
variables at randomization for LPV or NVP group. In the LPV group, the hazard of viral load 
>50 copies/mL was increased for LPV concentrations <1 mg/L versus >1 mg/L and for children 
with viral loads 51-400 copies/mL at randomization. In the NVP group, there was no 
association between viral load >50 copies/mL and NVP concentrations or any other variable.  
A population pharmacokinetic model of LPV was developed to describe LPV variability in 
children and relationships between LPV CL/F, Cmin and AUC, and genetic polymorphisms in 
genes relevant to LPV were examined.  A one compartment model with absorption lag time, 
first order absorption and elimination best described lopinavir pharmacokinetics. There was 
an age related influence on LPV bioavailability. Concomitant tuberculosis therapy increased 
LPV CL/F by 60%. After correcting for multiple testing, there was no statistically significant 
associations between LPV CL/F, Cmin and AUC and genetic polymorphisms in ABCB1, CYP3A4, 
CYP3A5 and SLCO1B1 genes.   
For NVP, a population pharmacokinetic model was developed with the aim of describing NVP 
variability and from the final model CL/F, Cmin and AUC were derived and were subsequently 
used to assess for relationships with preselected genes relevant to NVP. A one-compartment 




effect and transit absorption best described NVP pharmacokinetics. There was an age driven 
effect on NVP relative bioavailability. In a univariate analysis, CYP2B6 and genotypes were 
associated with NVP CL/F including CYP2B6 516G→T and CYP2B6 983T→C. CYP2B6 983T→C 
was associated with NVP Cmin and AUC in a univariate analysis and after adjusting for 
CYP2B6 516→T.There was a significant association CYP2B6 15582C→T with NVP CL/F, Cmin 
and AUC after adjusting for CYP2B6 516G→T and CYP2B6 983T→C. Additionally, 
polymorphisms in the ABCB1 and CYP3A5 were independently associated with NVP CL/F, Cmin 
and AUC.   
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Introduction   
Human immunodeficiency virus (HIV) is one of the most serious paediatric disease affecting 
an estimated 3.4 million children under the age of 15 years worldwide1,2. HIV in children is 
predominately acquired through mother to child transmission (MTCT) of the virus from HIV-
infected women during pregnancy, labour and/or breastfeeding3. Combination Antiretroviral 
therapy (ART) significantly reduces mortality and morbidity associated with HIV and thereby 
facilitating normal growth and development, and improved survival and quality of life in 
children 4. Significant progress has been made in early infant diagnosis of HIV and early 
paediatric ART initiation, however ART coverage in adults is still twice that of children5,6. ART 
requires maintenance of adequate drug exposure and, high levels of adherence in order to 
prevent viral resistance and ART failure4. However, both lopinavir (LPV) and nevirapine (NVP) 
concentrations display a high degree of variability even after observed doses. 
 
1.1 Antiretroviral Therapy in Children 
The main goal of ART is to maintain maximum virologic suppression and immune 
reconstitution2. Currently available antiretroviral (ARVs) drugs either block replication within 
the infected cell or prevent entry into the cell2. The efficacy of ART in the management of HIV 
in children and adolescents is measured by maintenance of virologic suppression below 
detectable thresholds or log10 drop in viral load (VL) as well as improvement or reservation 
of CD4+ T lymphocyte count and/or percentage2,3. These defined laboratory measurements 
are assessed at baseline and repeated after durations ranging mostly from 24 or 48 weeks 
post initiation ART2. Despite significant differences in immunologic function and responses to 
HIV between children and adults, thresholds for defining immunodeficiency and severity of 
VL are similar1,2. Thus both pharmacokinetic (PK) and pharmacodynamic (PD) targets for 
children have been largely derived from adult data and paediatric ART studies, which have 








1.1.1 Classes of Antiretroviral Drugs Used for Antiretroviral Therapy 
In order to understand how ARVs work, an understanding of HIV life cycle is required. Figure 
1 depicts the HIV life cycle with ARV targets. HIV is an RNA virus primarily infecting the CD4+ 
lymphocytes by attaching and binding to the CD4 receptor and specific chemokine co-
receptors (CXR5 and/or CCR4) and thus resulting in fusion of the virus and host cell 
membranes and thereby entry of HIV RNA into the target cell7 . The HIV RNA then undergoes 
reverse transcription from RNA to DNA, which is then transported into the nucleus integrating 
with the host DNA where multiple copies of full length and spliced HIV RNA are made and 
exported from the nucleus7. 
 
Figure 1: HIV life cycle with antiviral targets. CCR4, chemokine receptor type 4; CCR4 , 
chemokine receptor type 4; CXR5, chemokine receptor type 5; CD4+, CD4+ T lymphocyte  
receptor; HIV DNA, human immunodeficiency virus deoxyribonucleic acid; HIV RNA, human 
immunodeficiency virus ribonucleic acid; LTR, long terminal repeat; NRTIS, 
nucleoside/nucleotide reverse transcriptase inhibitors; NNRTIS, non-nucleoside reverse 






ART utilizes five classes of ARVs, namely: nucleoside/nucleotide reverse transcriptase 
inhibitors (NRTIs); non-nucleoside reverse transcriptase inhibitors (NNRTIs); protease 
inhibitors (PIs); entry and fusion inhibitors and intergrase inhibitors (Table 1). Combination 
ART regimens, uses three ARVs from at least two major classes so as to achieve maximal HIV 
replication suppression and immune function preservation affected by the HIV disease8. 
Moreover, ART has the added benefit of reducing HIV transmission from one person to 
another including the vertical transmission of the virus from the mother to her foetus, 
newborn and infant8,9.  
Table 1:  Different classes and types of antiretroviral drugs 
Antiretroviral Class  Site of Action  Representative Antiretroviral 
Drug 
Nucleoside Reverse Transcriptase 
Inhibitors (NRTIs) 
Interrupt the HIV replication cycle via 
competitive inhibition of HIV reverse 








Transcriptase Inhibitors (NNRTIs) 
 Bind to the p66 subunit at a 
hydrophobic pocket distant from the 
active site of the enzyme. This 
noncompetitive binding induces a 
conformational change in the enzyme 





Protease Inhibitors(PIs) Function as competitive inhibitors that 
directly bind to HIV protease and 





Tipranavir, Saquinavir (SQV), 
Indinavir(IDV) 
Fusion or Entry Inhibitors Act extracellularly to prevent the fusion 




Integrase Inhibitors Competitively inhibit the strand 
transfer reaction by binding metallic 










1.1.2 Current Recommendations for Antiretroviral Therapy in Children 
The current South African guidelines10 indicate that children younger than 3 years or older 
but weighing less than 10kg should be on first line ART including a combination of two NRTIs 
(ABC and 3TC) plus LPV/r.  Children between 3-10 years of age and weighing 10kg should be 
started on a combination including two NRTIs (as with the children <3 years) plus EFV. In 
adolescents <15 years and <40 kg, the regimen should be two NRTIs and EFV whereas in 
adolescents ≥15 years and ≥40kg their regimen should be TDF plus 3TC and EFV.  
The world health organization (WHO) guidelines6  similarly recommend that for children 
<3years LPV/r plus two NRTIs should be used as first line. For HIV infected infants previously 
exposed to single dose NVP or maternal NNRTIs-containing ART, PI-based regimen should be 
used. It is recommended that infants should start ART soonest regardless on immune status. 
Results in a recent study indicate that a LPV/r-based regimen is preferred to NVP-based 
regimen even in infants not exposed to ART. 
 
1.2 Drugs of Interest in This Thesis 
LPV (MW= 628.81 g/mol, EC50=6.5nM) is a second generation PI used both in drug naïve and 
drug experienced patients. LPV (Figure 2 was developed by Abbot Laboratories USA and is 
marketed co-formulated with ritonavir (LPV/r) under the name Kaletra® or Aluvia® since 
2000. LPV inhibits HIV-1 protease with an EC50 of 17nM11 and is dosed at 400mg with low 
dose RTV of 100mg in adults twice daily and is available as 80ml oral suspension for children.  
 






NVP(MW=266.30 g/mol, EC50=1.5nM) is a benzodiazepine derivative with a molecular weight 
of 266.3 grams/mole chemically synthesized as a non-nucleoside inhibitor of HIV-1 reverse 
transcriptase12 (Figure 3).  NVP is slightly soluble in water at neutral pH and is insoluble in 
nonpolar solvents13. Currently NVP is marketed as Viramune® (,Boehringer Ingelheim, 
Germany) and it is available as a 200mg tablet and a 10 mg/ml oral suspension14.  
 
Figure 3: Structure of Nevirapine 
1.2.1 Mechanism of Action of Lopinavir 
LPV is a highly potent and specific inhibitor of HIV-1 protease15,16. HIV-1 protease is an aspartyl 
protease responsible for post-translational processing of viral gag and gag-pol proteins into 
functional and active moieties17,18. This process occurs concomitantly with or instantaneously 
after the budding of an immature virion on the surface on an infected cell and is essential for 
production of mature infectious viral particles19. HIV PIs, including LPV, prevent cleavage of 
gag and gag-pol proteins leading to maturation arrest, thus resulting in blockage of infectivity 
of nascent virions20,21.  The main antiviral activity of PIs is to prevent infection of susceptible 
cells. LPV showed good antiviral activity against HIV strains in lymphoblastic cell lines and 
clinical HIV-1 isolates in peripheral blood lymphocytes in vitro15. LPV mean EC50 ranged from 
4-11nmol/L in the absence of serum against several isolates of HIV-1 subtype B22. LPV 
combined with other ART agents in vitro demonstrated additive to antagonistic activity 
against nelfinavir (NFV) and additive to synergistic activity with fosamprenavir(FSP), 
atazanavir(ATZ), indinavir(IDR), saquanavir(SQR) and tipranavir(TPR)22. Moreover, 0.5nmol/L 
LPV inhibited 93% of the wild-type virus protease activity and displayed a ≥105-fold specificity 






has low plasma concentrations and 10-fold lower antiviral activity than that of LPV; hence, 
the antiviral activity of fixed-dose combination of LPV and RTV is attributable to LPV22.  
1.2.2 Mechanism of Action of Nevirapine 
NVP is a non-competitive HIV-1 reverse transcriptase inhibitor with high specificity and 
minimal activity against HIV-2 reverse transcriptase inhibitor23,24. NVP inhibits HIV-1 reverse 
transcriptase by directly binding tyrosine residues at positions 181 and 188 on the p66 subunit 
close the catalytic side of the enzyme25. This binding results in reduced catalytic activity of the 
enzyme. NRTIs such as zidovudine (ZDV), lamivudine (3TC) etc. inhibit HIV replication by 
undergoing intracellular phosphorylation whereas NVP inhibits HIV-1 reverse transcriptase in 
its active state without requiring intracellular metabolism12. NVP penetrates cell free virions 
and thus inactivates virion-associated reverse transcriptase in situ26. The inactivation of cell 
free virions by NVP in maternal genital tract and breast milk is beneficial for preventing 
mother-to-child transmission of HIV12.  NVP has been shown to inhibit many HIV-1 strains in 
vitro27. Human T-lymphocyte cultures display 10 µg/L 50% inhibitory concentration (IC50)27. 
NVP has also been shown to be active against strains that are resistant to NRTIs28. NVP has 
been shown to have synergistic antiviral activity when combined with PIs and/or NRTIs28. NVP 
resistant HIV-1 isolates have been shown to have 100-250 fold decreased susceptibility to 
NVP in vitro29. HIV-1 reverse transcriptase single amino acid substitutions lead to resistance 
to NVP and drug resistant strains might exist at low frequencies prior NVP exposure30,31. Thus, 
resistant strains develop, when NVP is as monotherapy, within weeks32.  Combination of NVP 
with at least 2 other ARVs lead to sustained viral suppression and prevention of the 
development of resistance can achieved in many individuals14,33. 
 
1.3 Pharmacodynamics of Antiretroviral Drugs 
Pharmacodynamics(PD) is broadly defined as “what the drug does to the body” 34 and seeks 
to quantify mechanisms of drug action and/or the relationship between drug concentration 
and effect. The science of PD was defined early in the 1960s with the work of Levy and others 
illustrating correlation between reversible drug effects and drug concentrations35. It thus 






Though the goal of ART is good health, however in clinical practice it is difficult to measure 
this endpoint due to the overall efficacy of ARVs and a distant time-to-event horizon1,36. 
Nonetheless, the primary surrogate markers for antiretroviral studies typically include 
virological response (e.g. patients with viral load (VL) of <50 copies/mL), and/or 
immunological response (e.g. change in CD4+ lymphocyte count or increase in CD4+ 
lymphocyte percentage), which are all measured at baseline and after a defined period of 
treatment1. Immunological surrogates are usually tied to prediction of opportunistic 
infections and survival37, whereas virological markers are used to predict treatment success 
or failure8. Typically, both these markers are measured only after 12, 24 or 48 weeks post 
initiation therapy1.Consequently, numerous strategies have been proposed to predict ART 
outcomes even before the first dose, including therapeutic target concentrations38 and 
inhibitory quotients39 (e.g. phenotypic inhibitory quotient [PID] or genotypic inhibitory 
quotient [GIQ]).  Due to ARV’s viral molecular targets, a major assumption for paediatric 
therapy is that the PK-PD behaviour should be the same in children as in adults. Indeed, all 
ARVs PK studies in children have been designed to find the dose that is associated with 
exposures (e.g.  Maximum plasma drug concentrations [Cmax], area under the concentration 
time curve [AUC], and trough plasma concentrations [Ctrough/min]) similar to those found in 
adults1. Thus there are fewer children infected with HIV needing ART compared to adults, and 
therefore the majority of HIV therapeutic studies in children take advantage of this 
assumption and are small phase II or phase IIb trials instead of large phase III trials1.   
 
1.3.1 Pharmacodynamics of Lopinavir in Children  
The target LPV Cmin of ≥1.0 mg/L required to achieve virological suppression for wild type HIV 
has been established in adults and confirmed in several paediatric studies40–42. Studies in 
children, have shown that low LPV Cmin (<1.0 mg/L) is associated with increased risk of 
virologic failure43. Similar to adult data, minimum target plasma Cmin of LPV and other PIs are 
recommended for treatment-naïve children, and higher target trough concentrations are 
required in PI-experienced paediatric patients44. A  LPV population PK model of treatment 
experienced children aged 4-18 years found a median Cmin of 5.9 mg/L lower than that found 






children44. Nonetheless, simulations based on the model, showed that 90% of the children 
given the standard dose of LPV/r, achieved therapeutic LPV concentrations against the wild 
type virus44. Remarkably, a study of reduced LPV/r dose (70% of the recommended standard 
dose) illustrated adequate LPV exposure and virological suppression (VL<50 copies/mL) in 
83% of the children, compared to 50% in children receiving standard doses45. However, these 
24 children were PI naïve, strengthening the conclusions from the LPV population PK model 
that children with viral populations naïve to PIs are likely to achieve more than adequate 
lopinavir concentrations to maximize chances of virological suppression with standard or 
modestly reduced dosing; however, up to 10% may not do so44,45. Furthermore, low-dose 
LPV/r is inappropriate for PI-experienced children1,2. In addition to PK targets, several 
methods that incorporate both patient-specific drug exposure and HIV susceptibility have 
been established to improve predictions and virological suppression outcomes for LPV and 
other PIs. These include genotypic inhibitory quotients (GIQ) which incorporates both patient-
specific PK parameters (such as Cmin) and ARV susceptibility of the dominant strain expressed 
as a ratio of Cmin to IC50 (concentration of drug required for 50% inhibition of viral replication 
in vitro)1. The virtual GIQ uses the fold-change in virtual IC50 (derived from the genotype), 
multiplied by a reference wild-type protein-adjusted IC50 and the normalized GIQ is the 
patient-specific GIQ is divided by a reference GIQ calculated as the ratio of typical Cmin for a 
given dose and wild-type viral IC50, normalizing the GIQ target across PIs to a ratio of >1. 
Another tool for predicting virological response to specific ARV drugs (including PIs) has been 
introduced and is defined as the instantaneous inhibitory potential (IPP)46. IPP measures ARV 
activity by using the slope of the dose-response curve, directly quantifying the log inhibition 
of single-round infectivity at clinical concentrations. To date limited quantitative analysis has 
not shown advantage of the IPP to the GIQ. Nonetheless, assessment of the dose-response 
curve slope for various ARV drugs must be further investigated47,48.  Various GIQ targets have 
been proposed in adults for LPV and other PIs, and have been shown to be practical when 
evaluating exposure-virological suppression in children1. However, the clinical usefulness of 
this approach is restricted by limited data on their clinical application, lack of standardized 
methods for calculations, high intra-and-interpatient variability in the PK of ARV drugs, and 






combining both virological and pharmacological data for the therapeutic dose adjustment2.  
Except for poor palatability and gastrointestinal intolerance, LPV is well tolerated by children2. 
Nonetheless, concerns for adverse effects in paediatric HIV care are focused on PI-associated 
changes in lipids and the unknown long-term effects of elevated cholesterol and triglycerides 
during childhood on the development cardiovascular disease in adulthood2. Recently, a study 
of 156 children on mean duration of treatment 4.2±0.7 years, where 85 were randomized to 
the LPV-based regimen  and 71 to NVP-based regimen , showed that children on LPV-based 
regimen, had significantly lower mean high density lipoprotein and higher mean total 
cholesterol, low density lipoprotein, and triglycerides compared to those on NVP-based 
regimen49.    
 
1.3.2 Pharmacodynamics of Nevirapine in Children 
The relationship between plasma NVP concentrations and efficacy and toxicity has been well 
established in children and adults50–52.  Maintaining NVP Cmin above 3.0 mg/L has been 
associated with long term virological suppression53. Recently, as study in 322 African children 
showed that children with a Cmin <3.0 mg/L had increased hazard of virological non-
suppression54.  Moreover, some children and adult data showed that a higher NVP Cmin of 
>4.3 mg/L reduced emergence of resistance mutations compared with lower concentrations 
(3-4.3 mg/L)51,55,56. Interestingly, achieving efficacious concentrations for NVP and other 
NNRTIs, is mostly important during the first weeks and months of therapy and becomes less 
relevant in the later stages of therapy, because high level single mutation resistance is not 
repressed by increased dose and exposure.  A recent study of 31 children, showed that ART 
initiation in young children using the dose escalation strategy for NVP resulted in significant 
sub-therapeutic (<4.0 mg/L) NVP concentrations during the lead-in period compared to the 
steady state period57. Sub-therapeutic nevirapine concentration were more pronounced in 
children <8 years of age57; supporting the evidence that younger children metabolized NVP 
more rapidly than older children58–60. However, there was no clinically relevant effect of NVP 
concentration on virological outcome(viral load≥200 copies/mL)57.  Amazingly, in a study of 
323 children initiated on LPV/r whereby half (96) were later switched to NVP, there was no 






however girls tended to more robust CD4 count compared to boys61. The most common side 
effect associated with NVP concentrations is skin rash, whereas NVP-associated 
hepatotoxicity is not associated with NVP plasma concentrations62–66.   
 
1.4 Pharmacokinetics of Lopinavir in Children 
Several studies have been completed that assessed the PK of LPV/r in a capsule formulation67–
69. The corrected protein binding steady-state concentrations of LPV required to inhibit HIV 
replication by 50% (EC50) were shown to be 0.07 µg/mL in two studies with different dosing 
regimens70,71. LPV/r table formulation displays similar bioequivalence to both liquid and 
capsule formations in both the 400/100mg twice-daily and 800/100mg once daily regimens72.  
Both the soft-gelatin capsule and the tablet formulations comparatively displayed serum PK 
Cmin values of 5.17 µg/mL and 5.64 µg/mL respectively as well as respective Cmax values of 
6.97 µg/mL and 10.26 µg/mL. However, this differences were not statistically significant72.  
LPV/r capsule or liquid formulation has increased bioavailability(F) following moderate to high 
fat diet and thus its recommended to take this type of meals along with both formulations 
during prescription22. Evaluation of PK differences between the two formulations showed 
that the tablet formulation led to more consistent LPV and RTV exposure compared to the 
capsule or liquid formulations and that the ingestion of meal had no significant impact on 
LPV/r bioavailability73. Hence, LPV/r tablet formulation can be taken with or without food. 
Both LPV and RTV are highly protein bound at steady-state, 98-99% bound to plasma proteins 
albumin and α1 acid glycoprotein74. The mean plasma Cmax of LPV is 9.8±3.7 µg/mL, occurring 
approximately 4 hours post dose69,75. The mean trough concentration is 5.2 µg/mL with the 
mean elimination half-life(T1/2) of 2-3 hours after single dose administration and 4-6 hours 
with an apparent oral clearance (CL/F) of 6-7L/h following multiple doses67,69.   Examining the 
penetration of drugs such as LPV is important due to the fact that HIV replication occurs at 
intracellular level74.  LPV is insoluble in water and accumulates mostly in peripheral blood 
mononuclear cells and penetrates the cerebrospinal fluid and significantly reduces viral load 






blood mononuclear cells, EC50 was reached with a Cmax of 8.44 µg/mL and 13.40 µg/mL, 
respectively70.  
LPV is primarily metabolised by cytochrome (CYP) 3A4 and 3A5 whereas RTV is a potent 
inhibitor of CYP3A4 and thus co-administration of LPV with RTV leads to increased plasma 
concentrations of LPV. When administered together, RTV is given at a lower dose than when 
administered as monotherapy and acts as boosting agent with LPV producing the 
antiretroviral activity76,77. LPV together with its metabolites is primarily eliminated faecally. 
After 400/100mg LPV/r dose, 82.6% of the dose is found in faeces and 10.4% excreted in 
urine78.  
In paediatric patients, administration of LPV/r liquid suspension result in similar PK profiles to 
that shown in adults45,79. LPV undergoes extensive hepatic metabolism and thus patients with 
hepatic impairment might have increased concentrations, therefore great care should be 
taken when administering LPV/r to such patients80. Interestingly, in renally impaired patients, 
it is estimated that LPV/r concentrations will not be affected due minimal renal excretion81.  
 
1.5 Pharmacokinetics of Nevirapine in Children 
PK is characterised by rapid absorption and rapid distribution throughout the body and 
prolonged elimination32. Following oral administration of a tablet or liquid syrup, NVP 
bioavailability exceeds 90%82.NVP reaches plasma Cmax after 4 hours post dose83. 
Concomitant administration with food or antacids delays the rate but no the extent of NVP 
absorption, therefore no dose adjustment of NVP is required83.  NVP is highly lipophilic at 
physiological pH and the mean apparent volume of distribution of NVP exceeds total body 
water and is significantly higher in females (1.54 L/kg) compared to males (1.38 L/kg)12. 
Plasma protein binding of NVP is approximately 60%. Interestingly, a study in  6 children 
showed NVP concentrations in children CSF samples being 45% that of plasma concentrations, 
equivalent to free fraction in plasma33.  Moreover, another study in adults, showed that NVP 
concentrations in CSF ranged from 3.36-27.81 mg/mL well in excess of the IC50 for wild type 
HIV-1. In this study, the average ratio between plasma and CSF NVP concentration was 






NVP is mainly eliminated is via hepatic metabolism followed by renal excretion. Urine 
excretion of NVP is about 80% whereas faecal excretion is 10% after an administered dose85. 
NVP is extensively bio transformed by hydroxylation and glucuronidation into hydroxylated 
metabolites. In vitro studies have shown that NVP is primarily metabolised by CYP3A4/5 and 
CYP2B6 and to a lesser extent CYP2D6 and CYP2C913,85. NVP elimination half-life (T1/2) after 
single dosing is 45 hours (range 22 to 84 hours), and 25-30 hours during steady state dosing32. 
Long term therapy with NVP leads to induction of its elimination pathway. NVP auto-induction 
results in 1.5-2 fold increased NVP clearance after the first 2 weeks of treatment32,86. 
Therefore, NVP is initiated at 200mg daily dose, and increased to 200mg twice daily after two 
weeks on treatment. 
NVP plasma concentrations and PK are associated with significant sex differences. Regazzi et 
al, showed that women had 44% higher Cmax compared to males87. Moreover, NVP PK is not 
significantly affected by age (range 18-68 years)88. However, NVP PK is significantly associated 
with race, with black people having 39% higher concentrations that Caucasians89.   
In newborn infants, NVP washout elimination is extensive and highly variable with median 
T1/2 of 64.9 hours in two studies90,91. During the first days of life, elimination increases. In the 
same studies, after administration of 2mg/kg oral dosing at 48-72 hours following NVP birth, 
the median NVP T1/2 was 43.6 hours (range 23.6 to 81.6 hours) and the median CL/F was 36.1 
ml/h/kg (range 22-40 ml/h/kg)90,91.In new-borns, absorption was variable and extensive with 
Tmax  of 8.2 hours (range 2-26.1 hours)90. In older infants, NVP clearance is rapid, averaging 
around 120 ml/h/kg, during the first 2 years of life92. Thereafter, NVP clearance decreases 
gradually to an average of 60ml/h/kg by 8-10 years of age92.  
 
1.6 Therapeutic Drug Monitoring in Children  
Therapeutic drug monitoring (TDM) refers to the measurement of drug concentrations in a 
biologic matrix (e.g. serum, plasma or urine etc.) to assess correlation between patient’s 
clinical condition and whether there is need for adjustment for dose or dose intervals93,94. The 
process of TDM is based on the assumption that there is a precise relationship between dose 






criteria in children is almost the same as that of adults, though some additional factors must 
be considered: (i) In neonates, infants and children major rapid age-related physiologic and 
biochemical changes occur, more especially in the first year of life and thus resulting in 
clinically dissimilar PK and PD parameters from that of an adult95; (ii) Gastrointestinal 
absorption of drug in children greatly differs from that of adults, before the age of 5 years, 
the stomach pH in children is higher than that of adults96; (iii) gastric emptying time changes 
with age. In neonates, gastric emptying time is slower than that of adults, whilst in infants 
and older children, gastric emptying is faster than that of adults97,98. Furthermore, neonates 
have reduced intestinal motility and biliary function97;(IV)  Elimination of drugs in children is 
influenced by age related changes in hepatic enzyme activity and kidney maturation. In the 
liver, drug metabolism occurs through 2 hepatic enzyme phases: phase 1 reaction (oxidation, 
reduction and hydrolysis) and phase 2 reaction (reduction)99,100. In neonates, the CYP450 
mixed-function oxidation system activity is 20-70% of adult values101. This increases to adult 
levels by 6-12 months, and exceeds that of adults by 1-4 years and declines to that of adults 
at the end of puberty101.  With regards to the phase 2 enzyme-mediated system, 
glucuronidation is diminished at birth and reaches adult levels after 3 years.100 Drug 
elimination is influenced by age102. The glomerular filtration rate and tubular secretion are 
both reduced at birth and reach adult levels at during the first year of life95,103. Renal function 
reaches peak at 3-5 years and decline to average levels over time.  Thus drug administration 
to children must account for age-related changes in drug absorption, distribution, metabolism 
and clearance in order to optimize efficacy and avoid toxicity. Moreover, drug administration 
compliance by parents at the appropriate time interval my further complicate non-adherence 
in the paediatric population.  
For ART, TDM has another layer of complexity: incomplete suppression during therapy may 
lead to HIV mutations resulting in changes in drug susceptibility becoming a moving target104. 
This is unique compared to other diseases where TDM is applied whereby target 
concentration ranges remain the same throughout therapy104. HIV treatment uses 
concomitant ARVs to achieve durable viral suppression; however, TDM usually monitors only 






the effectiveness of TDM in achieving virologic end points consistent with treatment efficacy 
and/or decreasing incidences of toxicity in treatment-naïve patients109,110.   
In the literature, TDM of ART in children and adolescents is limited especially PK data in 
paediatrics compared to adults, multiple drug-drug and drug food interactions, a narrow 
margin between therapeutic and toxic 
1.5.1 Therapeutic Drug Monitoring of Lopinavir 
The HIV-NAT017 prospective study was conducted whereby 20 children were enrolled on 
230/57.5 mg/m2 LPV/r regimen BID plus SQV 50mg/kg. In 19 children, the PK showed a 
median Cmin of 5.9mg/L. Furthermore, 2 children with LPV <1.0 mg/L had VL>400 copies/mL 
compared with one child in a group of 17 with LPV Cmin>1.0 mg/L. Though the study found a 
similar cut-off of 1.0 mg/L previously proposed from in vitro data, nonetheless, SQV could 
have lowered the cut-off value due to synergism40.   
Another prospective study of 126 PI-experienced patients was done to explore the utility of 
GIQ by predicting virological response to LPV therapy40,111. Included in the GIQ model were 
HIV protease resistance mutations at positions 10, 20, 24, 30, 32, 33, 36, 46, 47, 48, 50, 53, 
54, 63, 71, 73, 77, 82, 84, 88, and 90. Virological response at 3 months was defined as VL<50 
copies/mL. The median (IQR) number of resistance mutations was shown to be 4(2-7), the 
median LPV Ctrough was 6.2(2.1-8.6) mg/L and the GIQ positively correlated with virological 
response. Furthermore, receiver operating characteristic (ROC) curves were used to find the 
LPV cut-off values. It was shown that patients with GIQ cut-off of >0.70 mg/L/mutation 
significantly achieved virological response than those with GIQ<0.70 mg/L/mutation.111   
Recently, a retrospective study on GIQ whereby 95 patients were treated with LPV/r 
evaluated the cut-offs based on different sets of mutations40,112. Included were PI-associated 
mutations (PAM), lopinavir associated mutations (LAM) and lopinavir mutation score (LMS), 
consisting of mutations at positions: 10, 20, 24, 46, 53, 54, 63, 71, 82, 84, and 90. In this study 
76% of patients showed virological response with median (IQR) LPV Ctrough of 5.2(3.7-6.3) 
mg/L. The median number of respective mutations for PAM, LAM and LMS were 4(2-7), 3(1-
6) and 3(1-6). ROC curves were used to find optimal cut-offs and the cumulative GIQ including 






response. The cut-off values found for PAM, LAM and LMS, respectively, were 0.9 
mg/L/mutation, 1.1 mg/L/mutation and 1.3 mg/L/mutation. Sensitivity was shown to be 0.74 
for all cut-offs whereas specificity was 0.78 for PAM cut-off and 0.83 for both LAM and LMS 
cut-offs112. 
1.5.2 Therapeutic Drug Monitoring of Nevirapine 
A prospective study was done where NVP plasma concentrations were measured in an 
unselected cohort of 189 patients40,53. In this study, patients were divided into two groups 
based on NVP concentrations below and equal to or above 3mg/L. Virologic failure was 
defined as VL >500 copies/mL for two consecutive occasions , >10 000 copies/mL for a single 
occasion or failure to achieve VL below 500 copies/mL for six months after commencing NVP 
treatment. The results revealed that 12% (22) and 7% (13) respectively, of patients had NVP 
concentrations <3mg/L. A multivariate analysis showed that the risk of virological failure was 
increased in patients NVP concentrations <3mg/L53.  
Another prospective study evaluated the efficacy of NVP in relation to plasma levels in 74 
patients50. All patients were PI-experienced with a baseline VL of <20 copies/mL and 
virological failure was defined as having VL>1000 copies/mL or 2 consecutive intermittent 
viremia episodes between 20 and 1000 copies/mL. The study showed that 14 patients had 
viremia at the same point during the study, versus 45 patients that remained suppressed for 
the duration of the study. The mean plasma NVP concentrations were 4.6 and 2.6mg/L, 
respectively (p=0.003), in responders compared to non-responders. A NVP cut-off of 3mg/L 
was shown to be efficacious, however the positive predictive value of the cut-off was 55% 
whereas the negative predictive value was 88%. 
In the PK sub-study of the 2NN trial, the risk of viremia was increased in patients with NVP 
Cmin <3.1 mg/L in 511 patients included in the study51. However, the results were not 
significant and the sensitivity parameter was 28%. Nonetheless, the negative predictive value 
was 78%, suggesting reasonable success with the determined NVP Cmin. Previous guidelines 
were based on the median Cmin value found in the INCAS trail113, however findings the studies 






1.6 Adherence Monitoring 
Adherence to ART directly correlates with clinical and virological outcomes.114,115 With more 
potent regimens, the adherence threshold required to achieve robust viral suppression has 
declined. Studies have shown that patients can achieve undetectable viral loads at adherence 
proportions as low as 70%116–119. Therefore, full and sustained benefit of ART can only be 
derived from high levels of adherence. Furthermore, it has been shown that adherence in 
Sub-Saharan African is comparable or even superior to that in Western countries, however 
retention in programmes is a serious challenge120,121. Both in high and low income countries, 
medication side effects and complexity of drug regimens, psychiatric of lack of social support 
are barriers of adherence122–125. Moreover, in Sub-Saharan Africa conditions of extreme 
poverty and livelihood insecurities add a further dimension to adherence costs125. Another 
factor that compounds to this problem include non-disclosure due to fear of 
stigmatization122,124. Medication related barriers to adherence include pill burden, dosing 
frequency, dietary restrictions and side effects. Currently, most first line regimens are one or 
two pills daily, however second regimens are more complex adding to complexity in 
adherence. Side effects related to ART use also greatly affects adherence with studies having 
shown that when patients experience side effects, they tend to stop taking treatment or 
irregularly take their medication126. 
In paediatric populations, maintaining adherence is even more challenging, especially over 
long periods. Factors relating to children, caregivers, medications and the interaction thereof 
all good adherence very challenging127. Currently, paediatric ART formulations are limited. 
Some have poor palatability, require high liquid volume or pill burden, frequent dosing or, 
dietary restrictions. Side effects also impact on the regular intake of medications128. In 
children, successful adherence to treatment requires commitment and involvement of the 
caregiver. 
Currently, there is no gold standard for the measurement of adherence. However, approaches 
such as patient self-reports, pill counts, and pharmacy refill records are used to monitor and 
evaluate medication adherence. Viral load and CD4 cell count are biological markers used to 






resistance, prior treatment failure or poor absorption of drugs. In the literature, discordance 
has been shown between viral suppression and adherence in those contexts129. Currently, no 
approach produces completely valid and reliable measure adherence and therefore, a new 
feasible and reliable method would be highly beneficial.  
 
1.7 Pharmacogenetics        
Pharmacogenetics is the science of discerning genetic variability between subjects to study 
host drug response and hence predict optimal treatment regimens, thus reducing expenses 
and often harmful trial and error methods currently used.130  Single nucleotide 
polymorphisms (SNPs) are defined as sequence variations occurring in human DNA as a single 
nucleotide changes at allele frequencies greater 1%131 . Nucleotide changes occurring at rate 
less this are referred to as mutations. Advances in genetic analyses technologies are 
generating great prospects in unveiling the role of sequence variations in the human genome 
that influence drug disposition, metabolism, efficacy and toxicity of ARVs. Interestingly, 
performing genome-wide analyses has disclosed new possibilities in this area of research132.  
However, current research mostly focuses on employing the hypotheses driven candidate 
gene approach to study phenotype-genotype relationships. In most studies, the hypotheses 
are to determine a plausible link between genetic variations that have possible impact on 
drug metabolism and/or drug toxicity and phenotype under study. Moreover, using the 
hypothesis-driven candidate gene approach in host genome variability influencing ARV 
efficacy and tolerability, relationships between genetic factors involved in immunological and 







Figure 2: Schematic representation of proteins involved antiretroviral drugs metabolism and 
disposition in various sites in the body. ABC, ATP-binding cassette transporters; CYP450s, 
cytochrome P450 enzymes; OAT, organic anion transporters; OATP, organic anion transporter 
polypeptide; OCT, organic cation transporters; UGTs, uridine diphosphate 







A great number of associations between host genetic variations and responses to ARVs have 
been reported. These include PK-PD, hypersensitivity reaction syndromes, hepatotoxicity, 
central nervous system side effects, hyperbilirubinemia, peripheral neuropathy, 
lipodystrophy, hyperlipidaemia, pancreatitis and renal toxicity130. Nonetheless, it remains 
important to note that numerous barriers exist in translating this body of knowledge into the 
ultimate goal represented by individualization of ART. Moreover, the risk of false discoveries 
due to multiple testing is a well-known phenomenon in statistical genetics and thus caution 
is needed in consideration of early reports on genotype-phenotype association studies. To 
date, most studies in the literature have significant limitations represented by small sample 
size, inadequate statistical power and selection bias. Additionally, very often the carriage of 
a variant is linked to ethnicity and as a consequence the risk of ethnic bias exists in most 
genotype-phenotype association studies. Thus, in order to successfully introduce 
pharmacogenetic testing into routine clinical practice several prerequisites must be met. 
Firstly, the test must be clinically relevant with high specificity and sensitivity. Secondly, there 
should be evidence on genotype-phenotype association ideally based on randomized, double-
blind, prospective studies involving patients of varying ethnicities. Finally, the genotypic test 
should be rapid, simple to interpret and cost effective. 
1.7.1 Pharmacogenetics of Protease Inhibitors 
PIs show marked inter-individual variability in bioavailability and plasma PK explainable by 
drug metabolism.  PIs are metabolised by CYP3A4 but also inhibit CYP3A133, hence the impact 
of polymorphisms in these genes on PI disposition is difficult to predict (Table 2). PIs are also 
substrates of drug transporter Pg-p134, expressed extensively in human cells of different 
tissues like liver, kidney, central nervous system, small intestine and lymphoid tissue (Table 
2). The impact of Pg-p variants on PI disposition has been widely studied. 
Additionally, polymorphisms in the apolipoproteins (APO) have been associated with 
hyperlipidaemia and cardiovascular events in the general population. Polymorphisms in APO 








Table 2: Genetic polymorphisms and the clinical relevance of proteins involved in PI 
metabolism and disposition   
Drug Gene(Protein) Variant PK Effect 
LPV CYP3A4 *22 TT:53% Lower CL/F137 
 SLCO1B1(OATP1B1) 521TC CT/TT: High plasma levels138 
ATV CYP3A5 *1 GG/GT: Lower CL/F139  
 UGT1A1 *28 High risk of hyperbilirubinemia140,141 
 ABCB1(Pg-p) 3435TC TT: Risk of sub-therapeutic levels140,142 
  2677GT Risk of sub-therapeutic levels140,142 
 SLCO1B1(OATP1B1) 521TC CT/TT: High plasma levels143 
 NR1I2(PXR) 63396CT TT: Risk of sub-therapeutic levels143–145 
IDV CYP2C19 *2 AA: 44% faster oral CL/F146 
 MRP2 -24CT CT/TT: Faster CL/F147 
 
1.7.1.1 Pharmacogenetics of Lopinavir 
LPV is mainly metabolised by CYP3A enzymes and is a substrate of efflux transporters Pg-p, 
ABCC1 and ABBC2 genes, contributing to its low and variable oral bioavailability148–150.  
A common SNP in the SLCO1B1 (521TC) gene leads to increased plasma LPV levels, however 
the clinical relevance remains controversial in the literature and thus further studies are 
required to confirm this association and to assess impact on LPV PK151–156. Similarly, a link 
between the 4544G>A polymorphism in the ABCC2 gene and accumulation of LPV in the 
peripheral mononuclear cells has been shown in a small cohort study of HIV-infected 
patients157. Nonetheless, more studies are required to confirm this findings and to explore 
the real PD impact. 
1.7.2 Pharmacogenetics of Non-Nucleoside Reverse Transcriptase Inhibitors 
NNRTIs are predominantly metabolized in the liver by CYP enzymes and are absorbed and 
distributed mainly by P-glycoprotein (P-gp)149. Both NVP and EFV are extensively metabolised 






associated haplotypes with genetic variability being assessed in different ethnicities leading 
to a number of functional variants being discovered.  Interestingly, more than 28 variants 
have been described and more than 100 SNPs have been determined for the CYP2B6 gene149. 
Amid various alleles, the CYP2B6*6 haplotype (516 GT and 785 AG) reduces enzymatic 
catalytic activity and significantly decreases protein expression. The CYP2B6*6 allele has been 
shown to vary between different ethnicities with 15 to 40% in Asians, 25% in Caucasians and 
more than 50% in African Americans and black Africans159–162. Moreover, though the 
CYP2B6*16 (785 AG, 983 TC) or CYP2B6*18(983 TC) polymorphisms are common in 
black populations and leads to decreased protein expression, they do not affect its intrinsic 
catalytic activity163.  
NVP is predominantly metabolized by CYP3A4 and 2B6 with a minor contribution from 
CYP3A5 to its hydroxynevirapine metabolites164. EFV is primarily CYP2B6 with a minor 
contribution from CYP3A4165. Thus, there is considerable inter-individual variability in the 
metabolism and disposition of NNRTIs. Hence, the CYP2B6, CYP3A4 and CYP3A5 genes have 
been extensively studied with regards to PK-PD, treatment response and toxicity of both NVP 
EFV (Table 3).  P-gp encoded by the MDR1(ABCB1) gene affects the oral absorption and tissue 















Table 3: Genetic polymorphisms and the PK effect of proteins involved in NNRTI metabolism 
and disposition   
 
Drug Gene(Protein) Variant PK  Effect 
NVP CYP3A4 *1B or -392AG *1/*1B: Higher Cmin146 
Not predictive of hepatoxicity167  
 CYP3A5 *1 or 6986A Higher AUC168 
No association with  Cmin167 
Not predictive of hepatoxicity167 
 CYP2B6 516GT Increased plasma levels164,169 
  983TC Increased plasma levels170,171 
  1459CT Decreased plasma levels146 
 ABCB1(Pg-p) 3435TCT TT: Higher Cmin172 
Decreased risk of hepatoxicity173,174  
 MRP7(ABCC10) c.28473TC CC: Lower plasma levels175 
EFV CYP3A4 *1B or -392AG GG: higher EFV AUC146 
 CYP3A5 *1 or A6986 No association with plasma levels160 
 CYP2B6 516CT TT: High plasma levels136 
Increased risk of CNS adverse events176,177 
  785AG High plasma levels178–180 
Increased risk of CNS adverse events160 
  983TC High plasma levels163,181,182 
Increased risk of CNS adverse events176 
 ABCB1(Pg-p) 3435TCT Dispute in the literature regarding 
influence on plasma EFV levels183,184  
Decreased likelihood of virological failure 
and decrease emergence of resistant 
virus185 






1.7.2.1 Pharmacogenetics of Nevirapine 
NVP is widely prescribed especially in resource limited settings for HIV-1 infection treatment 
for pregnant women and their children. Nonetheless, it has limited use due to drug related-
adverse effects appearing frequently in the first 6 weeks of treatment and has low barrier for 
developing drug resistance mutations186. The main adverse effects accompanying using NVP 
are rash, affecting 15% of patients initiating NVP, increased transaminases above 5 times the 
normal range in 20% of patients, fever and immune mediated hypersensitivity that may 
manifest as hepatotoxicity187,188. The mechanism involved in NVP associated adverse events 
has not been described. Nevertheless, the cutaneous effects might be mediated MHC class I 
influenced by CYP2B6 metabolism, whereas hepatotoxicity is most likely mediated by MHC 
class II and unaffected by CYP2B6 polymorphism.189 Interestingly, several human leukocyte 
class I and class II antigens have been associated with rash and/or hepatitis reactions 
development. The concurrent presence of HLA-DRB1*01:01 variant and CD4+ T lymphocyte 
count greater than 25% prominently increases the risk of developing NVP associated HSR and 
hepatotoxicity190,191. Similarly, other HLA class alleles such as HLA*B14:02, HLA-Cw08 and 
HLA-B*35:05 have been associated with NVP associated drug reactions192–194. Until recently, 
the majority of studies were largely focused on white populations, however Phillips et al 
published the first study carried out in black population, where the need for HLA studies being 
HLA variants are predominant195.  Interestingly, a GWAS study was conducted in Thai 
population whereby genetic variations in the CCHCR1 gene were strongly associated with 
NVP-induced rash196. 
NVP is metabolized into its major metabolites 2- and 3-hydroxynevirapine, respectively, 
mainly by CYPs 3A4 and 2B6136,164. In the literature, several studies have shown that the 516 
GT and 983TC polymorphisms in the CYP2B6 gene are associated with NVP PK in 
ethnically diverse populations136,162,171,168,197. However, the clinical impact of such findings 
remains controversial since the association between NVP exposure and toxicity has not been 
fully elucidated.  Nonetheless, NVP clearance was shown to be reduced significantly in 
Cambodian patients homozygous for the 516 GT polymorphism, 1.86 L/h compared to 2.95 
L/h in patients with wild type allele198. Additionally, Mahungu et al showed that the 516 GT 






that the CYP2B6 983 TC polymorphism heterozygosity was associated with significantly 
higher plasma NVP concentrations in black patients172. Furthermore, a population PK model 
was used to examine relationships between EFV and NVP exposure, weight and CYP2B6 516 
GT and 983 TC polymorphisms199. The results confirmed the significant effect of the 983 
TC variant heterozygosity with 40% decreased oral clearance. Moreover, a recent  
population PK multicentre study in African children revealed differences in evening Cmin based 
on metabolizer status of the CYP2B6 516/983 haplotypes (Ultraslow[USM], Slow[SM], 
Intermediate[IM] and Fast[FM]) and weight200.  The results showed that NVP doses in children 
belonging to USM and SM groups should be reduced by 50% and children weighing <6kg 
belonging to the IM and FM groups should receive the same dose as those weighing 6-10kg 
in order to achieve homogenous exposures200. Polymorphisms affecting Pg-p activity have 
been postulated to influence intracellular concentrations and might be related to toxicity. 
Interestingly, the ABCB1 3435CT shows decreased risk of hepatotoxicity related to NVP 
therapy197,174, however, such results are paradoxical since lower Pg-p expression would lead 
to increased NVP concentrations in hepatocytes and thus further studies are required to 
ascertain this findings. 
 
1.8 Pharmacometrics 
Pharmacometrics can be defined as “the science of developing and applying mathematical 
and statistical methods to characterize, understand and predict drug’s PK-PD behaviour; and 
quantify uncertainty of information about such behaviour; and rationalize data-driven 
decision making in drug development process and pharmacotherapy”201. Initially, 
pharmacometrics was developed to facilitate more efficient development and use of 
pharmaceuticals by applying mathematical and statistical models to clinical data. The 
nonlinear mixed-effects models are the most commonly used in population pharmacometric 
approaches, which particularly useful in application to heterogeneous biological data by their 
ability to characterise sources and levels of variability202. The model approaches are used to 
integrate prior knowledge and pool data across studies and therefore used to predict dosing 






using optimal design theory and clinical trial simulations; and to investigate optimal dosage 
for population and individual treatments154,203.  
1.8.1 Population Pharmacokinetic Modelling 
Population pharmacokinetic (PopPK) modelling involves using nonlinear mixed effects 
model(s) to simultaneously evaluate data from individuals in a population204,205(Table 4 
presents advantages and disadvantages of PopPK). “Nonlinear” can be defined as dependent 
variable (e.g. drug concentration) being nonlinearly related to model parameters and 
independent variable(s).  “Mixed effects” refers to model parameterization: “Fixed effects” 
are defined as parameters that do not vary across individuals whereas “random effects” are 
parameters that vary across individuals, including inter-individual variability (IIV); inter-
occasion variability (IOV), and residual unexplained variability (RUV). The general structure of 
a mixed effects is written as follows:  
𝑌𝑌𝑌𝑌𝑌𝑌𝑌𝑌 = 𝑓𝑓(𝑋𝑋𝑌𝑌𝑌𝑌𝑌𝑌,𝑃𝑃𝑌𝑌𝑌𝑌)  ………………………………………………………………………………Equation(1) 
Where Yijk is the jth observation of the dependent variable (usually drug concentrations) at 
the kth occasion in an individual i. Yijk  is described by a vector of individual parameters Pik and 
a vector independent variables xijk (e.g. time and dose). 
There are five major facets of PopPK model: (i) the data, (ii) structural model, (iii) statistical 
model, (iv) covariate models, and (v) modelling software205. The structural model describes 
the time course of drug concentrations within a population. The statistical models describes 
“unexplainable” variability of drug concentrations within a population (e.g. IIV, IOV, RUV etc.). 
Covariate model account for variability explained by subject specific characteristics (e.g. 
gender, age, weight etc.). The modelling software brings the data and all models together and 
implements an estimation method for finding parameters for the structural, statistical, and 
covariate models that best describes the data206.  
In comparison with traditional methods, PopPK is a powerful tool for summarizing large 
amounts of data and quantifying interactions. The model can be seen as repository of 
integrated knowledge and information about the biological system, disease and drug 






integrating new information to confirm previous findings as well as further model refinement. 
Furthermore, PopPK does not require “rich” data (many observations [>5 samples post dose] 
or many subjects), as with single-subject data analysis, as well as no need for structured 
sampling schedules. Using “sparse” data (few observations [<3 samples post dose]/few 
subjects) or combination of both “rich” and “sparse” can be done with the PopPK approach.     
The typical value of the population and individual random effect is defined as an individual 
parameter. The individual parameter is assumed to be log-normally distributed such that it 
only takes positive values as follows: 
𝑃𝑃𝑌𝑌𝑌𝑌 = 𝜃𝜃𝜃𝜃 ∗ 𝑒𝑒𝜂𝜂𝜂𝜂+𝑘𝑘𝜂𝜂   
........................................................................................Equation(2)                                                                                                               
where Pik is the individual parameter at the k occasion, is the typical parameter estimate and 
η i and ki  are the random effects that describe IIV and IOV, respectively. The variables are 
assumed to be normally distributed with mean zero and variance. Parameters are assumed 
to be log normally distributed and hence both BSV and BOV are described exponentially. 
A covariate model describes the relations between covariates and parameters. Covariates are 
characteristics describing the patient, conditions drug of treatment or other factors 
potentially influencing the outcome. Subject specific covariates, such as age, gender, weight, 
genetics, liver or kidney function, etc. often explains part of the variability between individual. 
Therefore, the typical parameter value will in part be a function of the individual parameter 
value to explain part of the IIV. 
The difference between the individual prediction and the observed value is described by RUV. 
RUV may occur due to mis-recording of the time of sampling, mistreatment of samples, error 
due induced by analytical methods, model misspecification207 etc.  In PopPK, RUV is 
investigated using additive and/or proportional models.  The jth individual observation can be 
expressed in the general equation 1 as follows: 






where Yijk represents the jth observation of the dependent variable at kth occasion in an 
individual. The individual predication f(….)  is described by the independent xijk  and individual 
parameters Pik, ɛ ijk is the residual error term defining the difference between observed value 
and individual prediction. The ɛ is assumed to be normally distributed with mean zero and 
variance δ2. 
 
Table 4:  Presents the advantages and disadvantages of population pharmacokinetic 
modelling  
Advantages Disadvantages 
pharmacokinetic analysis is usually 
conducted in patients taking the drug 
relatively large numbers of patients are 
required (typically >40) 
can accommodate flexible study designs 
which occur during treatment 
complex mathematical and statistical 
analyses  
only a few samples are needed from each 
patient 
requires collection, compilation and 
verification of large amounts of data 
opportunistic sampling has the potential to 
be cost-effective 
model building may be tedious, labour 
intensive and time-consuming 
screening and quantification of covariates 
for explaining variability 
model diagnostics are often complex and 
time-consuming 
can distinguish between interindividual and 
intraindividual variability 
difficulties with handling missing data (e.g. 
all covariates in all patients) 




1.8.2 Model Estimation 
Estimating PopPK can be done is a number of software packages, all of which are based on 
hierarchical nonlinear mixed effects modelling208,209. In this thesis, NONMEM210 was used for 
the analysis, which is based on parametric maximum likelihood method for parameter 






the data under the model. In NONMEM, parameters are estimated by minimizing the 
extended least objective function (OFV), which is approximately proportional to minus 2 the 
logarithm of the likelihood (-2LL) of the data. The difference between 2 nested models is 
approximately chi-squared distributed under the assumption that the model is correct and 
errors are normally distributed. The likelihood ratio test can be computed and nested models 
can be compared whereby a difference in OFV of 3.84 corresponds to a significance level of 
p<0.05211–214. Standard errors of parameters estimates are also obtained through maximum 
likelihood estimation. 
It is a challenge to specify and evaluate the explicit likelihood function due to the entrance of 
random effects in the model nonlinearly215. Nonetheless, in NONMEM, this handled by using 
approximations of the nonlinear model and also involve linearization of the random effects216. 
There are several alternative parametric methods available to approximate in NONMEM 
including first order method (FO), first order conditional method (FOCE), first order 
conditional with interaction method (FOCEI) and Laplacian second order estimation method 
(LAPLACE). Nonparametric estimation methods (NONP) are also available in NONMEM, 
whereby no assumption is made about the distribution shape, but only define the parameter 
space is defined217,218.  Although they relax distribution assumptions, NONP approaches also 
preserve mathematical and statistical consistency. Though powerful, NONP is associated with 
some drawbacks, such as increased computation time, no imprecision of measurements and 
the impossibility to estimate residual variability. In order to circumvent this drawbacks, a two 
stage estimation can be performed, where the first estimation step is parametric (FO or FOCE) 
and the second estimation step NONP218.   
1.8.3 Model Validation 
Model validation is always used throughout the model building process to evaluate the 
adequacy, accuracy and robustness of the model. The main objective of model validation is 
to assess whether the model best describes the validation dataset in terms of its behaviour 
and of the application proposed. Graphical and statistical techniques are the most widely 
used and help in understanding the data and lead to proficient analysis of the data. Graphic 
diagnostics are intuitive and provide powerful approaches in interpreting the mode219l. There 






different aspects of model adequateness220. Moreover, each diagnostic approach has 
assumptions, strengths and weaknesses220,221. As previously mentioned (1.8.2), OFV is the 
most used numerical diagnostic. OFV provides information on model robustness and identify 
poor model fit (SE of parameters). 
Typically the model predictions (PRED) and individual predications (IPRED) versus 
observations are routinely used as good of fits plots (GOFs). Both PRED and IPRED assess the 
fit of the data along the line of identity and outliers can be identified visually220–223. This plots 
follow trends of individuals and can be used to indicate bias with the use of a regression line. 
Residual based diagnostics such as individual weighted residuals (IWRES) and conditional 
weighted residuals (CWRES) are also used commonly as part of GOFs. Both IWRES and CWRES 
are used to assess model misspecification, CWRES may also improve model accuracy. IWRES 
are calculated using the FO method whereas CWRES are calculated using FOCE 
approximation220. Normalised prediction errors (NPDE) can also be used as part of GOFs. 
NPDE are not true residuals but are rather simulated based on the rank order of the 
observations of the original dataset in relation to the model224.  Generally, the residual based 
diagnostics should be normally distributed with mean 0 across any independent variable. 
Visual predictive check (VPC) is a powerful tool to assess models. VPC simulates data and 
computes 95% prediction intervals225. Simulated predictions include fixed and random (both 
IIV and IOV) effects variability as well as residual error. A plot is then generated displaying 
prediction intervals and the observed data. The model robustness is then assessed by 
comparing observations to simulations for a particular prediction interval, making VPC a 
powerful tool for model validation. 
Bootstrapping is resampling technique also commonly used in model validation226. 
Resampling generates multiple samples from the original dataset and calculates quantities 
based on the estimations obtained from each new set of data. Means, standard errors, and 
95% confidence intervals obtained from the bootstrap are compared with ones from the 
original dataset. Bootstrapping thus provides measures of the stability of the final parameter 








1.9 Thesis Rationale and Aims 
There are only few clinical trials strategies that optimally utilize currently approved drugs for 
long-term treatment of HIV-infected children in low resource settings.Treatment is 
complicated by selection of drug resistance in many children whose mothers receive NVP for 
prevention of mother to child transmission (PMTCT). A clinical trial was thus conducted at 
Rahima Moosa Mother and Child Hospital in Johannesburg to assess whether NVP can be re-
used (Post-randomization Phase) among 327 children exposed to NVP for PMTCT if they are 
first suppressed on ritonavir-boosted lopinavir based regimen (Pre-randomization Phase). 
Data on treatment response has been published227,228. 
This is a retro-prospective study of lopinavir (LPV) and nevirapine (NVP) pharmacokinetics 
(PK) in a cohort of children infected with HIV. Both LPV and NVP PK demonstrate considerable 
inter-individual variability, which may affect treatment outcomes. At least part of this 
variability may be explained by host genetic factors. In children, however associations 
between human genetic variants and LPV and NVP exposure are incompletely understood. 
The specific aims of the thesis were to: 
i) Firstly, assess the relationship between serial clinic visit LPV concentrations and virologic 
outcomes in the pre-randomization phase using Cox proportional hazard multiple failure 
event analysis. 
ii) Secondly, use Cox proportional hazard multiple failure event modeling to evaluate the 
relationships between serial clinic visit LPV and NVP concentrations and virologic outcomes 
in the post-randomization phase. 
iii) Thirdly, use a population pharmacokinetic-pharmacogenetic model to explore the 
relationship LPV and genetic polymorphisms in preselected drug metabolizing enzymes and 
drug transporters  
iv) Lastly, explore the effect of genetic polymorphisms in predetermined drug metabolizing 
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2.1 Study Population  
A randomized, open label trial involving a total of 195 children infected with HIV was 
conducted at one site in Johannesburg, South Africa. The randomized children were 
accumulated from an initial cohort of 323 NVP-exposed children who met clinical and 
immunologic criteria for treatment when younger than 24 months of age. Data of the children 
in the study population included data from two studies about immune reconstitution 
inflammatory syndrome and initial response to PI-based antiretroviral therapy, respectively. 
2.1.1 Study Design 
Women with HIV-infected children younger than 24 months of age who reported that 
nevirapine was used for prevention of mother-to-child transmission were identified and 
referred from inpatient wards and paediatric HIV clinics to one research site for a period  
between 8 April 2005 to 10 July 2007. Children were evaluated for eligibility for treatment 
based on South African guidelines. Eligibility criteria for treatment included World Health 
Organization (WHO) stage III or IV disease, CD4+ percentage less than 25 if younger than 12 
months or less than 20 if 12 months or older, or recurrent(>2times/year) or prolonged 
(>4weeks) hospitalization for HIV related complications. Children needing acute treatment for 
opportunistic infections (except tuberculosis) or tumours were excluded. These children were 
considered as candidates for ART initiation but were not eligible to be enrolled in the trial. For 
most children (n = 254) enrolled, treatment was initiated under supervision of the study team. 
A further 69 children were enrolled after initiating PI-based therapy elsewhere (other local 
paediatric antiretroviral treatment services) but who otherwise met all study eligibility criteria 
except that pre-treatment blood samples could not be stored for resistance testing. The 69 
children all initially began receiving ritonavir-boosted lopinavir, stavudine, and lamivudine, 
but not administered by our study team. During the pre-randomization phase, 323 children 
were first initiated onto LPV/r, lamivudine and stavudine and during phase were followed 
with regular viral load tests until they suppressed.  From this cohort, those who achieved a 
viral load < 400 copies/ml and sustained this level over a 3 month or longer period were 
eligible for randomization. A total of 195 children were randomized.  Half were randomized 






randomized to substitute nevirapine (NVP Group) for the LPV/r.  The NRTI backbone remained 
the same in both groups.  The randomized children were then followed for an additional 76 
weeks with regular viral load monitoring.  The schedule of blood sampling is shown below.   
PRE-RANDOMIZATION (n=263 children or 789 samples):  Blood sampling schedule for HIV-
infected children 




Weeks   Time –1 Time  0 2 4 8 12 24 36 52 
Blood sampling Yes Yes No Yes No Ye Yes Yes Yes 
Toxicity ALT/FBC/ 
Lipids 
No No No No No FBC diff** FBC diff** FBC diff** 
CD4 counts No Yes No No No No Yes Yes Yes 
HIV RNA quantity No Yes (std) No No No Yes (std) Yes (ultra*) Yes (ultra*) Yes (ultra*) 
Plasma & cell pellets 
stored 
Yes Yes No Yes No Yes Yes Yes Yes 
ALT, alanine transferase; FBC diff**, differential full blood count; HIV RNA, human immunodeficiency 
virus ribonucleic acid  
POST-RANDOMIZATION (n=195 children or 780 samples):  Blood sampling schedule for 
both LPV Group and NVP Group  
Months after randomized treatment 1 
started -    
0.5 1 2 4 6 9 12 15 18 
Weeks - Time 0-R 2 4 8 16 24 36 52 64 76 
Blood sampling Yes Yes Yes No Yes Yes Yes Yes Yes Yes 
Toxicity  ALT/FBC/ Lipids 
 
ALT FBC diff  ALT ALT Lipids/ALT ALT ALT ALT 
CD4 counts No No No  Yes Yes Yes Yes Yes Yes 
HIV RNA quantity No No Y(ultra*)  Y(ultra*) Y(ultra*) Y(ultra*) Y(ultra*) Y(ultra*) Y(ultra*) 
Plasma & cell 
pellets stored 
Yes Yes Yes  Yes Yes Yes Yes Yes Yes 
ALT, alanine transferase; FBC diff**, differential full blood count; HIV RNA, human immunodeficiency 








Additionally, weight and height measurements were recorded at each visit as well as clinical 
information concerning illness, hospitalization or other events since the last visit and 
concomitant medications including TB treatment.  At each visit, the medication bottles were 
weighed by the pharmacist to determine the amount of liquid consumed and the percentage 
“adherence” was calculated based on the syrup reconciliation.  Questions were also asked of 
caregivers concerning reported adherence. 
2.1.2 Ethical Consideration 
The study was approved by the Ethic Committee of the University of the Witwatersrand and 
Columbia University, New York.  All care-givers signed informed consent for participation in 
the trial (Appendix I).  
2.1.3 Laboratory Methods 
2.1.3.1 Pharmacokinetic Assays 
The samples collected as described above were tested for concentrations of lopinavir and 
nevirapine depending on the regimen the child is receiving.  This testing was done at UCT.  
The time the sample was collected and the time of the last dose were recorded for most of 
the samples.  Stored plasma samples were assayed for LPV and NVP by existing validated 
liquid chromatography mass spectrometry methods which have quantitative sensitivity to 
concentrations 0.1 mg/L or lower. The laboratory, at which the concentrations were assayed, 
participates in the International Inter-laboratory Pharmacology Quality Control Program, the 
AIDS Clinical Trial Group. Assays were performed in batch mode and results were provided 
electronically to the NEVEREST2 Data Management Centre.  The Data Management Centre 
merged the results with clinically relevant data.  Results were not be reported back to the 
patients or to the clinicians providing care for the patients. 
2.1.3.2 DNA Extraction 
Human DNA was extracted from buffy coats using the QIAsymphony (QIAGEN, Hilden, 
Germany) DNA midi kit. The QIAsymphony DNA midi Kit is designed for automated isolation 
and purification of total DNA from human whole blood, buffy coat, human and animal tissues, 






DNA is free of proteins, nucleases and other impurities. Up to 96 samples were processed in 
a single run. QIAsymphony technology combines the speed and efficiency of silica-based DNA 
purification with the convenient handling of magnetic particles. The purification procedure is 
designed to ensure safe and reproducible handling of potentially infectious samples, and 
comprises 4 steps: lyse, bind, wash, and elute (Figure 1).The patient’s sample (buffy coat) was 
400µl and smaller sample  with volumes were adjusted to 400µl final volume with 
physiological saline before loading to the QIAsymphony machine. The elution volume chosen 
was 200µL. DNA was transferred from the 96 well plate into pre-labelled Eppendorf tubes. 
The DNA concentration in the Eppendorf tube was determined using nano drop 
spectrophotometer. The tube was stored at stored at -20oC before further analysis.  
                                                            
                                                      
                                                      
                                                                                                  
                                                         
                                                             
                                    






2.3 Statistical Modelling 
The general purpose this section is outlined below, with more specific issues being found in 
the appropriate sections of the following chapters. 
2.3.1 Multiple Imputation in R Package Amelia II (Paper 1 and Paper 2)  
Amelia II performs multiple imputation, a general-purpose approach to data with missing 
values1. Multiple imputation reduces bias and provides increased efficiency compared to list-
wise deletion. Moreover, ad-hoc methods of imputation, for example mean imputation, lead 
to serious bias in variances and covariances. However, due to the technical naturel of 
algorithms involved, creating multiple imputations can be cumbersome. Amelia simply 
provides a way to create and implement an imputation model, generate imputed datasets, 
and check its fit using diagnostics. Furthermore, expectation maximum likelihood bootstrap 
(EMB) algorithm included in Amelia II imputes many variables, with more observations, in a 
short amount of time. The simplicity and power of the EMB algorithm makes it possible to 
write Amelia II so that it virtually never crashes, which it unique among all existing multiple 
imputation software and is much faster than the alternatives. Additionally, Amelia II has 
features to make valid and much more accurate imputations for cross-sectional, time-series, 
and time-series-cross-section data, and allows the incorporation of observation and data-
matrix-cell level prior information. Furthermore, Amelia II provides diagnostic functions that 
help in checking the validity of the imputation model. The Amelia II software implements the 
ideas developed by Honaker and King2.  
2.3.1.1 How Amelia Works 
Multiple imputation involves creating m completed data sets by imputing m values for each 
missing cell in the data matrix. Across completed data sets, the observed values are the same, 
whereas missing values are filled in with a distribution of imputations that reflect the 
uncertainty about the missing data. After imputation with Amelia II’s EMB algorithm, any 
statistical method can be applied as if there had been no missing values to each of the m data 
sets, and a simple procedure is used to combine the results. Normally, imputation is done 






wished. The advantage of Amelia II is that it combines the comparative speed and ease-of-
use of the EMB algorithm with the power of multiple imputation. Unless the rate of 
missingness is very high, m = 5 (the program default) is probably adequate 
2.3.1.2 Assumptions in Amelia  
The imputation model in Amelia II assumes multivariate normal distribution for complete data 
(includes both observed and unobserved). If the (n × k) dataset are denoted as D (with 
observed part Dobs and unobserved part Dmis), then this assumption is 
𝐷𝐷~𝒩𝒩𝒩𝒩(𝜇𝜇,∑)…………………………………………………………………………………(1) 
Stating that D has a multivariate normal distribution with mean vector µ and covariance 
matrix Σ. The multivariate normal distribution is a crude approximation of the true 
distribution of the data. It has been shown that this model works as well as other, more 
complicated models even in the face of categorical or mixed data3,4. Furthermore, 
transformations of many types of variables can often make this normality assumption more 
plausible (transformations include; ordinal, nominal, natural log, square root, and logistic). 
Essentially, the problem of imputation is that only Dobs is observed, not the entirety of D. In 
order to gain traction, the usual assumption in multiple imputation that the data are missing 
at random (MAR) is made. This assumption means that the pattern of missingness only 
depends on the observed data Dobs and not the unobserved data Dmis. Let M to be the 
missingness matrix, with cells mij = 1 if dij ∈ Dmis and mij = 0 otherwise.  Simply, M is a matrix 
that indicates whether or not a cell is missing in the data. With this, MAR assumption can be 
defined as: 
𝜌𝜌(𝑀𝑀|𝐷𝐷) = 𝜌𝜌(𝑀𝑀|𝐷𝐷𝑜𝑜𝑜𝑜𝑜𝑜)……………………………………………………………………(2) 
Importantly, MAR includes the case when missing values are created randomly, but it also 
includes many more sophisticated missingness models. When missingness is not dependent 
on the data at all, then data are missing completely at random (MCAR). Amelia requires both 
the multivariate normality and the MAR assumption (or the simpler special case of MCAR). 






in the dataset D in the imputation dataset than just those eventually envisioned to be used in 
the analysis model. 
2.3.1.3 The Amelia Algorithm 
Multiple imputation is concerned with the complete-data parameters, θ = (µ, Σ). When writing 
down a model of the data, the observed data is actually Dobs and M, the missingness matrix. 
Thus, the likelihood of the observed data is p(Dobs, M|θ). Using the MAR assumption, this can 
be broken up as: 
𝜌𝜌(𝐷𝐷𝑜𝑜𝑜𝑜𝑜𝑜,𝑀𝑀�𝜃𝜃) = 𝜌𝜌(𝑀𝑀|𝐷𝐷𝑜𝑜𝑜𝑜𝑜𝑜)𝜌𝜌(𝐷𝐷𝑜𝑜𝑜𝑜𝑜𝑜|𝜃𝜃)………………………………………..…(3) 
Because inference on the complete data parameters is important, the likelihood can be 
written as: 
𝐿𝐿(𝜃𝜃�𝐷𝐷𝑜𝑜𝑜𝑜𝑜𝑜)  ∝  𝜌𝜌(𝐷𝐷𝑜𝑜𝑜𝑜𝑜𝑜|𝜃𝜃)……………………………………………………………..…(4) 
which can be rewritten using the law of iterated expectations as: 
𝜌𝜌(𝐷𝐷𝑜𝑜𝑜𝑜𝑜𝑜�𝜃𝜃) = ∫ 𝜌𝜌(𝐷𝐷|𝜃𝜃)𝑑𝑑𝐷𝐷𝑚𝑚𝑚𝑚𝑜𝑜……………………………..………………………….(5)  
With this likelihood and a flat prior on θ, then the posterior is 
𝜌𝜌(𝜃𝜃�𝐷𝐷𝑜𝑜𝑜𝑜𝑜𝑜)  ∝  𝜌𝜌(𝐷𝐷𝑜𝑜𝑜𝑜𝑜𝑜�𝜃𝜃) ….……………………………..…………………………….(6) 
The main computational difficulty in the analysis of incomplete data is taking draws from this 
posterior. The EM algorithm approach is computationally simplified to finding the mode of 
the posterior5dde (Figure 2). Amelia II’s EMB algorithm combines the classic EM algorithm 
with a bootstrap approach to take draws from this posterior. For each draw, data are 
bootstrapped to simulate estimation uncertainty and then run the EM algorithm to find the 
mode of the posterior for the bootstrapped data, giving fundamental uncertainty as well1. 
Once posterior of the complete-data parameters is drawn, imputations are made  by drawing 
values of Dmis from its distribution conditional on Dobs and the draws of θ, which is a linear 







Figure 2: Schematic of Multiple Imputation Approach with the EMB Algorithm, Adapted from 
Honaker et al 2011 
2.3.2 Cox Proportional Hazards Model for Multiple Failure Events (Paper 1 and Paper 2) 
Survival analysis wherein time from exposure to outcome is analyzed, is considered a 
powerful and flexible approach6. Nevertheless, in studies where the outcome of interest 
occurs multiple times in one individual, this approach prohibits measurement of the exposure 
effect on repeated occurrences and thus becomes inefficient. Cox’s proportional hazards 
model provides reliable estimates of survival times, as well as the relative risk associated with 
time-to-event occurrence7. As a semiparametric model, it does not have any constraints on 
distributional assumptions, making it more attractive than a fully parametric model. 
Nonetheless, survival time in the standard Cox model terminates at an event and discards any 
information past that point. A solution is to use multiple failure times instead whereby not 
only the first, but the event time within individuals are correlated6. However, the assumption 
of independence is violated using the standard Cox regression model, and this introduces 
statistical complications. To avoid error resulting from analysing correlated repeated events, 
the time to first event is commonly used for events that occur repeatedly. 
Survival analysis typically examines the relationship of the survival distribution to covariates. 
Most commonly, this examination entails the specification of a linear-like model for the log 
hazard. The parametric model based on the exponential distribution is written as: 







ℎ𝑖𝑖(𝑡𝑡) = exp(𝛼𝛼 + 𝛽𝛽1Χ𝑖𝑖 + 𝛽𝛽2Χ𝑖𝑖2 + ⋯+ 𝛽𝛽𝛽𝛽Χ𝑖𝑖𝛽𝛽)  
that is, as a linear model for the log-hazard or as a multiplicative model for the hazard. Where 
𝑖𝑖 is the individual observation, x covariates, α log-baseline hazard, since log hi(t) = α [or hi(t) 
= eα] when all of the covariates(x) are 0. In contrast, the Cox model leaves the baseline hazard 
function α(t) = log h0(t) unspecified:  
𝑙𝑙𝑙𝑙𝑙𝑙ℎ𝑖𝑖(𝑡𝑡) = 𝛼𝛼(𝑡𝑡) + 𝛽𝛽1Χ𝑖𝑖1 + 𝛽𝛽2Χ𝑖𝑖2 + ⋯+ 𝛽𝛽𝛽𝛽Χ𝑖𝑖𝛽𝛽………….………………(8) 
or equivalently, 
ℎ𝑖𝑖(𝑡𝑡) = ℎ0(𝑡𝑡) exp (𝛼𝛼 + 𝛽𝛽1Χ𝑖𝑖1 + 𝛽𝛽2Χ𝑖𝑖2 + ⋯+ 𝛽𝛽𝛽𝛽Χ𝑖𝑖𝛽𝛽)…..……………(9) 
The model is semi-parametric because whilst the baseline hazard takes any form, the 
covariates enter the model linearly. Consider, now, two observations i and i0 that differ in 
their x-values, with the corresponding linear predictors is independent of time t. 
𝜂𝜂𝑖𝑖 = 𝛽𝛽1Χ𝑖𝑖1 + 𝛽𝛽2Χ𝑖𝑖2 + ⋯+ 𝛽𝛽𝛽𝛽Χ𝑖𝑖k ………………………………………………(10) 
And 
𝜂𝜂𝑖𝑖′ = 𝛽𝛽1Χ𝑖𝑖′1 + 𝛽𝛽2Χ𝑖𝑖′2 + ⋯+ 𝛽𝛽𝛽𝛽Χ𝑖𝑖′k ……………………………………….…(11) 
The hazard ratio for these two observations, 
ℎ𝑚𝑚(𝑡𝑡)
ℎ𝑚𝑚(𝑡𝑡)′ = ℎ0(𝑡𝑡)𝑒𝑒𝜂𝜂𝜂𝜂ℎ0(𝑡𝑡)𝑒𝑒𝜂𝜂𝜂𝜂′ ………………………….…………………………………………………(12) 
            = 𝑒𝑒𝜂𝜂𝜂𝜂
𝑒𝑒𝜂𝜂𝜂𝜂′
  
The time to virological failure was used as the endpoint for the multiple-failure models. Thus, 
a person with one virological failure at a point in time is considered the same as someone 
with more than one episode of virological failure at that point in time. In multiple-failure 






(episodes) they have had during the study period. The Andersen-Gill approach was used to 
model repeated virological failure episodes for each person as separate observations, with 
the risk set not constrained by the number of events occurring within an individual, and makes 
a strong assumption of independence among multiple observations per person over time8. 
Nonetheless, a robust sandwich covariance matrix structure for the intra-individual 
correlation is used to overcome this assumption. Survival time for the Andersen-Gill model is 
calculated as the time since the beginning of the study to the first episode and the time 
between episodes thereafter. It uses a common baseline hazard function for all events and 
estimates a global parameter for the intervention. In this thesis Cox proportional-hazards 
regression model was fitted in R with the coxph function (located in the survival package)9. 
The Cox proportional hazard model was used in this thesis because it accommodates 
repeated events over time for a single measurement of the dependent variable (viral load) in 
an individual, allows for estimation of the effects of an intervention on the hazard of 
continued events10,11. Like time series, series hazard modelling relies upon the variation in 
activity for one unit. Unlike time series, it relies on the duration between activities instead of 
artificially aggregating the activities to multiple time periods. It only works with event data 
that record discrete incidents for one unit over time and include the exact date of all events 
so that the dependent variable can be calculated as the duration until the next event. A 
second criterion is that the events must occur with relative frequency to produce enough 
statistical power to efficiently estimate parameters.  
2.4 Pharmacometric Analyses  
The aim this section is to give a general outline below, with more specific issues being found 
in the appropriate sections of the following chapters. 
2.4.1 Population Pharmacokinetic Modelling (Paper 3 and Paper 4) 
The nonlinear mixed effects modelling implemented in the software NONMEM version7.3 
(ICON Development Solutions, Ellicott City, MD, USA) was used for parameter estimation. A 
cluster of LINUX operating machines using Intel fortran compiler was used to operate 






covariate modelling building and bootstrap procedures as well as calculations of the VPC.    
Concentration-time data was fitted using a two-step estimation method. In the first step, 
NONMEM simply runs a parametric method, first order conditional estimation with 
interaction (FOCEI) whereby the empirical Bayes estimates (EBEs) are computed. The EBEs 
are reserved as the support points of the nonparametric distribution. Once NONMEM has 
obtained support points, it proceeds to the second step where maximum likelihood estimates 
of the probability associated with each support point are obtained. From this joint probability, 
the marginal cumulative probability for each parameter is calculated. Model parameters were 
generally added stepwise starting from the base model. A decrease in the goodness-of-fit 
criterion, the objective function value (OFV) of at least 3.84 points (p< 0.05) when comparing 
2 hierarchical models was regarded as statistically significant for the addition of a single model 
parameter.  
Various model structures and features were evaluated: one- and two-compartment 
disposition; zero- and first-order absorption; and absorption with lag time and a series of 
transit compartments as proposed by Savic12.  Absorption lag (ALAG) and Mean transit time 
(MTT) was used to describe the drug absorption delay, respectively. The transit absorption 
rate (ktr) was used to describe the transit absorption rate between different transit 
compartments. The calculation of ktr is indicated as follows: ktr =  𝑛𝑛+1
𝑀𝑀𝑀𝑀𝑀𝑀
 …..…………………………………………………………………………….….(13) 
where n is the number of transit compartments. 
The IIV and IOV of the pharmacokinetic parameters of lopinavir and nevirapine were modelled 
using log-normal distribution i.e.: 
𝑃𝑃𝑖𝑖𝑃𝑃 = 𝑇𝑇𝑇𝑇(𝑃𝑃𝑖𝑖𝑃𝑃) ∗ 𝐸𝐸𝐸𝐸𝑃𝑃𝜂𝜂𝑚𝑚𝜂𝜂……………………………………………………………………………………(14) 
where Pij is the jth pharmacokinetic parameter for the ith individual; TV(Pij) is the typical 
value of the jth population parameter, and ηij represents a random variable for the ith 






first-order approximation, the variability of the lognormal distributions is reported as % 
coefficient of variation (CV). 
Different error structures describing of the residual unexplained variability (RUV) were tested: 
additive, proportional, combined error models. A combined proportional and additive error 
model (the difference between the observed and predicted concentrations) was described as 
follows: 
𝐶𝐶𝑖𝑖𝑃𝑃 = 𝐶𝐶𝑖𝑖𝑃𝑃′ ∗ (1 + 𝜖𝜖1) + 𝜖𝜖2……………………………………………………………………..…………(15) 
where Cij and Cij’ are the jth observed and predicted blood concentrations for the ith 
individual, respectively. ε1 and ε2 are random variables distributed with a mean of zero and 
variances of σ1 and σ2, respectively. 
For concentrations below the limit of quantification (BLQ), the  Beal M5 method was used13. 
For this method, whenever a measurement was recorded as being BLQ in the dataset, the 
observation was replaced with BLQ/2 and the likelihood of the observation being below BLQ 
was maximised. The M5 method is particularly useful when there are very few observations 
e.g. one early observation and one late observation.  
 Covariates were added to the base model using a forward inclusion and backward elimination 
stepwise approach. Selection of a covariate was guided by a decrease in standard error of the 
parameters, reduction in IIV, IOV and RUV, and goodness-of-fit plots (GOFs). Available 
continuous covariates in this thesis included age, body weight and, sex (Male=0, Female=1) 
and concomitant TB therapy (No=0, Yes=1) as a categorical covariates.  
Graphical diagnostics of the model fit was performed using Xpose (version 4.5.0) 
implemented in R. The graphical diagnostics included GOFs, individual plots, scatterplots, 
boxplots and VPC plots. GOFs include observed concentrations versus population predicted 
concentration (PRED), observed concentrations versus individual predicted concentration 
(IPRED), IWRES versus IPRED, and normalised prediction errors (NPDE) versus time as 
explained in the introduction. The regression lines in these plots represent equal predicted 
concentrations to observed ones and thus, indicate how close the predicted concentrations 






be a good evidence for model predicted profiles. VPC was used diagnose model adequacy. 
The purpose of these plots is to compare if the 5th, 50th, 95th percentile of observed data 
(solid and dotted lines) are agreement with the 95% confidence interval of each percentile of 
simulated data (shaded areas) based on the model. This approach is based on simulation and 
is a more robust approach for model validation. 
The minimum concentrations(Cmin) and area under curves (AUC0-12) were derived for each 




Cmin = (𝐵𝐵𝐵𝐵𝐵𝐵∗𝐴𝐴𝐴𝐴𝐴𝐴2 )∗1/𝜏𝜏((𝑉𝑉−(𝜏𝜏−𝑘𝑘)∗((1/(1−𝐸𝐸𝐸𝐸𝐸𝐸(−𝐾𝐾∗12))−((1
1
−𝐸𝐸𝐸𝐸𝐸𝐸(−𝜏𝜏∗12))……………………………..(17) 
Where AUC is the area under curve from 0-12 hours, AMT is the dose, CL is the clearance. 
Cmin is the minimum concentration, V is the volume of the central compartment, K is the 
elimination rate constant, τ is the inter-dosing interval  
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3.1 Abstract 
3.1.1 Background: Poor adherence to antiretroviral therapy contributes to pharmacokinetic 
variability and is the major determinant of virologic failure. However, measuring treatment 
adherence is difficult, especially in children. We investigated the relationship between plasma 
lopinavir concentrations, pre-treatment characteristics and viral load >400 copies/mL. 
3.1.2 Methods: Two-hundred and thirty seven HIV-infected children aged 4-42 months on 
lopinavir/ritonavir oral solution were studied prospectively and followed for up to 52 weeks. 
Viral load and lopinavir concentration were measured at clinic visits 12, 24, 36 and 52 weeks 
after starting treatment. Cox multiple failure events models were used to estimate the crude 
and adjusted effect of lopinavir concentrations on the hazard of viral load >400 copies/mL.  
3.1.3 Results: The median (IQR) pre-treatment CD4% was 18.80 (12.70, 25.35) and 53% of 
children had a pre-treatment viral load higher than 750 000 copies/mL. The median (IQR) 
weight-for-age and height-for-age z-scores were -2.17 (–3.35, -2.84) and -3.34 (-4.57, -3.41) 
respectively. Median lopinavir concentrations were 8.00 (IQR: 4.11, 12.42) mg/L a median 
3.50 (IQR: 2.67, 4.25) hours after the dose. The hazard of a viral load >400 copies/mL 
increased with lower lopinavir concentrations (crude and hazard ratios: 4% [95% CI: 2-7%] for 





>1.0mg/L) and height-for-age z-scores in relationships that were preserved in adjusted 
models.      
3.1.4 Conclusions: Low lopinavir concentrations (<1.0 mg/L) are associated with viremia in 
children. This measure could be used as a proxy for adherence and to determine which 
children are more likely to fail.  
 
3.2 Introduction 
Approximately 20-50% of children on antiretroviral therapy (ART) do not achieve viral 
suppression during first year of treatment1–3 . Failure to achieve virological suppression may 
be due to the presence of HIV quasispecies resistant to antiretroviral drugs4 or inadequate 
adherence, amongst other factors. 
A first-line ART regimen, including ritonavir-boosted lopinavir (LPV/r), is recommended for 
children exposed to non-nucleoside reverse transcriptase inhibitors (NNRTI) used to prevent 
mother-to-child transmission (PMTCT) of HIV 5,6. LPV/r has a high barrier for the development 
of resistance.  However, the oral suspension of LPV/r has poor palatability7,8, which may result 
in poor adherence. Most children with virologic failure on a first line LPV/r regimen do not 
have protease inhibitor (PI) mutations, suggesting that adherence rather than resistance is 
the cause of failure9. Establishing that adherence rather than resistance is the reason for 
virologic failure will reduce inappropriate ART switches and expenditure on resistance testing. 
In a small study of South African adults, low lopinavir concentrations were shown to be 
associated with virologic failure10. However, wide inter-individual variability is observed in the 
concentrations of lopinavir even after observed doses and few data exist on the relationship 
between lopinavir concentrations and virologic failure in children. 
We measured lopinavir concentrations in plasma samples collected at the same time as viral 
load tests in a cohort of children initiated on a first line LPV/r-based ART regimen and followed 
them prospectively to determine whether plasma lopinavir concentrations measured in the 










3.3.1 Study Participants 
Plasma lopinavir concentrations were retrospectively analyzed in samples collected at clinic 
visits during the pre-randomization period from participants of the Neverest2 trial11,12. The 
Neverest2 trial was a randomized open-label clinical trial investigating treatment options for 
nevirapine exposed children who initiated PI-based ART when less than 24 months of age.  
Treatment responses during the pre-randomization phase have been previously 
described[13].  The study population included HIV infected children attending the Rahima 
Moosa Mother and Child Hospital, Johannesburg, South Africa. Treatment eligibility criteria 
included WHO stage III or IV disease, CD4+ lymphocyte percentage (CD4%) of less than 25% if 
younger than 12 months or less than 20% if older than 12 months, or recurrent (more than 
twice yearly) or prolonged (>4 weeks) admission to hospital for HIV related complications. 
Children being treated for opportunistic infections including tuberculosis were excluded from 
this analysis. All children received 230/57.5 mg/m2 LPV/r (Kaletra® oral solution, Abott 
laboratories, USA), 1 mg/kg stavudine and 4 mg/kg lamivudine as oral solutions 12 hourly. At 
each visit, drug doses were adjusted according to growth. The caregivers of the children were 
provided with comprehensive counseling about treatment adherence. Treatment doses were 
typically taken in the morning prior to the clinic visit. The time of dosing was as reported by 
the caregiver and the time of sample collection was recorded. 
Data collected included age at starting LPV/r therapy, sex, pre-treatment viral load (VL), pre-
treatment CD4% and WHO stage. Pre-treatment weight-for-age z-score (WAZ) and height-for-
age z-score (HAZ) were calculated using WHO software14. Blood samples were collected pre-
treatment and at clinic visits 12, 24, 36 and 52 weeks after starting treatment, and at 
unscheduled clinic visits. Caregivers were requested to return medication bottles at each visit. 
The bottles were weighed, and the contents reconciled with the expected usage of each 
medication to determine the extent of adherence. Adherence was defined as returning less 
than 20% of the expected volume of any of the three drugs whereas returning more than 20% 
was defined as non-adherence. Children exited the pre-randomization phase of the study 





were followed as part of the post-randomization study (not analyzed here). Some children 
were retained for longer than the planned 52 weeks in an attempt to achieve viral 
suppression. These children were not eligible for randomization but were included in this 
analysis. 
3.3.2 Laboratory Methods 
Plasma HIV-1 RNA measurement (Roche Amplicor assay version 1.5; Roche, Branchburg, New 
Jersey, quantification range, 400-750 000 copies/mL) and CD4+ cell counts were determined 
on pre-treatment samples. The ultrasensitive assay (quantification range 50-150 000 
copies/mL) was used for VL determination post ART initiation.  
Plasma lopinavir concentrations were assayed using validated liquid chromatography tandem 
mass spectrometry methods developed in the Division of Clinical Pharmacology, Cape Town, 
South Africa. An AB Sciex 4000 mass spectrometer was operated at unit resolution in the 
multiple reaction monitoring mode. The assay was validated over the concentration range of 
0.16-20 mg/L. Inter- and intra-day coefficients of variation were below 10% for all quality 
control concentrations. The laboratory participates in the International Inter-laboratory 
Control Program Therapeutic Drug Monitoring in HIV Infection (KKGT; Hague, Netherlands) 
and the AIDS Clinical Trial Group (ACTG), Pharmacology Quality Control Program. 
 
3.3.3 Statistical Analysis 
Children with a pre-treatment WAZ below -3 (i.e. >3 standard deviations below the average 
weight of comparable children in the reference population) were categorized as severely 
underweight; a WAZ from -3 to -2 was defined as moderate underweight and a WAZ higher 
than -2 was regarded as normal. HAZ below -3, from -3 to -2, and more than-2 were defined 
respectively as severe stunting, moderate stunting and normal. Pre-treatment immunity was 
categorized as low (CD4% less than 25%) or high (CD4% greater than or equal to 25%). Pre-
treatment VL was expressed on a log scale and categorized as low or high for log10 VL greater 
than or less than or equal to 5 respectively.  We defined WHO stages 1 and 2 as early disease 
and stages 3 and 4 as moderate disease. Lopinavir concentrations reported as below the limit 





Pre-treatment characteristics were described with summary statistics (median, interquartile 
range (IQR) and proportions). Individual lopinavir concentrations during follow-up were 
presented by means of time-series plots and summary statistics. To account for missing data, 
10 multiple imputations were conducted using the Amelia II software package[15] in R. We 
imputed 10 datasets for pre-treatment WAZ, pre-treatment HAZ, pre-treatment CD4%, WHO 
stage, log10 pre-treatment VL, adherence and lopinavir concentrations. The imputation model 
included all pre-treatment (WAZ, HAZ, CD4%, WHO stage, VL) and follow-up (adherence and 
lopinavir concentration) variables, as well as time (weeks on treatment) and viral load (<400, 
or >400 copies/mL). All results of our multivariate analysis are based on the imputed datasets 
and combined using Rubin’s rules16. 
Cox proportional hazard regression modeling for multiple failure events was used to estimate 
the crude and adjusted hazard ratios of VL >400 copies/mL for the following pre-determined 
pre-treatment and follow-up variables: age at starting ART, pre-treatment WAZ and HAZ 
respectively, pre-treatment log10 VL, pre-treatment CD4%, pre-treatment WHO stage and 
lopinavir concentrations. Hazard ratios (HR) are reported together with the 95% confidence 
intervals (CI). In addition to the crude and adjusted hazard ratios, we also present the hazard 
ratios obtained for a model, with variables selected by Akaike’s information criterion (AIC). 
We assumed the model to include log10 pre-treatment VL and adjusted the AIC with inverse 
probability weights (AICw) due to missing data17.   
We modeled the effect of lopinavir concentration on the hazard of VL >400 copies/mL in the 
adjusted models as a dichotomous variable based on cut-offs of 1 mg/L and 4 mg/L. 
Additionally, we modeled the effect of lopinavir concentrations on VL >400 copies/mL non-
linearly via penalized splines, representing this in a figure.  Finally we compared two adjusted 
models by means of AICw: the first model included all pre-treatment variables and lopinavir 
concentrations at each visit whereas and the second model also included all pre-treatment 
variables and percentage adherence at each visit. Data was analyzed using the statistical 









 3.4.1 Study Population 
A total of 322 children exposed to nevirapine for PMTCT who met clinical and immunological 
criteria were enrolled into the study. All participants were initiated on LPV/r-based regimen.  
Thirty-eight (12%) children died and 40 (12%) were lost to follow-up before samples were 
collected for lopinavir concentration measurement. Four (2%) children on TB treatment and 
3 (1%) on full-dose ritonavir (previously used instead of LPV/r for treatment of children less 
than six months of age) were excluded from this analysis. The sample size for analysis was 
thus reduced to 237 children. Table 1 shows the pre-treatment characteristics of the study 
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3.4.2 Plasma lopinavir Concentrations 
 A total of 487 plasma samples from 237 children with a median number of 2 samples per 
child were analyzed to determine plasma concentrations of lopinavir. The median (IQR) 
sampling time was 3.50 (2.67-4.25) h after the dosing time reported by the caregiver, and 
12% of the samples were BLQ. Figure 1 presents plasma lopinavir concentrations of all 
children from 10 to 80 weeks of the study. We determined the population median lopinavir 
concentrations at each scheduled visit and found it to be similar for all visits. Sampling times 
after the dose were similar for samples <1.0 mg/L vs. >1.0 mg/L (median 3.37 [IQR: 2.60-4.42] 
h vs. 3.50 [2.67-4.25] h) and for samples <4.0 mg/L vs. >4.0 mg/L (median 3.33 [2.58-4.17] h 
vs. 3.50 [2.75-4.25] h). The percentage of samples below 1mg/L and 4mg/L at each clinic visit 
are shown in Figure 1 and Table 2.  
3.4.3 Predictors of Viral Load >400 copies/mL 
We performed Cox proportional hazards regression analysis to evaluate the risks for VL >400 
copies/mL. The results showed reduced risk of VL >400 copies/mL for increased lopinavir 
concentrations (HR=0.96 [95%Cl: 0.93-0.98] for each 1 mg/L, p=0.002), and increased risk for 
pre-treatment HAZ (HR=2.24 [95%Cl: 1.17-4.28] for moderate stunting, p=0.015; and HR=2.92 
[95%Cl: 1.67-5.03] for severe stunting, p=0.0001 relative to those with normal HAZ). After 
adjustment for other covariates both lopinavir concentrations and pre-treatment HAZ 
remained significant (Table 3). Utilizing model selection with AICw yields a model with similar 
estimated hazard ratios for low lopinavir concentrations (HR= 0.96 [95%CI: 0.93-0.99], 





[95%CI: 0.24-0.84], p=0.009), confirming the stability of the adjusted model.  A high log10 pre-
treatment VL was associated with hazard ratios >1 although these did not reach significance 
in either the crude (HR= 1.62 [95%CI: 0.77-3.34], p=0.205) or adjusted (HR= 1.56 [95%CI: 0.91-
3.54], p=0.269) models. Due to the high percentage (38%) of missing data, adherence was not 
included in the primary analysis. However, in a sensitivity analysis we compared two adjusted 
models using AICw, where the first model included lopinavir concentrations and the second 
model included recorded adherence. The results revealed that the AICw favors the model 
including lopinavir concentrations (AICw= 1220.7) compared with the model including 
adcherence (AICw= 1228.4).  
We also fitted separate models where lopinavir concentrations were dichotomized based on 
the cut-offs of 1.0 mg/L (Table 4) and 4.0 mg/L (Table 5), respectively. The results showed 
that children with lopinavir concentrations of less than 1.0 mg/L or 4.0 mg/L (crude 
HR=2.3[95% CI: 1.63-3.26]; adjusted HR=1.74[95% CI: 1.36-2.23]) have an increased hazard of 
VL >400 copies/mL in both crude and adjusted models. Similarly we showed that moderate 
and severe stunting were significantly associated with increased hazards of VL>400 copies/mL 
in both crude and adjusted models. We compared the two models by means of AICw and 
showed that the model with 1.0 mg/L cut-off (AICw=1326.34) described the data better than 
the model with 4.0 mg/L cut-off (AICw=1331.03).   
3.4.4 Non-linear Effect of Lopinavir Concentrations on the Risk of Viremia   
We modeled the non-linear effect of lopinavir concentrations on the hazard of VL >400 
copies/mL and failed to show any distinct threshold. Nonetheless, we showed that increasing 
lopinavir concentrations were associated with reduced hazard of VL >400 copies/mL across 
the full range of LPV concentrations studied (Figure 2).   
 
3.5 Discussion 
We used Cox regression models to describe the association of lopinavir concentrations during 
the first year of treatment and pre-treatment characteristics with the hazard of viraemia (VL 
>400 copies/mL) in a cohort of young, nevirapine-exposed South African children initiated on 
a PI-based regimen. Our data suggests that with increasing lopinavir concentrations the 





moderate (HAZ -2 to -3) and severe (HAZ <-3) pre-treatment stunting with a greater chance 
of VL >400 copies/mL, while no association was found for the other pre-treatment 
characteristics, including WAZ.  
Using the Cox regression models, we found that children with lopinavir concentrations below 
the cut-offs of 1.0 mg/L or 4.0 mg/L have an increased hazard of virologic failure, but the 
effect was stronger at the lower threshold. Moreover, we determined the non-linear effect 
of lopinavir concentrations on the hazard of VL >400 copies/mL (Figure 2) and showed that 
decreased concentrations correlated with increased risk of virological failure across the full 
range of lopinavir concentrations studied. This suggests that in addition to adherence related 
changes in drug exposure, individual variability in lopinavir concentrations may be important 
for therapeutic outcomes. However, high lopinavir concentrations would likely increase the 
risk of toxicity. Low lopinavir concentrations, especially below 1.0 mg/L, are likely to reflect 
poor adherence and could provide an objective measure of non-adherence. ART adherence 
is difficult to assess in paediatric patients as there is considerable social pressure for 
caregivers to report complete adherence and measuring returned medication is difficult, 
when compared to pill counts which can be done for adults. An objective adherence measure 
would be useful in children failing a LPV/r-based regimen as PI mutations are rarely found, 
provided that there was no prior exposure to other protease inhibitors9. Antiretroviral 
resistance testing, which is expensive, could be limited to children with lopinavir 
concentrations that are above 1.0 mg/L, as has been suggested in pilot study in adults10.   
HIV infection adversely affects growth. Prior to ART, studies demonstrated that perinatally 
acquired HIV is associated with poor growth outcome marked by high mortality, stunting and 
wasting. In our data, we found a significant association with pre-treatment HAZ, but not with 
WAZ. This suggests that children who are stunted have a higher hazard of virologic failure.  
Our data is consistent with other reports in the literature with regard to the effect of stunting 
on virologic failure19.   
Our study has several limitations that are worth highlighting. Firstly, in our study, there was 
missing data, which we dealt with by multiple imputation. This approach has been shown to 
be superior to complete case analysis in which only subjects who do not have missing values 
are analyzed16. If data are missing at random and thus the probability for value to be missing 





random assumption to be reasonable in our study given that the missing data related mainly 
to data not being measured, or due to insufficient sample volume or a lost sample. Secondly, 
we did not observe the time of morning dose prior to sampling for lopinavir concentration. 
Hence our analysis did not include adjustment of lopinavir concentrations for the time after 
the dose. Nevertheless, we have shown that the lopinavir concentrations in samples taken 
0.42-9.00 hours after the last dose predict VL >400 copies/mL, which would allow laboratories 
to do lopinavir assays to decide whether to proceed to the much more expensive genotypic 
resistance tests. To exclude potential bias due to inclusion of 1) early viral load data which (if 
>400 copies/mL) may indicate failure to suppress at that time point, rather than virological 
failure, and, 2) children followed up to more than 52 weeks, we conducted two sensitivity 
analyses (not shown), the first excluding visits before 24 weeks, and the second excluding 
visits after the planned follow up period. Our findings were not substantially altered in either 
analysis. 
The use of TDM is complicated by insufficient knowledge of the target plasma concentrations 
particularly in children on ART in whom the optimal drug concentrations have not been clearly 
defined20. In this study, we used reference values for plasma lopinavir concentrations derived 
largely from adult studies. The recommended minimum lopinavir trough concentrations are 
1.0 mg/L in treatment naïve patients and 4.0 mg/L in treatment experienced patients21. We 
found that lopinavir concentrations 0.42-9.00 hours after the last dose (analogous to the time 
after dose for samples collected at a typical clinic visit when the child has taken his/her ART 
in the morning) predicted the risk of viraemia. The lopinavir concentrations taken during the 
clinic visits were in keeping with those described in other studies amongst children of a similar 
age22,23.  
Strengths of the study include a relatively large sample size and the cohort design, which 
provides a higher level of evidence for the relationship between explanatory and outcome 
variables compared to studies with a cross-sectional or case-control design. Another strength 
of the study was repeated plasma drug concentration measurement, at each follow-up visit, 
which made it possible to assess each child’s lopinavir concentration profile and its correlation 






In conclusion lopinavir concentrations were associated with the hazard of VL >400 copies/mL. 
Low lopinavir concentrations could be used as a proxy for treatment non-adherence to guide 
determination of eligibility for resistance testing. Furthermore, our findings provide 
preliminary data to support developing optimal target concentrations of lopinavir required 
for viral suppression in children, which could be used as part of therapeutic drug monitoring 
to optimize the efficacy of ART regimens in children. Moderate and severe stunting were also 
associated with virological response to LPV/r-based ART suggesting that the reasons for poor 
responses in stunted children should be investigated further and that this group may be 
targeted for appropriate interventions.  
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Table 1: Characteristics of the 237 HIV-infected children initiating LPV/r-based antiretroviral 
therapy (ART) and included in this analysis. 
Variable Median IQR Missing Data (%) 
Age Start ART (Months) 10 5-14 0 
Pre-treatment  VL(copies/mL)  
<100 000 







Pre-treatment WAZ -2.17 -3.35 to -1.21 11 
Pre-treatment HAZ -3.34 -4.57 to -3.41 12 
































Figure 1: Lopinavir concentrations at scheduled visits of all children in the study. The 
individual lines connect each child 
 
 
Table 2: Lopinavir concentrations, time of sampling, body weight and lopinavir dose, by study 
week 

















%Samples<1mg/L, n(%) 13 (18) 16 (12) 18 (14) 16 (16) 16 (30) 
%Samples<4mg/L, n(%)  17 (23%) 16 (17) 23(18) 19(19) 16(30) 



































Table3: Cox Proportional Hazards regression analysis for failure to achieve virological 
suppression for crude and the adjusted models after multiple imputation of all covariates. 
Characteristic Crude Model Adjusted Model AICw 
 HR 95%Cl P Value HR 95%Cl P Value HR 95%Cl P Value 
lopinavir (for each   1.0 
mg/L lopinavir ) 
0.96 0.93-0.98 0.005 0.96 0.94-0.99 0.019 0.96 0.93-0.99 0.005 
Age (>9 months.) Reference   Reference      
Age (<9 months) 1.21 0.54-2.73 0.64 1.24 0.56-2.74 0.59    
Pre-treatment 
WAZ(normal) 
Reference   Reference      
Pre-treatment 
WAZ(Moderate) 
1.06 0.75-1.48 0.72 0.91 0.61-1.33 0.63    
WAZ(severe) 1.87 0.61-1.25 0.45 1.15 0.77-1.72 0.49    
Pre-treatment 
HAZ(normal) 
Reference   Reference   Reference   
 Pre-treatment 
HAZ(Moderate) 
2.24 1.17-4.28 0.015 2.20 1.18-4.09 0.012 2.19 1.19-4.05 0.011 
Pre-treatment 
HAZ(Severe) 
2.92 1.69-5.03 0.0001 2.83 1.66-4.82 0.0001 2.83 1.67-4.78 0.0001 
Pre-treatment Log10 VL 
<5 
Reference   Reference   Reference   
Pre-treatment Log10 VL 
>5 
1.62 0.77-3.44 0.21 1.56 0.91-3.54 0.27 1.58 0.72-3.44 0.252 
Pre-treatment CD4%≥25 Reference   Reference      
Pre-treatment CD4%<25 1.02 0.68-1.53 0.91 1.09 0.73-1.65 0.65    
WHO Stage(Early) Reference   Reference      














Table 4: Cox Proportional Hazards regression analysis for failure to achieve virological 
suppression for the crude model and the adjusted model after multiple imputation of all 
covariates using lopinavir with a cut-off of 1mg/L 
Characteristic Crude Model Adjusted Model AICw 
 HR 95%Cl P Value HR 95%Cl P Value HR 95%Cl P Value 
lopinavir >1.0 mg/L Reference   Reference   Reference   
lopinavir <1.0 mg/L 2.3 1.63-3.26 0.0001 2.11 1.62-2.75 0.001 2.14 1.52-3.02 0.0001 
Age (>9 months.) Reference   Reference      
Age (<9 months.) 1.21 0.53-2.76 0.76 1.23 0.60-2.73 0.50    
Pre-treatment 
WAZ(normal) 
Reference   Reference      
Pre-treatment 
WAZ(Moderate) 
1.06 0.75-1.48 0.72 0.91 0.61-1.33 0.63    
Pre-treatment 
WAZ(severe) 
1.87 0.61-1.25 0.45 1.15 0.77-1.72 0.49    
Pre-treatment 
HAZ(normal) 
Reference   Reference   Reference   
Pre-treatment 
HAZ(Moderate) 
2.24 1.17-4.28 0.015 2.20 1.18-4.09 0.012 2.32 1.24-4.37 0.009 
Pre-treatment 
HAZ(severe) 
2.92 1.69-5.03 0.0001 2.83 1.66-4.82 0.0001 2.90 1.67-5.05 0.0001 
Pre-treatment Log10 
VL <5 
Reference   Reference   Reference   
Pre-treatment Log10 
VL >5 
1.67 0.79-3.50 0.17 1.69 0.81-3.53 0.16 1.58 0.72-3.44 0.252 
Pre-treatment 
CD4%≥25 
Reference   Reference      
Pre-treatment 
CD4%<25 
1.09 0.69-1.72 0.71 1.15 0.74-1.77 0.53    
WHO Stage(Early) Reference   Reference      











Table 5: Cox Proportional Hazards regression analysis for failure to achieve virological 
suppression for the crude model and the adjusted model after multiple imputation of all0 
covariates using lopinavir with a cut-off of 4mg/L 
Characteristic Crude Model Adjusted Model AICw 
 HR 95%Cl P Value HR 95%Cl P Value HR 95%Cl P Value 
lopinavir >4.0 mg/L Reference   Reference   Reference   
lopinavir <4.0 mg/L 2.3 1.63-3.26 0.0001 1.74 1.36-2.23 0.019 1.77 1.29-2.43 0.0001 
Age (>9months.) Reference   Reference      
Age (<9months.) 1.21 0.53-2.76 0.76 1.23 0.60-2.73 0.50    
Pre-treatment 
WAZ(normal) 
Reference   Reference      
Pre-treatment 
WAZ(Moderate) 
1.06 0.75-1.48 0.72 0.91 0.61-1.33 0.63    
Pre-treatment 
WAZ(Severe) 
1.87 0.61-1.25 0.45 1.15 0.77-1.72 0.49    
Pre-treatment 
HAZ(normal) 
Reference   Reference   Reference   
Pre-treatment 
HAZ(Moderate) 
2.24 1.17-4.28 0.015 2.20 1.18-4.09 0.012 2.19 1.19-4.21 0.012 
Pre-treatment 
HAZ(Severe) 
2.92 1.69-5.03 0.0001 2.83 1.66-4.82 0.0001 2.83 1.64-4.87 0.0001 
Pre-treatment Log10 VL 
<5 
Reference   Reference   Reference   
Pre-treatment Log10 VL 
>5 
1.67 0.79-3.50 0.17 1.79 0.88-3.63 0.21 1.58 0.72-3.44 0.252 
Pre-treatment 
CD4%≥25 
Reference   Reference      
Pre-treatment 
CD4%<25 
1.02 0.68-1.53 0.906 1.14 0.73-1.78 0.46    
WHO Stage(Early) Reference   Reference      
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4.1 Abstract 
4.1.1 Background: Adequate exposure to antiretroviral drugs is necessary to achieve and 
sustain viral suppression. However, the target antiretroviral concentrations associated with 
long term viral suppression have not been adequately defined in children. 
4.1.2 Aim: We assessed the relationship between plasma lopinavir or nevirapine 
concentrations and the risk of subsequent viremia in children initially suppressed on 
antiretroviral therapy. 
4.1.3 Methods: After an induction phase of antiretroviral treatment, 195 children with viral 
suppression (viral load ≤400 copies/mL) were randomized to remain on a lopinavir/ritonavir-
based regimen or to switch to a nevirapine-based regimen (together with lamivudine and 





4, 8, 12, 16, 20, 24, 36, 52, 64 and 76 weeks post-randomization. Cox multiple failure event 
models were used to estimate the effects of drug concentrations on the hazard of viremia 
(viral load >50 copies/mL) 
4.1.4 Results: At randomization, the median (IQR) age, CD4+ T-Lymphocyte percentage, 
weight-for-age and weight-for-height z-scores were 19 (16-24) months, 29 (23-37) %, -0.6(-
1.3 to 0.2) and -3.2 (-4.1 to -2.1) respectively. The proportion of children with viral load 51-
400 copies/mL at randomization was 43%.  The hazard of subsequent viremia during follow-
up was increased for lopinavir concentrations <1.0 mg/L vs ≥1.0 mg/L (adjusted hazard ratio 
0.62 [95% CI, 0.40-0.94]) and for children with viral loads 51-400 copies/mL at randomization. 
Nevirapine concentrations were not significantly associated with subsequent viremia. 
4.1.5 Conclusion: Plasma lopinavir concentrations predicted viral outcomes in children 
receiving lopinavir-based antiretroviral therapy. Our findings support a minimum target 
concentration of ≥1.0 mg/L of lopinavir to ensure sustained viral suppression.  
 
4.2 Introduction 
Combination antiretroviral therapy (ART) has significantly improved survival and quality of life 
of HIV infected children worldwide1. The maintenance of adequate drug exposures is 
necessary to prevent viral resistance and ART failure, and high levels of adherence are critical 
for maintaining viral suppression2,3.  
Current ART treatment guidelines for HIV-infected children recommend combination therapy 
of dual nucleoside analogue reverse transcriptase inhibitor (NRTI) combined with either a 





Nevirapine (NVP) has a low barrier to develop viral resistance. Suboptimal NVP concentrations 
have been shown to select for the development of drug resistance mutations4. An ART 
regimen including the co-formulated PI lopinavir/ritonavir (LPV/r) has been shown to be 
superior to a NVP-based regimen for treating infants exposed to NVP perinatally5. LPV/r has 
a high barrier for resistance, however, the oral suspension of LPV/r has poor palatability which 
may result in poor treatment adherence6,7.  
Based largely on studies in adults, minimum trough concentrations of 1.0 mg/L and 3.0 mg/L 
are recommended for LPV and NVP, respectively8,9. Therapeutic drug monitoring is 
recommended by some guidelines for children on LPV or NVP10, as the plasma concentrations 
of both drugs are highly variable even after observed doses. However few data exist on the 
relationship between plasma drug concentrations of LPV or NVP, and viral response in 
children. 
We measured serial LPV and NVP concentrations from stored plasma in children enrolled in a 
clinical trial7,10. Once they had achieved viral suppression (<400 copies/mL), children were 
randomized to continue LPV/r or to switch to NVP.  The purpose of our analysis is to evaluate 
the plasma LPV and NVP concentrations associated with maintenance of viral suppression. 
 
4.3 Methods 
4.3.1 Study Participants 
Plasma LPV and NVP concentrations were retrospectively analyzed in samples collected from 
participants of the Neverest2 trial at clinic visits during the post-randomization period7,11. The 
Neverest2 trial was a randomized open-label clinical trial investigating treatment options for 
NVP exposed children who initiated PI-based ART when less than 24 months of age. HIV 





South Africa, who achieved a viral load (VL) ≤400 copies/mL for at least 2 consecutive visits 
on LPV-based ART were eligible for randomization.  Once criteria for randomization were met, 
the children were randomized 1:1 to continue their LPV/r regimen or switch LPV/r to NVP. 
NVP (Viramune® oral solution, Boehringer Ingelheim) was introduced at 120 mg/m2 once daily 
for the first 2 weeks and thereafter at 200mg/m2 12 hourly. Children randomized to continue 
LPV/r (Kaletra® oral solution, Abbott Laboratories, USA), received doses of 230 mg/m2 12 
hourly. Lamivudine and stavudine were used as the other two drugs. Doses were adjusted 
according to the growth of the children at each visit. Both NVP and LPV groups received 
additional adherence counselling, including specific instructions concerning the lead-in 
schedule and possible adverse effects for children switching to NVP.  
Data collected at randomization included age, sex, VL and CD4+ T lymphocyte percentage 
(CD4%). Weight-for-age z-score (WAZ) and height-for-age z-score (HAZ) at randomization 
were calculated using WHO software7.  In both groups, blood samples were collected at 
randomization and at 4, 8, 12, 16, 20, 24, 36, 52, 64 and 76 weeks post-randomisation and at 
unscheduled clinic visits.  Blood samples collected at each visit post-randomization were used 
to measure VL (post-randomization viremia was defined as VL >50 copies/mL), and LPV or 
NVP concentrations. The time of blood sample collection was documented, as was the time 
of the morning dose of antiretrovirals, as reported by the caregiver. Caregivers were 
requested to return medication bottles at each visit. The bottles were weighed and the 
contents reconciled with the expected usage of each medication to determine the degree of 
adherence. Adherence was defined as returning less than 20% of the expected volume of any 
of the three drugs, whereas returning more than 20% was defined as non-adherence. In 





recorded at each visit. After 76 weeks, all children were enrolled in an extended follow-up 
period during which clinical care was provided and monitored.  
4.3.2 Laboratory Methods 
Plasma LPV and NVP concentrations were assayed using validated liquid chromatography 
tandem mass spectrometry methods developed in the Division of Clinical Pharmacology, Cape 
Town, South Africa. An AB Sciex 4000 mass spectrometer was operated at unit resolution in 
the multiple reaction monitoring (MRM) mode. The validated concentration range for the LPV 
assay was 0.16 mg/L to 20 mg/L and that for NVP was 0.1 mg/L to 15 mg/L. Inter- and intra-
day coefficients of variation were below 10% for all quality control concentrations. The 
laboratory, at which the concentrations were assayed, participates in the International Inter-
laboratory Pharmacology Quality Control Program, the AIDS Clinical Trial Group (ACTG). 
4.3.3 Statistical Analysis 
Children with a WAZ > -2 SD below the norm, were categorized as underweight. HAZ < -2 was 
regarded as indicating stunting. Immunity at randomization was categorized as low (CD4% 
less than 25%) or high (CD4% greater than or equal to 25%) whilst VL was categorized as low 
level viremia (VL 51-400 copies/mL) or suppressed (VL ≤50 copies/mL). TB treatment was a 
dichotomous variable (present or absent at each post-randomization visit). LPV and NVP 
concentrations below the limit of quantification (BLQ) were assigned values of 0.08 and 0.05 
mg/L respectively (half the limit of quantification). Characteristics at randomization were 
described with summary statistics (median, interquartile range (IQR) and proportions).  
Cox proportional hazard regression for multiple failure events was used to estimate the crude 
and adjusted hazard ratios for viremia (VL >50 copies/mL) associated with the following pre-





randomization, and LPV or NVP concentration at the current visit.  In secondary analyses, we 
determined the crude and adjusted hazards of viremia associated with LPV or NVP 
concentration at the previous visit, and the crude and adjusted hazards of viremia associated 
with the average of two drug concentrations, derived from the current and prior visits, 
respectively. To account for missing CD4% and adherence data, as well as LPV and NVP 
concentrations, 10 multiple imputations were conducted using the Amelia II software package 
in R13. The imputation model included variables for WAZ, HAZ, VL and CD4% at the time of 
randomization as well as repeated measures of adherence, TB treatment, and NVP and LPV 
concentrations during follow-up, along with the time (weeks on treatment). All results in our 
crude and adjusted analyses are based on the imputed datasets and combined using Rubin’s 
rules14. Hazard ratios (HR) are reported together with the 95% confidence intervals (CI). 
Akaike information criterion (AIC) for each imputed dataset was used to compare all the 
adjusted models.  
We modelled the effect of LPV and NVP on the hazard not only linearly but also using binary 
cut-offs for drug concentrations.  We determined Mixed effects logistic regression models 
were used to describe the hazard of viremia (VL >50 copies/mL) for concentrations below 
each cut-off value respectively compared to higher concentrations.  Multivariate models were 
used to adjust for the time post-randomization (in weeks), and clustering by individual was 
used. We compared LPV cut-offs [0.5, 1.0, 2.0, 3.0, 4.0, 5.0 & 6.0 mg/L] and NVP cut-offs [2.0, 
3.0, 4.0, 5.0, 6.0, 7.0 & 9.0 mg/L] by means of generalized cross validation (GCV)15.  
To graphically display the non-linear effects of LPV and NVP concentrations on the hazard of 
viremia we used penalized splines16.   
Finally, we compared two adjusted models by means of AIC in each imputed dataset; the first 





whereas and the second model included all variables at randomization and percentage 
adherence at each visit in both the LPV and the NVP groups. Data was analysed using the 
statistical software package R17. 
 
4.4 Results 
4.4.1 Study Population 
A total of 195 children from the initial 322 children were enrolled in the post-randomization 
phase of the NEVEREST2 study. Of the 195 children, 96 were switched to NVP whilst 99 
remained on a LPV regimen. Table 1 shows the characteristics of children in both groups in 
the study at randomization, and indicates missing data.  The characteristics in the two groups 
were similar.  
4.4.2 Plasma Lopinavir and Nevirapine Concentrations 
For the LPV group, a total of 1134 plasma samples from 99 children with a median of 8 
samples per child were collected from 3 weeks to 209 weeks post-randomization 
(Supplementary Figure 1A). The blood was sampled a median 3.00 (IQR 2.00-3.91) hours after 
the reported dose of antiretrovirals, and 7% of the samples were BLQ with 6% missing.  The 
median population LPV concentrations determined at 24, 50, 76, and 100 and 150 weeks, 
respectively, and were similar across all visits (Table 2).  
For the NVP group, a total of 764 samples plasma samples from 96 children, with a median of 
6 samples per child, were collected from 3 to 196 weeks post-randomization. For the NVP 
group, a total of 764 samples plasma samples from 96 children, with a median of 6 samples 
per child, were collected from 3 to 196 weeks post-randomization. The median time of 
sampling was 3.00 (IQR 2.17-3.92) hours after the reported dose, and 1% of samples were 





were similar across all visits (Table 2). Five children had exceptionally high NVP concentrations 
i.e. NVP concentrations consistently above 40 mg/L for an average of 2 visits (Supplementary 
Figure 1B). The data for these five children were excluded in subsequent analyses. Two of 
these children had TB post-randomization and were switched to another ART regimen. One 
child who experienced toxicity and one child with viral failure were withdrawn, and one child 
was lost to follow-up.  
4.4.3 Predictors of Viremia (Viral load >50 copies/mL) in the LPV Group 
As shown in Table 3, the risk of viremia (VL >50 copies/mL) was estimated to be reduced by 
5% for each 1.0 mg/L increment in the current visit LPV concentration (HR: 0.95 [95% CI 0.92, 
0.98]; P<0.01). Children with low level viremia (VL 51-400 copies/mL) at the time of 
randomization had a 2.62-fold increased risk of viremia (HR: 2.62 [95% CI 1.62, 4.24]; P<0.01) 
(Table 3) compared to children with VL <50 copies/mL.  After adjusting for other covariates 
both LPV concentrations (HR: 0.96 [95% CI 0.94, 0.99]; P=0.01) and VL at randomization (HR: 
2.66 [95% CI 1.68, 4.22]; P <0.01) remained significant predictors of post-randomization 
viremia.   We found the average of two LPV concentrations (at the current visit and previous 
visit, respectively) were predictive of viremia in the crude (HR: 0.94 [95% CI 0.91, 0.98]; 
P<0.01) and adjusted (HR: 0.96 [95% CI 0.92, 1.00; P=0.05) models (Supplementary Table 1), 
whereas LPV concentrations at the previous visit was less predictive of viremia in both crude 
(HR: 0.98 [95% CI 0.96, 1.01]; P=0.15) and adjusted (HR: 0.99[95% CI 0.96, 1.02]; P=0.36) 
models (Supplementary Table 1). The effect of low level viremia at randomization remained 
significant in all models. When we compared the three models by means of AIC in each 
imputed dataset, we showed that the models which included current visit LPV concentrations 
or the average of LPV concentrations at two visits described the data better than the model 





adherence was not included in the primary analysis. However, in a secondary analysis we 
compared two models using AIC in each imputed dataset, where the first model included 
current LPV concentrations and the second model included recorded adherence 
(Supplementary Table 2). In each imputed dataset the model including LPV (low AIC values) 
was more predictive of viremia compared to model with adherence.  
We used predictive modelling to compare logistic regression models (using GCV values) and 
thereby evaluating the effects of various cut-off concentrations, we showed that a cut-off 
concentration of 1mg/L best predicted viremia (Figure 1). A separate Cox regression model, 
in which LPV concentrations were dichotomized with a cut-off of 1.0 mg/L (Table 3), a 41% 
reduction in the risk of viremia in children with LPV concentrations ≥1.0 mg/L compared to 
children with LPV concentrations <1.0 mg/L was shown. These associations were preserved 
in the adjusted models in which low level viremia at randomization was also significantly 
associated with increased hazard of viremia.   
4.4.4 Predictors of Viremia (Viral load>50 copies/ml) in the NVP Group 
We assessed the risk of viremia (VL>50 copies/mL) in the NVP group using Cox proportional 
hazards models. Neither current visit concentrations (Table 4),  previous visit (supplementary 
Table 3) NVP concentrations nor average of two NVP (supplementary Table 3) concentrations 
taken at the current and previous visits respectively, were associated with the risk of viremia 
in crude or adjusted models. We compared the three models by means of AIC in each imputed 
dataset and showed that the model with current visit and average of two visit NVP 
concentrations described the data similarly but better compared with the model with 
previous visit NVP concentration. Consistently high NVP concentrations were measured in 5 





the sensitivity analysis we included the 5 children and they were influential, biasing results to 
significance (data not shown).  Due to high percentage of missing data (29%), adherence was 
not included in the primary analysis. As for the LPV arm, we showed that current visit NVP 
concentrations described the data better than recorded adherence in a sensitivity analysis 
(supplementary Table 4).  
Based on GCV values for the logistic regression evaluating the effect of NVP concentration 
thresholds, an NVP concentration cut-off values of 5.0 mg/L best predicted viremia in the 
respective arm (Figure 1). A separate Cox regression model was performed where NVP was 
dichotomized to evaluate the effects of NVP concentrations ≥5.0 mg/L vs. <5.0 mg/L. While 
not statistically significant, there was a trend to a reduction in the risk of viremia in children 
with NVP concentrations ≥5.0 mg/L (crude HR: 0.64[95% CI 0.33, 1.27]; P=0.20) (Table 4) 
 
4.5 Discussion 
We evaluated the risk of viremia (VL >50 copies/mL) in treatment experienced children 
achieving viral suppression (VL <400 copies/mL) after switching to NVP or remaining on LPV/r.  
In keeping with our analysis of the pre-randomization phase of the same study18, higher LPV 
concentrations are associated with sustained viral suppression. Our data suggests that 
children with LPV concentrations >1.0 mg/L have a reduction in the risk of viremia of about 
40%, compared to children with LPV <1.0 mg/L. In children established on ART a LPV 
concentration of 1.0 mg/L (taken 2-4 hours after the claimed morning dose time) may 
therefore be used as a threshold for therapeutic drug monitoring (TDM).  
We found 1.0 mg/L and 5.0 mg/L to be the most predictive threshold values of LPV and NVP, 





<5.0 mg/L and viremia was not significant in the regression model. This finding is consistent 
with other reports that NVP concentrations do not predict viral response9.  Pre-existing drug 
resistance most likely accounts for the viremia in the NVP group as all children enrolled in this 
trial had past exposure to single-dose nevirapine used for PMTCT7,11.  
Low level viremia at randomization was associated with increased risk of ongoing viremia. 
This finding was more marked in children on the LPV/r-based regimen, and was independent 
of other effects captured by the multivariate models. This suggests that the risk of future 
viremia, conferred by low level viremia at randomization was not modified by LPV exposure 
post-randomization, however our study was not designed to evaluate whether interventions 
to increase LPV exposure in those children with low level viremia would lead to suppression.  
In contrast to NVP, a high proportion (55-100%) of LPV concentrations below the threshold of 
1.0 mg/L were below the quantifiable limit of the LPV assay (0.16 mg/L) across all visits (Table 
2). This suggests that poor adherence accounts for most LPV concentrations <1.0 mg/L, which 
were associated with viremia, and supports efforts to develop LPV/r formulations with 
improved palatability.  
This study has several limitations that are worth highlighting. Firstly, antiretroviral drug dosing 
was not directly observed therefore, our only measure of adherence was caregiver-reported 
adherence, which likely contributed to intra-individual variability in LPV and NVP 
concentrations. Secondly, the time of sampling in relation to the dose is a key determinant of 
drug concentration. In this study we did not observe the time of dosing and this was not 
included in our analysis.  Despite this limitation, we have shown that LPV concentrations taken 
after 3.0 (2.0-3.9) hours after the last dose predict viremia, suggesting that a sample taken at 





missing data, which was dealt with by multiple imputation. Previous studies have shown 
multiple imputation to be superior to complete case analysis in which only patients with 
complete data across all variables are analyzed19. If data are missing at random and thus the 
probability for value to be missing randomly depends only on observed quantities, then no 
bias is introduced.  We assumed data to be missing at random and found it to be a reasonable 
assumption given that the missing data related mainly to insufficient sample volumes or a lost 
samples. Lastly, we acknowledge that there was some model uncertainty in the choice of the 
best cut-off. Nonetheless, we used generalized cross validation to find a model that minimizes 
the expected prediction error, however, it may well be that other models with other cut-offs 
have good predictive ability too. 
Strengths of the study include a relatively large sample size with viral load and plasma drug 
concentration measurements at repeated clinic visits, which made it possible to assess the 
relationship between each child’s LPV or NVP concentration and their VL at successive 
intervals.  
Measuring drug concentrations can be used as an effective tool in ensuring that therapeutic 
targets of ART are met20. However, TDM is not routinely used in any low and middle income 
country programs to our knowledge. There is also currently insufficient knowledge of target 
plasma concentrations in children. Moreover, although minimum trough concentrations for 
LPV and NVP of 1.0 mg/L (in treatment naïve children) and 3.0 mg/L, respectively, have been 
recommended7,20,it is challenging to obtain a sample 12 hours post dose in clinical practice.   
Our findings suggest that a single sample taken 2-4 hours after the dose is a useful predictor 





In conclusion, LPV concentrations were associated with the hazard of viremia. Our analysis 
suggests that LPV plasma concentration monitoring at a routine clinic visit may be a useful 
tool in identifying sub-therapeutic antiretroviral concentrations in children, and thereby assist 
with adherence support.   
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Table 1: Characteristics at randomization of the 195 HIV-infected children remaining on a 
lopinavir/ritonavir-based regimen or switched to nevirapine-based antiretroviral therapy 
 Characteristics of children in the LPV group 
(n=99) 
Characteristics of children in the NVP group (n=96) 
Variable Median IQR Missing Data Median IQR Missing Data 
Age(months) 20 16-25 0 18 15-22.25 0 




 0 53(55%) 
43(45%) 
 0 
CD4% 28.05 21.65-35.20 4 29.55 22.95-36.70 3 
WAZ -0.60 -1.26 to 0.07 0 -0.60 -1.17 to-0.13 0 














Data are in Median (IQR) or n(%).Age, Age at randomization; VL, viral load at randomization; CD4%, CD4+ T 
lymphocyte percentage at randomization; WAZ, weight for age z-scores at randomization; HAZ, height for age 





Table2:  Lopinavir and nevirpine concentrations, time of sampling, body weight and dose by study week 
Data are in Median (IQR), unless otherwise stated; LLQ, lower limit of quantification; BLQ, below the assay limit of quantification; LPV, lopinavir; NVP, 
nevirapine
Characteristics LPV Group NVP Group 





































% Samples between 
LLQ and 1 mg/L for 
LPV, between LLQ and 
3 mg/L  for NVP 
8 12 10 9 9 7 3 6 2 4 3 7 
% BLQ 6 12 9 5 9 6 0 2 1 3 1 1 










































































































Table 3: Cox proportional hazards regression analysis describing the risk of viremia (VL >50 copies/mL) post-randomization in 99 children randomized to 
LPV/r-based treatment. 
HR, hazard ratio; LPV, lopinavir concentration at each visit; Age, age at randomization; VL, viral load at randomization; CD4%, CD4+ T lymphocyte percentage 
at randomization; WAZ, weight for age z-scores at randomization; HAZ, height for age z-score at randomization; TB Treatment, concomitant tuberculosis 
treatment post-randomization. 
Characteristic  Crude Adjusted Characteristic Crude Adjusted 
 HR 95%Cl P Value HR 95%Cl P Value  HR 95%Cl P Value HR 95%Cl P Value 
LPV (mg/L)  0.95 0.92-0.98 <0.01 0.96 0.94-99 0.01 LPV <1 mg/L Reference   Reference   
Age ≥20 months Reference   Reference   LPV ≥1 mg/L) 0.59 0.40-0.94 0.03 0.62 0.40-0.95 0.03 
Age <20 months 1.48 0.91-2.39 0.11 1.47 0.92-2.34 0.11 Age ≥20 months Reference   Reference   
Normal WAZ Reference   Reference   Age <20 months 1.48 0.91-2.39 0.34 1.47 0.92-2.34 0.09 
Underweight 2.36 0.77-7.25 0.13 2.62 0.94-7.24 0.06 Normal WAZ Reference   Reference   
Normal HAZ Reference   Reference   Underweight 2.36 0.77-7.25 0.13 2.90 1.04-8.42 0.05 
Stunted 0.64 0.36-1.12 0.12 0.78 0.43-1.39 0.40 Normal HAZ Reference   Reference   
VL ≤50 Reference   Reference   Stunted 0.64 0.36-1.12 0.16 0.76 0.43-1.34 0.34 
VL 51-400 2.62 1.62-4.24 <0.01 2.66 1.68-4.22 <0.01 VL ≤50 Reference   Reference   
CD4% ≥25 Reference   Reference   VL 51-400 2.62 1.62-4.24 <0.01 2.73 1.72-4.33 <0.01 
CD4% <25 1.25 0.75-2.06 0.38 1.05 0.66-1.66 0.85 CD4% ≥25 Reference   Reference   
TB Treatment (No) Reference   Reference   CD4% <25 1.25 0.75-2.06 0.28 1.05 0.66-1.66 0.85 
TB Treatment (Yes) 0.36 0.13-1.05 0.07 0.41 0.15-1.15 0.09 TB Treatment (No) Reference   Reference   





Table 4: Cox proportional hazards regression model describing the risk of viremia (VL >50 copies/mL) in children (n=96) associated with current visit plasma 
nevirapine concentrations. 
HR, hazard ratio; NVP, nevirapine concentration at each visit; Age, Age at randomization; VL, viral load at randomization; CD4%, CD4+ T lymphocyte percentage 
at randomization; WAZ, weight for age z-scores at randomization; HAZ, height for age z-score at randomization; TB Treatment, concomitant tuberculosis 
treatment post-randomization 
 
Characteristic  Crude Adjusted Characteristic Crude Adjusted 
 HR 95%Cl P Value HR 95%Cl P Value  HR 95%Cl P Value HR 95%Cl P Value 
NVP(mg/L)  0.95 0.90-1.01 0.11 0.96 0.91-1.01 0.13 NVP ≥5mg/L Reference   Reference   
Age ≥18 months Reference   Reference   NVP <5mg/L 0.64 0.33-1.27 0.20 0.69 0.33-1.41 0.31 
Age <18 months 1.31 0.69-2.47 0.42 1.48 0.77-2.84 0.26 Age ≥18 months Reference   Reference   
Normal WAZ Reference   Reference   Age <18 months 1.31 0.69-2.47 0.42 1.48 0.77-2.82 0.24 
Underweight 1.28 0.37-4.44 0.69 1.39 0.34-5.62 0.64 WAZ(normal) Reference   Reference   
Normal HAZ Reference   Reference   WAZ(advanced) 1.28 0.37-4.44 0.69 1.43 0.36-5.64 0.61 
Stunted 0.87 0.46-1.66 0.67 0.88 0.47-1.65 0.67 HAZ(normal) Reference   Reference   
VL ≤50 Reference   Reference   HAZ(advanced) 0.87 0.46-1.66 0.67 0.90 0.47-1.73 0.76 
VL >50 1.69 0.91-3.16 0. 09 1.75 0.92-3.35 0.09 VL ≤50 Reference   Reference   
CD4% ≥25 Reference   Reference   VL >50 1.69 0.91-3.16 0. 09 1.79 0.93-3.44 0.08 
CD4% <25 1.21 0.61-2.49 0.59 1.23 0.63-2.39 0.64 CD4% ≥25 Reference   Reference   
TB Treatment (No) Reference   Reference   CD4% <25 1.21 0.61-2.49 0.59 1.19 0.61-2.31 0.61 
TB Treatment(Yes) 1.12 0.34-3.64 0.86 1.19 0.28-5.33 0.82 TB Treatment (No) Reference   Reference   





FIGURE 1. Nonlinear effect of lopinavir and nevirapine concentrations on the hazard of viremia with 
determination of cutoffs using generalized cross validation. Left panel demonstrates lopinavir and the 
right panel presents nevirapine. GCV indicates generalized cross validation values; LPV cutoff, lopinavir 














Supplementary Tables  
Table 1: Cox Proportional Hazards regression analysis for the risk of viremia (VL>50/copies/mL) 
using previous visit lopinavir concentrations (n=99) 
Characteristic Crude Model Adjusted Model 
 HR 95%Cl P Value HR 95%Cl P Value 
LPV(mg/L)  0.98 0.96-1.01 0.15 0.99 0.96-1.02 0.36 
Age ≥20 months Reference   Reference   
Age <20 months 1.48 0.91-2.39 0.34 1.43 0.90-2.27 0.13 
Normal WAZ Reference   Reference   
Underweight 2.36 0.77-7.25 0.13 2.83 0.99-8.07 0.05 
Normal HAZ Reference   Reference   
Stunted 0.64 0.36-1.12 0.16 0.77 0.43-1.38 0.39 
VL ≤50 Reference   Reference   
VL 51-400 2.62 1.62-4.24 <0.01 2.71 1.70-4.31 <0.01 
CD4% ≥25 Reference   Reference   
CD4% <25 1.25 0.75-2.06 0.28 1.06 0.66-1.69 0.82 
TB Treatment (No) Reference   Reference   
TB Treatment(Yes) 0.36 0.13-1.05 0.07 0.40 0.15-1.10 0.07 
HR, hazard ratio; LPV, previous visit lopinavir concentration; Age, age at randomization; VL, viral load 
at randomization; CD4%, CD4+ T lymphocyte percentage at randomization; WAZ, weight for age z-
scores at randomization; HAZ, height for age z-score at randomization; TB Treatment, concomitant 











Table 2: Cox proportional hazards regression model describing the risk of viremia (VL >50 copies/mL) 
associated with the average of two lopinavir concentrations taken at the current and previous visits 
respectively. 
Characteristic Crude Model Adjusted Model 
 HR 95%Cl P Value HR 95%Cl P Value 
LPV(mg/L)  0.94 0.91-0.98 <0.01 0.96 0.92-1.00 0.05 
Age ≥20 months Reference   Reference   
Age <20 months 1.48 0.91-2.39 0.34 1.47 0.91-2.34 0.09 
Normal WAZ Reference   Reference   
Underweight 2.36 0.77-7.25 0.13 2.58 0.92-7.22 0.07 
Normal HAZ Reference   Reference   
Stunted 0.64 0.36-1.12 0.16 078 0.44-1.42 0.42 
VL ≤50 Reference   Reference   
VL 51-400 2.62 1.62-4.24 <0.01 2.64 1.66-4.19 <0.01 
CD4% ≥25 Reference   Reference   
CD4% <25 1.25 0.75-2.06 0.28 1.02 0.66-1.69 0.81 
TB Treatment (No) Reference   Reference   
TB Treatment(Yes) 0.36 0.13-1.05 0.07 0.39 0.14-1.09 0.07 
HR, hazard ratio; LPV, average of previous and current visit lopinavir concentration; Age, age at 
randomization; VL, viral load at randomization; CD4%, CD4+ T lymphocyte percentage at 
randomization; WAZ, weight for age z-scores at randomization; HAZ, height for age z-score at 













Table 3: Cox Proportional Hazards regression evaluating the risk of viremia (VL >50 copies/mL) 
associated with adherence (volume of lopinavir/ritonavir oral solution returned, divided by the 
volume dispensed at the previous visit, expressed as a percentage), in the lopinavir group (n=99). 
Characteristic Crude Model Adjusted Model 
 HR 95%Cl P Value HR 95%Cl P Value 
Adherence (%) 0.99 0.96-1.03 0.62 0.99 0.96-1.02 0.43 
Age ≥20 months Reference   Reference   
Age <20 months 1.48 0.91-2.39 0.34 1.44 0.91-2.28 0.12 
Normal WAZ Reference   Reference   
Underweight 2.36 0.77-7.25 0.13 2.91 1.02-8.30 0.05 
Normal HAZ Reference   Reference   
Stunted 0.64 0.36-1.12 0.16 0.77 0.43-1.40 0.39 
VL ≤50 Reference   Reference   
VL 51-400 2.62 1.62-4.24 <0.001 2.78 1.76-4.40 <0.001 
CD4% ≥25 Reference   Reference   
CD4% <25 1.25 0.75-2.06 0.28 1.08 0.68-1.73 0.74 
TB Treatment (No) Reference   Reference   
TB Treatment(Yes) 0.36 0.13-1.05 0.07 0.39 0.14-1.06 0.07 
HR, hazard ratio; Age, age at randomization; VL, viral load at randomization; CD4%, CD4+ T lymphocyte 
percentage at randomization; WAZ, weight for age z-scores at randomization; HAZ, height for age z-













Table 4: Cox Proportional Hazards regression analysis describing the risk of viremia (VL 
>50/copies/mL) in 96 children, associated with the plasma nevirapine concentration at the previous 
visit. 
Characteristic Crude Model Adjusted Model 
 HR 95%Cl P Value HR 95%Cl P Value 
NVP(mg/L)  0.96 0.91-1.01 0.13 0.96 0.91-1.02 0.17 
Age ≥18 months Reference   Reference   
Age <18 months 1.31 0.69-2.47 0.42 1.46 0.76-2.80 0.26 
Normal WAZ Reference   Reference   
Underweight 1.28 0.37-4.44 0.69 1.35 0.34-5.35 0.67 
Normal HAZ Reference   Reference   
Stunted 0.87 0.46-1.66 0.67 0.91 0.47-1.75 0.79 
VL ≤50 Reference   Reference   
VL 51-400 1.69 0.91-3.16 0. 09 1.79 0.94-3.42 0.07 
CD4% ≥25 Reference   Reference   
CD4% <25 1.21 0.61-2.49 0.59 1.20 0.61-2.34 0.60 
TB Treatment (No) Reference   Reference   
TB Treatment(Yes) 1.12 0.34-3.64 0.86 1.19 0.27-5.40 0.81 
HR, hazard ratio; NVP, previous visit nevirapine concentration; Age, age at randomization; VL, viral 
load at randomization; CD4%, CD4+ T lymphocyte percentage at randomization; WAZ, weight for age 
z-scores at randomization; HAZ, height for age z-score at randomization; TB Treatment, concomitant 













Table 5: Cox proportional hazards regression analysis for the risk of viremia (VL >50 copies/mL) 
associated with the average of two nevirapine concentrations taken at the current and previous 
visits, respectively, in 96 children. 
Characteristic Crude Model Adjusted Model 
 HR 95%Cl P Value HR 95%Cl P Value 
NVP (mg/L)  0.94 0.88-1.01 0.07 0.95 0.88-1.01 0.09 
Age ≥18 months Reference   Reference   
Age <18 months 1.31 0.69-2.47 0.42 1.47 0.76-2.84 0.26 
Normal WAZ Reference   Reference   
Underweight 1.28 0.37-4.44 0.69 1.35 0.34-5.34 0.68 
Normal HAZ Reference   Reference   
Stunted 0.87 0.46-1.66 0.67 0.89 0.47-1.67 0.71 
VL ≤50 Reference   Reference   
VL 51-400 1.69 0.91-3.16 0. 09 1.74 0.91-3.32 0.09 
CD4% ≥25 Reference   Reference   
CD4% <25 1.21 0.61-2.49 0.59 1.22 0.62-2.39 0.56 
TB Treatment (No) Reference   Reference   
TB Treatment(Yes) 1.12 0.34-3.64 0.86 1.19 0.27-5.40 0.81 
HR, hazard ratio; NVP, average of previous and current visit nevirapine concentration; Age, age at 
randomization; VL, viral load at randomization; CD4%, CD4+ T lymphocyte percentage at 
randomization; WAZ, weight for age z-scores at randomization; HAZ, height for age z-score at 













Table 6: Cox Proportional Hazards regression analysis evaluating the risk viremia (V L>50/copies/mL) 
associated with adherence (the amount of nevirapine returned, divided by the amount dispensed 
at the previous visit, expressed as a percentage) in the NVP group (n=96). 
Characteristic Crude Model Adjusted Model 
 HR 95%Cl P Value HR 95%Cl P Value 
Adherence (%)  0.98 0.93-1.06 0.64 0.99 0.93-1.04 0.65 
Age ≥18 months Reference   Reference   
Age <18 months 1.31 0.69-2.47 0.42 1.66 0.89-3.10 0.11 
Normal WAZ Reference   Reference   
Underweight 1.28 0.37-4.44 0.69 1.04 0.32-3.32 0.94 
Normal HAZ Reference   Reference   
Stunted 0.87 0.46-1.66 0.67 0.92 0.47-1.81 0.82 
VL ≤50 Reference   Reference   
VL 51-400 1.69 0.91-3.16 0. 09 2.12 1.12-3.99 0.02 
CD4% ≥25 Reference   Reference   
CD4% <25 1.21 0.61-2.49 0.59 1.06 0.56-2.01 0.85 
TB Treatment (No) Reference   Reference   
TB Treatment(Yes) 1.12 0.34-3.64 0.86 1.00 0.24-4.17 0.99 
HR, hazard ratio; Age, age at randomization; VL, viral load at randomization; CD4%, CD4+ T lymphocyte 
percentage at randomization; WAZ, weight for age z-scores at randomization; HAZ, height for age z-












Supplementary Figure 1A: Plasma lopinavir concentrations measured in samples taken at clinic visits. 
Lines connect the individual concentrations taken at serial visits (indicated in weeks after 
randomization) in each child in the lopinavir group. 
Supplementary Figure 1B: Plasma nevirapine concentrations plotted over time (weeks after 
randomization). The lines connect the individual concentrations of each child in the nevirapine group, 
which were measured in samples taken at serial clinic visits. 
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5.1 Abstract 
5.1.1 Aims: To quantify demographic and host genotypic effects on lopinavir (LPV) disposition 
in HIV-positive children. 
5.1.2 Methods: Steady-state LPV pharmacokinetics were predicted using a population 
nonlinear mixed effects model. Using the final model we estimated individual clearance 
(CL/F), area under concentration time curve (AUC0-12) and minimum concentrations (Cmin). 
We explored associations between pharmacokinetic parameters and genotypes in selected 




5.1.3 Results: A one compartment model with absorption lag time best described 1683 LPV 
plasma concentrations in 237 children. There was an age-driven effect on relative 
bioavailability of LPV. After correcting for multiple testing, there was no statistically significant 
associations between LPV CL/F, Cmin or AUC0-12 and polymorphisms in ABCB1, CYP3A4, 
CYP3A5 or SLCO1B1.  
5.1.4 Conclusions: Relative bioavailability of lopinavir was driven by age in South African 
children. Genetic polymorphisms in candidate genes were not significantly associated with 
LPV pharmacokinetics. 
 
5.2 Introduction   
Lopinavir (LPV) co-formulated with ritonavir is recommended as first-line antiretroviral 
treatment (ART) in children infected with HIV in South Africa.  LPV has low oral bioavailability 
due its high first pass metabolism mediated by cytochrome P450 (CYP) 3A4, and is a substrate 
of efflux transporter P-glycoprotein (P-gp)1,2. Co-formulation with low-dose ritonavir leads to 
increased LPV exposure via inhibition of intestinal and hepatic CYP3A and P-gp, respectively3.  
LPV is characterized by large pharmacokinetic inter-individual variability, which in part can be 
explained by body weight, age, sex, orsomucoid plasma levels, drug-drug interactions, liver 
disease, pregnancy and host genetics4–7.  
Genetic polymorphisms in the CYP3A4 and A5 have been reported to affect  inter-individual 
variability in the absorption and disposition of several HIV protease inhibitors including LPV8–
11. Moreover, polymorphisms in the ABCB1 (which encodes Pg-p) have been reported to be  
associated with variability in absorption, disposition, drug response and toxicity of other PIs 




associated with higher plasma concentrations and virological response to nelfinavir whereas 
there was no association LPV pharmacokinetics(PK) 12,13. The SLCO1B1 521T→C(rs4149056) 
polymorphism has been associated with increased LPV trough concentrations in adult male 
patients and increased LPV area under concentration time curve (AUC) in children13,14. 
However the clinical importance of this polymorphism for LPV PK is uncertain. 
Studies of LPV to date have been performed largely in adults of European descent. The aim 
of the present study was to investigate whether genetic polymorphisms in ABCB1, CYP3A4, 
CYP3A5 and SCLO1B1 affect the steady-state PK of LPV in a cohort of South African children.  
 
5.3 Methods 
5.3.1 Study Population 
Plasma LPV concentrations were retrospectively analyzed in stored samples collected at clinic 
visits during the pre-randomization and post-randomization periods from participants of the 
NEVEREST2 trial15,16. Treatment responses during both phases have been previously 
described15,16.  The study population included HIV-positive children attending the Rahima 
Moosa Mother and Child Hospital, Johannesburg, South Africa. At baseline, treatment 
eligibility criteria included WHO stage III or IV disease, CD4+ lymphocyte percentage (CD4%) 
of less than 25% if younger than 12 months or less than 20% if older than 12 months, or 
recurrent (more than twice yearly) or prolonged (>4 weeks) hospitalization for HIV related 
complications. All children received 230/57.5 mg/m2 of ritonavir-boosted LPV (Kaletra® oral 
solution, Abbott laboratories, USA), 1 mg/kg of stavudine and 4 mg/kg of lamivudine as oral 
solutions every 12 hours. At each visit, drug doses were adjusted according to growth. The 





The children randomized into the NEVEREST2 study were accrued from a cohort of 323 
nevirapine-exposed children less than 24 months of age, who met clinical and immunologic 
criteria for treatment, and who initiated a LPV-based regimen as their first treatment 
regimen. Data from children in the NEVEREST2 study population were included in prior 
publications about immune reconstitution inflammatory syndrome17 and initial response to 
LPV-based antiretroviral therapy18. Data collected prior to starting LPV/r therapy included, 
age, sex, pre-treatment HIV plasma viral load (VL), pre-treatment CD4% and WHO stage. 
Weight-for-age z-score (WAZ) and height-for-age z-score (HAZ) collected pre-treatment and 
post-treatment initiation were calculated using World Health Organization (WHO) software. 
Blood samples for LPV concentration determination were collected during the pre-
randomization phase at clinic visits 12, 24, 36 and 52 weeks after starting treatment, and at 
unscheduled clinic visits. After randomization additional samples were collected at 0, 4, 8, 12, 
16, 20, 24, 36, 52, 64 and 76 weeks post-randomisation and at unscheduled clinic visits.  The 
time of blood sample collection was documented, as was the time of the morning dose of 
antiretrovirals, as reported by the caregiver. Caregivers were requested to return medication 
bottles at each visit. Bottles were weighed and the contents reconciled with the expected 
usage of each medication to determine the degree of adherence. Adherence was defined as 
returning less than ≤20% of the expected volume of any of the three drugs, whereas non-
adherence was defined as returning >20%. In children with tuberculosis (TB), concomitant TB 







5.3.2 Laboratory Analysis 
Plasma LPV concentrations were measured using validated liquid chromatography tandem 
mass spectrometry methods developed in the Division of Clinical Pharmacology, University of 
Cape Town, South Africa. An AB Sciex 4000 mass spectrometer was operated at unit 
resolution in the multiple reaction monitoring mode. The assay was validated over the 
concentration range of 0.16-20 mg/L. Inter- and intra-day coefficients of variation were below 
10% for all quality control concentrations. The assay laboratory, participates in the 
International Inter-laboratory Pharmacology Quality Control Program, the AIDS Clinical Trial 
Group. 
5.3.4 Genotyping 
Human DNA was extracted from buffy coats using the QIAsymphony DNA midi kit which 
utilises magnetic-particle technology to isolate and purify DNA. Targeted genotyping of 
CYP2A6 -48T→G (rs28399433) was done by TaqManTM (Applied Biosystems, Foster City, CA). 
Genotyping of SLCO1B1 521T→C (rs4149056) and SLCO1B1 rs4149032 was done as part of a custom 
designed MassARRAY® iPLEX Gold  (Sequenom Inc., San Diego, California, USA). Genotypes were 
confirmed by visual inspection of plots, and all samples were genotyped in duplicate. 
Additional genotyping was done by Illumina HumanCore Exome assay (Illumina, San Diego, 
CA).Each HumanCore Exome plate included a HapMap trio, as well as duplicates scattered 
across each plate for QC purposes. The average genotype call rate for each sample was 98.7%, 
and call rates for 93% of samples exceeded 98%. Genotyping was done at the Vanderbilt 
Technologies for Advanced Genomics (VANTAGE), by laboratory personnel with no 





5.3.5 LPV Model Development 
The population means and variances of LPV pharmacokinetic parameters at steady state were 
estimated using non-linear mixed-effects regression. NONMEM software version7.3 (ICON 
Development Solutions, Ellicott City, MD, USA) was used to fit the LPV concentration-time 
data using two-step estimation method : (i) first-order conditional estimation method with 
interaction was used to generate population typical parameters and support points from the 
empirical Bayes estimates (EBE); (ii) the nonparametric estimation was used to estimate the 
population probability of each support point19. LPV concentrations below 0.08 mg/L, were 
treated as values below the  limit of quantification (BLQ) samples using the M5 method, 
where all BQL observations are replaced by BQL/2 as suggested by Beal et al 20.  PsN 4.6.8, 
Pirana and Xpose were used to facilitate the model building process and for diagnosing the 
model. The stepwise model building process was guided by differences in the objective 
function value (OFV; proportional to -2 log likelihood), inspection of goodness of fit plots and 
visual predictive checks, biological plausibility and clinical relevance. The differences of >3.84 
drop in OFV between two nested models after adding one parameter to the model was 
considered significant. Nonparametric bootstrap (n=200) was used to evaluate the stability 
and robustness of final parameters estimates of the model. Both LPV minimum 
concentrations (Cmin) and AUC were calculated using model derived EBE for individual 
parameters for each sampling occasion and patient.  
One or two compartment disposition models with first order absorption and elimination were 
tested, as well as delayed absorption using previously published models21,22. The inter-
individual (IIV) and inter-occasion (IOV) variability of LPV pharmacokinetic parameters were 




proportional to the typical value, and is reported as %CV. Correlation between of 
pharmacokinetic parameters were also investigated especially at the IIV level.   Residual 
unexplained variability (RUV) was tested using the combined proportional (PROP) and 
additive (ADD) structure. Implausible outliers were identified using visual inspections and 
excluded based on normalised prediction distribution errors (NPDE >2.5).  
 
5.3.6 Covariate Model 
Clearance (CL/F) and volume (V/F) parameters were scaled allometrically at early stage as 
previously suggested23. Maturation on CL/F was tested using exponential or sigmoidal 
function with or without the Hill coefficient models. Other covariates tested include sex and 
concomitant TB treatment.  
5.3.7 Statistical Analysis 
Genetic associations were tested for significance against model derived PK parameters CL, 
AUC and Cmin. Geometric means were calculated for each individual for all PK parameters and 
were used in the subsequent analysis. Bonferroni correction was used to account for multiple 
testing. Hardy-Weinberg equilibrium was assessed using exact tests for all genotypes. Data 
was analysed using Plink version 1.90(http://pgnu.mgh.harvard.edu/~purcell/plink).  
Haplotypic blocks were defined using the D’ confidence intervals method in Haploview24 and 
haplotype phases were inferred using the standard E-M algorithm in PLINK25. Linkage 








5.4.1 Study Population 
Pharmacokinetic data was available in 237 children with a median of 2 samples per child, and 
a total of 487 plasma samples during the pre-randomization phase. Post-randomization, 1134 
plasma samples from 99 children with a median of 8 samples per child were available for 
pharmacokinetic analysis. Of the 237 children, 176 were successfully genotyped and were 
analysed further. Table 1 presents the characteristics of the study population. 
5.4.2 Genotyping 
Among the 237 study participants, 100 polymorphisms (27 in ABCB1; 6 in CYP3A4; 10 in 
CYP3A5; 59 in SLCO1B1) were genotyped in 174 patients, of which 21 were monomorphic. 
The remaining 79 polymorphisms were in Hardy-Weinberg equilibrium (HWE) based on the 
Bonferroni adjusted P value threshold of 0.0005; eight had unadjusted P values of <0.05 
(SCLO1B1 rs1084178, P=0.003; SLCO1B1 rs7967354, P=0.01; SLCO1B1 rs4149008, P=0.02; 
SLCO1B1 rs4140389, P=0.02; ABCB1 rs6465118, P=0.03; SLCO1B1 rs4149009, P=0.03; CYP3A4 
rs28451617, P=0.04; ABCB1 rs10225473, P=0.05). Supplementary Table 1 presents minor 
allele frequencies, genotype frequencies and HWE P-values of the 100 polymorphisms in 176 
patients. We did not observe any strong LD association (r2>0.80) with ABCB1 3435CT 
(rs1045642) and 4036AG (rs3842) and other polymorphisms (Supplementary Figure 1). 
Furthermore, no strong LD association with polymorphisms in the CYP3A4 were observed 
(Supplementary Figure 2). In CYP3A5, there was a strong LD association between rs1859690, 
rs15524 and rs10211 or rs15524 and rs10211. There was a strong LD between rs10256106 
and rs10264272 (Supplementary Figure 3). There was no strong LD association with between 




and other genotypes. SLCO1B1 463CA (rs11045819) was in LD (r2 >0.6) with rs11045852, 
rs11045854, rs74064211, rs74064213 and rs11045863 (Supplementary Figure 4).    
5.4.3 LPV Model Description 
LPV pharmacokinetics were best described using a one compartment model with first order 
absorption and elimination. Final model estimates of the PK parameters are presented in 
Table 2.  Allometric scaling based on body weight on both CL/F and V/F improved the model 
(Equations 1.1 and 1.2). Inclusion of sex did not improve the model. Our model did not find a 
maturation effect on CL/F, but there was an age-driven effect on bioavailability (Figure 1A), 
which was described using a sigmoidal model (Equation 2). Bioavailability was 60% after 3 
months and reached 90% after 56 months. Concomitant TB treatment increased CL of LPV by 
59.5% (Figure 1B). The correlation between IIV CL and V was not supported by the data.  
The absorption parameters were not well estimated in our model and therefore were fixed 
to the values reported in the literature21,22 and this improved the stability of the model. We 
did not have intravenous data so we could not estimate bioavailability and so we fixed to it 1 
and IIV and IOV were estimated. We derived individual estimates for CL/F, Cmin and AUC from 
our final model and used in the subsequent analysis. 
5.4.4 Model Evaluation  
Visual predictive checks (500 simulations) for the final LPV model is shown in Figure 2. The 
5th, 50th and 95th percentiles of the data are in agreement with the 95% confidence interval 
of each percentile of the simulated data, supporting adequacy of the model. Bootstrap results 





5.4.5 Association between Genetic Polymorphisms and Model Derived CL/F, AUC0-12 and 
Cmin  
A total of 131 individuals with genotype and phenotype were included in the analysis. Table 
3 presents a summary of data for LPV PK and genotype. The pharmacokinetic data (CL/F, Cmin, 
and AUC) were not normally distributed and therefore individual geometric means were 
calculated and used for subsequent analysis. The median Cmin was 4.27(3.42-5.29) mg/L and 
the median AUC0-12 was 113.31(94.32-134.28) mg.h/L. There was no significant association 
between any polymorphism and LPV CL, Cmin or AUC, after adjusting for multiple comparisons 
(Bonferroni P-value of 0.0005) (Table 3). Without adjusting for multiple comparisons, there 
were nominally significant associations with LPV CL/F and  ABCB1 rs10267099 [β:-0.10(-0.17 
to -0.02, P= 1.71 x 10-02)], CYP3A4 rs473706 [β:-0.05(-0.10 to -0.004, P= 3.54 x 10-02)], and 3 in  
SLCO1B1 rs73250843 [β:0.12 (0.04-0.19, , P= 4.04 x 10-03)], rs11045819 [β:-0.08(-0.15 to -0.01 
P= 2.85 x 10-02], and rs4149032 [β:-0.05(-0.10 to -0.003, P= 3.91 x 10-02)]).  
We found nominally significant associations between LPV Cmin and SLCO1B1 rs112403792 
[β:0.73(0.30-1.16, P=1.12 x 10-03)], rs11045819 [β:0.78(0.25-1.30, P=4.35 x 10-03)], 
rs4149057[β:0.72(0.22-1.21, P=5.06 x 10-03)], rs7975594 [β:0.70(0.07-1.32, P= 3.02 x 10-02)], 
rs2306283[β:0.52(0.05-0.99, P= 3.13 x 10-02)], and rs1000691 [β:-0.40(-0.78 to -0.02, P= 4.02 
x 10-02)], rs112108376 [β:0.61(0.02-1.19, P= 4.02 x 10-02)], without adjustment for multiple 
comparisons.  
Lastly we found nominal associations with LPV AUC and seven SLCO1B1 polymorphisms in the 
gene (rs112403792[β:16.60(7.17-26.04, P=7.58 x 10-04)], rs11045819 [β:16.86(5.29-28.43, 
P=4.99 x 10-02)],  rs4149057 [β:15.69(4.80-26.58, P=5.49 x 10-02)], rs2306283 [β:12.11(0.72-
22.50, P=2.39 x 10-02)],  rs7975594 [β:15.26(1.47-29.05, P=3.19 x 10-02)], rs112108376 





5.5 Discussion  
This study evaluated associations between of CYP3A4, CYP3A5, ABCB1 and SLCO1B1 
polymorphisms on and LPV PK in a cohort of South African children. A model based approach 
was used to satisfactorily describe LPV PK. A one compartment with first order absorption, 
delay and linear elimination, including body weight effects on CL/F and V/F described LPV PK. 
We also found an age-driven effect on relative bioavailability and an effect of concomitant TB 
therapy effect on CL/F, similar to previous reports21,26.  Our model estimates for both CL/F 
and V/F were consistent with values in previous studies21,22,27. We also found  results of model 
derived Cmin and AUC0-12 similar to those in the literature28. Our dataset was sparse (1 sample 
per occasion) and we had limited data in the absorption phase, hence we could not estimate 
both absorption rate constant (KA) and absorption lag time (ALAG). Nonetheless, both inter-
individual and inter-occasion variability for both parameters were well estimated in our 
model.      
We used candidate gene approach to evaluate associations between polymorphisms in 
ABCB1, CYP3A4, CYP3A5 and SLCO1B1 genes and LPV PK. LPV is a substrate of SLCO1B1, and 
at least one genetic variant is known to affect LPV PK. Indeed reports have shown that 
521T→C (rs4149056) is associated with increased plasma LPV concentrations4,14,29,30. In our 
study, we found no significant association between 56 polymorphisms in SLCO1B1 and LPV 
CL/F, Cmin and AUC0-12 after adjusting for multiple comparisons. Specifically, we found no 
association between SLCO1B1 521T→C (rs4149056) and LPV PK (p-values 0.47, 0.67 and 0.70 
for CL, Cmin and AUC0-12, respectively. This is mostly likely due to the low frequency of the 
521CC allele. Only 1 patient had heterozygous SLCO1B1 521CT genotype and the rest had wild 




We found nominally significant negative association between SLCO1B1 rs4149032 and LPV 
CL/F, but no associations were found between this polymorphism and LPV Cmin or AUC0-12. 
These data are in contrast with a previous report, which showed an association between 
SLCO1B1 rs4149032 and LPV PK4. This polymorphism was common in our population (MAF 
21%). Therefore, the lack of an association cannot be attributed to low frequency. We also 
found a nominal negative association between SLCO1B1 463C→A (rs11045819) and LPV CL/F, 
with positive association with LPV Cmin and AUC0-12. These data are in contrast with a previous 
report, which showed an association between SLCO1B1 rs4149032 or 463C→A (rs11045819) 
and increased LPV CL/F4. 
We found nominal association between SLCO1B1 388A→G (rs2306283) and increased Cmin 
and AUC0-12. This is in contracts to previous reports which found no association between this 
polymorphism and LPV concentrations in children13 or adults14.   We found trends between 
SLCO1B1 rs112403792 and rs4149057 with increased LPV Cmin and AUC0-12. There are no 
previous reports regarding these trends and these polymorphisms. 
There was no significant association between polymorphisms in ABCB1 and LPV CL/F, Cmin and 
AUC0-12 after adjusting for multiple comparisons, similar to previous reports in  children13 or 
adult studies31.  We found nominally significant association of rs10267099 with LPV CL/F. This 
association has not been reported.  
In our study neither polymorphisms in the CYP3A4 and/or CYP3A5 genes were associated with 
LPV CL, Cmin and AUC0-12 after adjusting for multiple comparisons. Our results were consistent 
with previously published data on the lack of effect of polymorphisms in both genes on LPV 




In summary, this is the first study to quantify effects of ABCB1, CYP3A4, CYP3A5 and SLCO1B1 
polymorphisms on LPV PK. These results increase our understanding of factors that influence 
LPV PK variability. Effects of interaction between these genes remain to be elucidated.   
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Table 1: Summary of the All the Data of Participants Pre-and-Post Randomization 
Characteristic Median(IQR) Range 
Age(Months) 32(21-44) 4-74 
BW(Kg) 12.5(10.5-14.65) 4.03-27.65 
Dose(mg/m2) 226 222-232 
CD4+(%) 29(20.7-34.8) 7.87-64 























Table 2: Final Model Parameter Estimates 
Parameter Typical Values (Of Typical Child Weighting 13 
Kg)  
Bootstrap Values[Median(97.5%CI)] 
CL/F[L/hr] 1.05 1.04(0.68-1.61) 
V/F[L] 8.03 8.03(6.51-10.88) 
Ka[hr-1] 0.74 FIX -------- 
Alag[hr] 0.37 FIX -------- 
HILL 1 FIX  
PMA50[months]  26.7 26.51(9.68-31.75) 













































Alag, absorption lag time; Add, additive error; CL/F, clearance; F, bioavailability; IIV, inter-individual 
variability; IOV, inter-occasion variability; KA, absorption rate constant; PMA50, post menstrual age; Prop, 





Table 3: Genetic associations with lopinavir CL, Cmin and AUC 
 
LPV CL/F LPV Cmin AUC 
CHR SNP(Gene) β(95%CI,P Value) CHR SNP(Gene) β(95%CI,P Value) CHR SNP(Gene) β(95%CI,P Value) 
12 rs73250843 
(SLCO1B1) 
0.12(0.04-0.19,P=0.004) 12 rs112403792 
(SLCO1B1) 





-0.10(-0.17 to -0.02, P= 0.02) 12 rs11045819 
(SLCO1B1) 





-0.08(-0.15 to -0.01,P=0.03) 12 rs4149057 
(SLCO1B1) 





-0.05(-0.10 to -0.004,P=0.03) 12 rs7975594 
(SLCO1B1) 





-0.05(-0.10 to -0.003,P=0.04) 12 rs2306283 
(SLCO1B1) 





-0.08(-0.17 to 0.002,P=0.06) 12 rs1000691 
(SLCO1B1) 





0.06(-0.002 to 0.13,P=0.06) 12 rs112108376 
(SLCO1B1) 
0.61(0.02-1.19, P=0.05) 12 rs1000691 
(SLCO1B1) 
-8.99(-17.35 to -0.64, P=0.04) 
12 rs112403792 
(SLCO1B1) 
-0.06(-0.12 to 0.002,P=0.06) 12 rs6487213 
(SLCO1B1) 





0.05(-0.003 to 0.11, P=0.06) 7 rs113539362 
(CYP3A5) 
0.52(-0.06 to 1.10, P=0.08) 7 rs473706 
(CYP3A4) 
7.54(-0.004 to 15.08, P=0.05) 
12 rs11045852 
(SLCO1B1) 
-0.08(-0.17 to 0.006,P=0.07) 7 rs1002204 
(ABCB1) 
-0.39(-0.87 to 0.09, P=0.11) 7 rs10267099 
(ABCB1) 




Figure 1: Covariate associated relationships with LPV PK Parameters, A age related changes on LPV 













Supplemental Table S1: Minor allele frequencies of the 100 polymorphisms in 174 South 
African Children 





ABCB1 rs1002204 7 T G 0.12 1/40/135 0.47 
ABCB1 rs10225473 7 G A 0.14 7/36/133 0.05 
ABCB1 rs10248420 7 A G 0.34 19/83/74 0.62 
ABCB1 rs10260862 7 C G 0.33 21/74/79 0.61 
ABCB1 rs10267099 7 G A 0.09 0/30/146 0.62 
ABCB1 rs10276036 7 C T 0.15 4/46/126 1 
ABCB1 rs1045642 7 T C 0.09 3/26/147 0.15 
ABCB1 rs11760837 7 C T 0.20 9/52/115 0.34 
ABCB1 rs17064 7 T A 0.16 4/50/122 1 
ABCB1 rs17209837 7 C T 0.27 11/73/92 0.57 
ABCB1 rs1858923 7 C T 0.07 0/23/153 1 
ABCB1 rs1882478 7 C T 0.31 22/66/88 0.11 
ABCB1 rs1922240 7 C T 0.24 7/69/100 0.30 
ABCB1 rs1989830 7 T C 0.27 12/71/93 0.85 
ABCB1 rs2229107 7 T A 0.12 0/42/134 0.14 
ABCB1 rs2235023 7 A G 0.31 18/73/85 0.72 
ABCB1 rs2235033 7 T C 0.46 35/93/48 0.45 
ABCB1 rs28364275 7 C T 0.10 1/32/143 1 
ABCB1 rs28364277 7 T C 0.12 2/39/135 1 
ABCB1 rs28364278 7 I D 0.13 2/41/133 0.74 
ABCB1 rs3747806 7 C T 0.27 17/62/97 0.13 
ABCB1 rs3789243 7 A G 0.35 16/88/69 0.13 
ABCB1 rs3842 7 C T 0.18 4/57/115 0.45 
ABCB1 rs4148751 7 G A 0.26 10/70/96 0.69 
ABCB1 rs6465118 7 A G 0.23 4/73/99 0.03 
ABCB1 rs6961419 7 C T 0.48 35/98/43 0.17 
ABCB1 rs8187789 7 A G 0.05 0/19/157 1 
CYP3A4 rs17161886 7 C A 0.25 9/69/97 0.55 
CYP3A4 rs28451617 7 T C 0.15 8/38/130 0.04 
CYP3A4 rs3735451 7 A G 0.13 3/40/133 1 
CYP3A4 rs473706 7 T C 0.25 14/58/103 0.16 
CYP3A4 rs651430 7 T C 0.13 3/38/135 0.74 
CYP3A4 rs667660 7 A C 0.24 10/66/100 1 
CYP3A4 rs7801671 7 A C 0.22 7/62/107 0.82 
CYP3A5 rs10211 7 A G 0.32 21/70/85 0.30 
CYP3A5 rs10256106 7 G C 0.18 8/47/121 0.21 
CYP3A5 rs10264272 7 T C 0.20 9/51/116 0.34 
CYP3A5 rs113539362 7 A G 0.09 0/30/146 0.62 




CYP3A5 rs1859690 7 A G 0.32 20/72/84 0.49 
CYP3A5 rs2687134 7 C A 0.37 25/79/71 0.75 
CYP3A5 rs6977165 7 C T 0.16 3/51/122 0.58 
CYP3A5 rs773049150 7 I D 0.10 2/32/142 0.70 
CYP3A5 rs8175345 7 T C 0.10 1/33/142 1 
SLCO1B1 rs1000691 12 A G 0.18 9/44/123 0.07 
SLCO1B1 rs10841763 12 C T 0.13 3/41/132 1 
SLCO1B1 rs10841778 12 G T 0.13 0/31/145 0.37 
SLCO1B1 rs10841781 12 G A 0.28 6/87/83 0.003 
SLCO1B1 rs10841782 12 T C 0.18 3/59/114 0.21 
SLCO1B1 rs11045819 12 A C 0.08 1/27/148 1 
SLCO1B1 rs11045852 12 G A 0.06 0/21/155 1 
SLCO1B1 rs11045854 12 A G 0.06 0/21/155 1 
SLCO1B1 rs11045863 12 T C 0.06 0/22/154 1 
SLCO1B1 rs11045917 12 A G 0.05 0/17/158 1 
SLCO1B1 rs11045919 12 T G 0.49 45/83/48 0.45 
SLCO1B1 rs11045920 12 A C 0.08 1/25/150 1 
SLCO1B1 rs112108376 12 A G 0.08 1/25/150 1 
SLCO1B1 rs112403792 12 T C 0.14 3/44/129 1 
SLCO1B1 rs113341884 12 T G 0.05 0/17/157 1 
SLCO1B1 rs11568557 12 C G 0.08 0/27/149 0.60 
SLCO1B1 rs11568565 12 A G 0.08 1/27/148 1 
SLCO1B1 rs11835045 12 C T 0.27 11/73/89 0.57 
SLCO1B1 rs12317843 12 T C 0.46 40/83/53 0.54 
SLCO1B1 rs12578392 12 C T 0.23 8/64/104 0.83 
SLCO1B1 rs2010668 12 A C 0.24 11/63/102 0.84 
SLCO1B1 rs2291075 12 C T 0.44 37/81/58 0.36 
SLCO1B1 rs2306283 12 A G 0.13 3/39/134 1 
SLCO1B1 rs34671512 12 C A 0.11 3/34/139 0.47 
SLCO1B1 rs4140389 12 C A 0.49 49/71/53 0.02 
SLCO1B1 rs4149006 12 T G 0.15 0/53/123 0.02 
SLCO1B1 rs4149008 12 G A 0.39 34/68/74 0.02 
SLCO1B1 rs4149009 12 C T 0.31 23/63/90 0.03 
SLCO1B1 rs4149014 12 G T 0.05 0/16/160 1 
SLCO1B1 rs4149032 12 C T 0.21 10/55/110 0.37 
SLCO1B1 rs4149050 12 T C 0.43 37/76/63 0.12 
SLCO1B1 rs4149056 12 C T 0 0/1/175 1 
SLCO1B1 rs4149057 12 C T 0.1 1/34/141 1 
SLCO1B1 rs4149063 12 T G 0.25 12/65/99 0.84 
SLCO1B1 rs4149087 12 G T 0.23 8/64/104 0.83 
SLCO1B1 rs4149088 12 G A 0.23 8/64/104 0.83 
SLCO1B1 rs57040246 12 T C 0.04 1/12/163 0.24 
SLCO1B1 rs6487213 12 C T 0.3 17/71/88 0.59 




SLCO1B1 rs7302619 12 A G 0.27 10/75/91 0.34 
SLCO1B1 rs73241802 12 A C 0.08 0/28/148 0.60 
SLCO1B1 rs73250843 12 A G 0.07 1/23/152 0.60 
SLCO1B1 rs74064211 12 T C 0.06 0/21/155 1 
SLCO1B1 rs74064213 12 G A 0.05 0/19/157 1 
SLCO1B1 rs75967989 12 G A 0.08 1/26/149 1 
SLCO1B1 rs78801100 12 T C 0.06 1/20/153 0.51 
SLCO1B1 rs7966613 12 G A 0.17 6/48/122 0.60 
SLCO1B1 rs7967354 12 T C 0.39 35/68/73 0.01 
SLCO1B1 rs7975594 12 C T 0.06 1/18/157 0.44 
SLCO1B1 rs7976818 12 T C 0.22 9/59/108 0.83 
SLCO1B1 rs852550 12 G A 0.28 15/70/91 0.85 
SLCO1B1 rs981262 12 C T 0.48 39/91/46 0.76 
SLCO1B1 rs999278 12 A C 0.04 0/13/163 1 
SLCO1B7 rs111512821 12 C T 0.08 0/28/148 0.60 
SLCO1B8 rs11045927 12 G T 0.22 35/91/50 0.65 
SLCO1B9 rs11045906 12 G A 0.46 7/63/106 0.66 
CHR, chromosome; SNP, single nucleotide polymorphism 
 





Supplementary Figure 2: Shows the linkage disequilibrium of ABCB1 gene 
 
 
















𝑪𝑪𝑪𝑪 𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭⁄ = 𝑪𝑪𝑪𝑪 𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭⁄ ∗ (𝑻𝑻𝑻𝑻𝑻𝑻𝑻𝑻
𝟏𝟏𝟏𝟏.𝟓𝟓 )𝟎𝟎.𝟕𝟕𝟓𝟓                           (1.1) 
𝑽𝑽 𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭⁄ = 𝑽𝑽 𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭⁄ ∗ (𝑻𝑻𝑻𝑻𝑻𝑻𝑻𝑻
𝟏𝟏𝟏𝟏.𝟓𝟓 )𝟏𝟏                                     (1.2) 
Equation 2 
PMA    = AGE + (9/12) 
TVPMA   = MEDAGE +  (9/12) 
𝑭𝑭 = 𝟏𝟏/ �𝟏𝟏 + 𝑷𝑷𝑷𝑷𝑷𝑷
𝑻𝑻𝑽𝑽𝑷𝑷𝑷𝑷𝑷𝑷+𝑷𝑷𝑷𝑷𝑷𝑷𝟓𝟓𝟎𝟎
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6.1 Abstract 
6.1.1 Aims: To assess whether clinical factors or host genotype are associated with nevirapine 
pharmacokinetics of nevirapine (NVP) at steady-state in HIV-positive South African children. 
6.1.2 Methods: Steady-state population pharmacokinetic parameters for NVP were 
estimated using nonlinear mixed-effects modelling. The final model was used to derive 
individual oral clearances (CL/F), minimum concentrations (Cmin) and area under the 
concentration time curves (AUC0-12). We explored relationships with genotypes in selected 





6.1.3 Results: A total of 95 children were included in the analysis. Nevirapine 
pharmacokinetics were best described by a one-compartment disposition model coupled 
with elimination through a well-stirred liver model accounting for first-pass effect and transit 
absorption.  Among 60 children with genotype data, there were 16 CYP2B6 extensive 
metabolizer, 40 CYP2B6 intermediate metabolizer and 4 CYP2B6 slow metabolizer genotypes, 
and based composite CYP2B6 15582/516/983 genotypes. By univariate analysis, several 
CYP2B6 and genotypes were associated with NVP pharmacokinetics: CYP2B6 516G→T and 
983T→C were associated with CL/F. CYP2B6 983T→C was associated with Cmin and AUC0-12 in 
a univariate analysis and after adjusting for CYP2B6 516G→T. CYP2B6 15582C→T was 
associated with and CL/F, Cmin and AUC0-12 after adjusting for CYP2B6 516G→T and 983T→C. 
Polymorphisms in ABCB1 and CYP3A5 were independently associated with CL/F, Cmin and 
AUC0-12         
6.1.4 Conclusions: In HIV-positive Black South African children, CYP2B6 genotype was 
associated with NVP pharmacokinetics 
 
6.2 Introduction 
Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor used as part of  
combination antiretroviral therapy (ART) for HIV-1 infection in adults and children in 
resource-limited settings1.   The success of NVP in African nations has been partly  due its 
affordability and availability in fixed-dose combinations2–4. Though efficacious and safe, NVP 
has a low genetic barrier to resistance, and sub-therapeutic drug exposure can increase the 
risk of drug resistance and treatment failure5,6. Nonetheless, NVP still has several advantages 





fewer potential drug-drug interactions, particularly with anti-tuberculosis medications. Also, 
the bioavailability of NVP is not affected by food intake and does not cause significant central 
nervous system compared adverse events, unlike the non-nucleoside reverse transcriptase 
inhibitor efavirenz7.   
Antiretroviral agents, including NVP are characterised by considerable inter-individual 
variability in metabolism, some of which is due to genetic differences in drug-metabolising 
enzymes and efflux/influx transporters. NVP is metabolised predominantly by cytochrome 
(CYP) 2B6 and CYP3A isoforms8. Previous studies have shown an association between the 
CYP2B6 516G→T (rs3745274) polymorphism and NVP concentrations in children and adults9–
11. Patients homozygous for CYP2B6 516TT genotype had lower oral clearance and higher 
trough concentrations9,12. A less frequent CYP2B6 polymorphism, 983T→C (rs28399499), has 
been associated with increased steady-state exposure of NVP13. Both CYP2B6 516T and 983C 
are more frequent with African ancestry than with European ancestary14,15. A genome wide  
association study of White, Black and Hispanic adults in the United States found an 
independent association between a third polymorphism, CYP2B6 15582C→T (rs4803419) and 
efavirenz  trough concentrations 16. Subsequently, a study in South African adults and children 
showed that the composite genotype defined by CYP2B6 516G→T, 983T→C and 15582C→T 
was associated with increased plasma efavirenz exposure17. CYP2B6 15582C→T has been 
associated with slower clearance (CL/F) of NVP in Cambodian adults18, and longer time for 
plasma concentrations to fall below the protein-adjusted IC50 in women of African ancestry19.  
The impact of CYP3A4 and CYP3A5 genetic polymorphisms on NVP pharmacokinetics is less 





The aims of the present study were to characterise the steady-state population 
pharmacokinetics of NVP in South African children, and to quantify associations between 
polymorphisms in selected genes and NVP disposition in this patient population.  
 
6.3 Methods 
6.3.1 Study Participants 
Pharmacokinetics of NVP were retrospectively analyzed in samples collected from 
participants of the NEVEREST2 trial at clinic visits during the post-randomization period20,21. 
The NEVEREST2 trial was a randomized, open-label clinical trial investigating treatment 
options for NVP exposed children who initiated protease inhibitor-based ART when less than 
24 months of age. Children eligible for randomization were HIV-positive, attending the 
Rahima Moosa Mother and Child Hospital in, Johannesburg, South Africa, and who achieved 
plasma HIV-1 RNA ≤400 copies/mL for at least 2 consecutive visits on lopinavir/ritonavir 
(LPV/r) based ART. Once criteria for randomization were met, the children were randomized 
1:1 to continue their LPV/r regimen or switch from LPV/r to NVP. NVP (Viramune® oral 
solution, Boehringer Ingelheim) was administered at 120 mg/m2 once daily for the first 2 
weeks and thereafter at 200mg/m2 every 12 hours thereafter. Lamivudine and stavudine 
were used as concomitant nucleoside reverse transcriptase inhibitors. Doses were adjusted 
at each visit according to the growth of the children. Additional adherence counselling was 
offered, including specific instructions concerning the lead-in schedule and possible adverse 
effects of switching to NVP.  
  
Data collected at randomization included age, sex, plasma HIV-1 RNA and CD4+ T lymphocyte 





calculated using WHO software20.  Blood samples for measuring NVP concentrations were 
collected at randomization at 4, 8, 12, 16, 20, 24, 36, 52, 64 and 76 weeks post-randomisation 
and at unscheduled clinic visits. The time of blood sample collection was documented, as was 
the time of the morning dose of antiretrovirals, as reported by the caregiver. In children who 
were diagnosed with tuberculosis, concomitant tuberculosis treatment was recorded at each 
visit. 
6.3.2 Quantification of Nevirapine in Plasma 
Plasma NVP concentrations were assayed using validated liquid chromatography tandem 
mass spectrometry methods developed in the Division of Clinical Pharmacology, University of 
Cape Town, South Africa. An AB Sciex 4000 mass spectrometer was operated at unit 
resolution in the multiple reaction monitoring mode. The validated concentration range for 
NVP was 0.1 mg/L to 15 mg/L. Inter- and intra-day coefficients of variation were below 10% 
for all quality control concentrations. The laboratory, at which the concentrations were 
assayed, participates in the International Inter-laboratory Pharmacology Quality Control 
Program of, the AIDS Clinical Trial Group22. 
6.3.3 Genotyping  
Human DNA was extracted from buffy coats using the QIAsymphony (QIAGEN, Hilden, 
Germany) DNA midi kit which utilises magnetic-particle technology to isolate and purify DNA. 
Targeted genotyping of CYP2B6 516G→T (rs3745274), CYP2A6 -48T→G (rs28399433) and 
CYP2B7 rs4124633 were done by TaqManTM (Applied Biosystems, Foster City, CA). Genotyping 
of CYP2B6 983T→C (rs28399499), 15582C→T (rs4803419) was done as part of a custom 
designed MassARRAY® iPLEX Gold (Sequenom Inc., San Diego, California, USA). Genotypes 
were confirmed by visual inspection of plots, and all samples were genotyped in duplicate. 





(Illumina, San Diego, CA). All HumanCore Exome plates contained a HapMap trio, as well as 
duplicates scattered across each plate for QC purposes. Call rates for 93% of samples 
exceeded 98%, and the average call rate for the project was 98.7%. All genotyping was done 
at the Vanderbilt Technologies for Advanced Genomics (VANTAGE). Laboratory personnel 
with no knowledge of clinical data performed genotyping.  
6.3.4 Population Pharmacokinetic Analysis 
A population pharmacokinetic analysis of steady state NVP plasma concentration data was 
performed to estimate average population pharmacokinetic parameters and interpatient 
variability. Non-linear mixed effects modelling software NONMEM 7.323 was used and 
concentration-time data was fitted using a two-step estimation method (i) first-order 
conditional estimation method with interaction was used to generate support points from 
the empirical bayes estimates (EBES); (ii) the nonparametric estimation was used to estimate 
the population probability of each support point. PsN 4.6.8, Pirana 2.9.6 and Xpose 4.5.3 were 
used to facilitate the model-building process and for model assessment24. A stepwise model 
building process was guided by changes in the objective function value (OFV; equivalent to -
2 log likelihood), inspection of goodness-of fit plots and visual predictive checks (VPC), 
biological plausibility and clinical relevance. A >3.84 point drop in OFV between two nested 
models after adding one parameter was considered statistically significant (p≤0.05, chi square 
distribution with one degree of freedom). Nonparametric bootstrap (n=200) was used to 
evaluate the stability and robustness of final parameter estimates of the model. Both NVP 
Cmin and AUC0-12 were calculated using model-derived empirical Bayes estimates (EBE) of 







6.3.5 Structural Model 
We used a model previously developed by Bienczak et al11. One or two compartment 
disposition models with first-order absorption and elimination were tested, as well as delayed 
and transit-compartment absorption25. Hepatic elimination of NVP was tested using a 
previously described semi-mechanistic well-stirred model26. The hepatic model assumed the 
following parameters: i) fraction unbound (fu) of NVP of 40%, hepatic plasma flow (QH) of 50 
L/h27 and a liver volume (VH) of 1L26, allometrically scaled for a typical individual weighing 70 
kg. Inter-individual (IIV) and inter-occasion variability (IOV) were tested on all 
pharmacokinetic parameters assuming a log-normal distribution.  Residual unexplained 
variability (RUV) was tested using the combined proportional (PROP) and additive (ADD) 
model structures. Samples below the limit of quantification (BLQ) were handled using the M5 
method28 and implausible outliers were identified using visual inspections and excluded 
based on normalised prediction distribution errors (NPDE >2.5). 
6.3.6 Covariate Model 
Clearance (CL/F) and volume (V/F) parameters were scaled allometrically at an early stage as 
previously suggested29. Maturation of intrinsic clearance (CLint) and pre-hepatic bioavailability 
(FPREH) were tested using power, exponential and sigmoidal functions with or without fixing 
the Hill coefficient29. Other covariates tested include sex and concomitant tuberculosis 
treatment.  
6.3.7 Statistical Analysis 
The model derived pharmacokinetic parameters CL/F, AUC and Cmin were used to test for 
genetic associations. Bonferroni correction was used to account for multiple testing. Hardy-
Weinberg equilibrium was assessed using exact tests. Composite CYP2B6 516/983/15582 





15582CT-516-GG-983-TT), intermediate metaboliser (15582TT-516GG-983TT, 15582CC-
516GT-983TT, 15582CC-516GG-983CT, 15582CT-516GT-983TT or 15582CT-516GG-983CT), 
slow metaboliser (15582CC-516TT-983TT, 15582CC-516GT-983CT or 15582CC-516GG-
983CC). For exploratory analyses, an additional 61 polymorphisms (in ABCB1, CYP2B6, 
CYP3A4, and CYP3A5) were analyzed.  All tests used a 5% two-sided significance level. Data 
was analysed using Plink version 1.90 (http://pgnu.mgh.harvard.edu/~purcell/plink).   
Haplotypic blocks were defined using the r2 method in Haploview30 and haplotype phases 
were inferred using the standard E-M algorithm in PLINK31. Linkage disequilibrium (LD) plots 
and values were generated with Haploview (www.broad.mit.edu/mpg/haploview/).  
  
6.4 Results 
6.4.1 Study Participants 
Pharmacokinetic data were available from 96 children, from which 764 plasma samples were 
collected, with a median of 6 samples per child over a follow-up period of 3 to 196 weeks.  Of 
the 96 DNA samples, 60 were successfully genotyped and were included the subsequent 
analyses. Table 1 presents characteristics of the study population. 
6.4.2 Genetic Polymorphisms 
Among 60 children with genotype data, 66 polymorphisms were genotyped (28 in ABCB1, 1in 
CYP2A6, 21 in CYP2B6, 1 in CYP2B7, 7 in CYP3A4, 11 in CYP3A5). All genotypes were in Hardy-
Weinberg equilibrium (HWE) based on an adjusted Bonferroni P value threshold of 0.001, 
except CYP2B6 rs707265 (P=0.0009); three had unadjusted P values ≤ 0.05 (ABCB1 rs6465116, 
P=0.03; ABCB1 rs1022547, P=0.05; CYP3A4 rs2845161, P=0.04). Minor allele frequencies, 





composite CYP2B6 15582/516/983 genotype, there were 16 extensive metabolizer, 40 
intermediate metabolizer and 4 slow metabolizer genotypes. No polymorphisms were in 
strong LD with CYP2B6 516G→T (rs3745274), 983T→C (rs28399499) or 15582C→T (4803417), 
based on threshold of r2≥0.80 (Supplementary Figure 1). Furthermore, no strong LD 
association with ABCB1 3435C→T (rs1045642), 4036A→G (rs3842) and other polymorphisms 
were observed (Supplementary Figure 2).  No strong LD association with polymorphisms in 
the CYP3A4 were observed (Supplementary Figure 3). However, in CYP3A5, there was strong 
LD between rs1859690, rs15524 and rs10211 or rs15524 and rs10211 as well as rs10256106 
and rs10264272 (Supplementary Figure 4). 
6.4.3 Nevirapine Population Pharmacokinetic Model 
A one compartment disposition model best described NVP pharmacokinetics. A transit 
compartment was used to describe absorption, and elimination was described using a semi-
physiological hepatic extraction. The absorption parameters could not be estimated in our 
model due to sparseness of the data (1 sample per occasion) and were therefore fixed 
previously published values11. Table 2 presents final NVP population pharmacokinetic 
parameter estimates, their precision (obtained through non-parametric bootstrap) and 
inclusion of covariates and random effects based on statistical significance (drop in OFV value) 
and biological plausibility. Model adequacy was evaluated using GOF plots and VPC (Figure 
2A).  
The effect of body size was accounted for on all CL/F and V/F parameters and significantly 
improved the model fit (21 point drop in OFV). Implementing a well-stirred liver model 
resulted in a drop in OFV of 150 points, without adding extra parameters. CLint was used to 





because changes in the liver activity mechanistically also affected FH. FpreH was fixed to one, 
whereas BSV and BOV were estimated. Our model did not find an age driven effects on CLint. 
Age-driven differences were identified on FpreH using an exponential model (Figure 2B). FpreH 
was estimated to be 50.4% from older children, with a half-life of 0.84 years.  
BSV was identified for all parameters except for MTT. Absorption parameters KA and MTT 
displayed the largest BOV of all parameters, 40.2% and 244.1%, respectively. The combined 
error model (additive and proportional error) best described the RUV.    
6.4.4 Effects of ABCB1, CYP3A4, CYP3A5 and CYP2B6 Genetic Polymorphisms on Model-
Derived Nevirapine Indices  
Pharmacokinetic data were not normally distributed in 55 children with both phenotype and 
genotype, so we used geometric means for subsequent analysis. The median Cmin and AUC0-
12 were 4.67 mg/L (IQR 3.71- 5.77) and 48.03 mg.hr/L (IQR 38.66-57.91), respectively. 
Regarding NVP CL/F, in univariate (unadjusted) linear regression models, there were no 
significant associations with genotypes when using Bonferroni-adjusted P≤0.001. 
Nonetheless, we found nominal associations with  ABCB1 rs1002204 (β:0.32[0.05-0.59, P= 
2.29 x 10-2]), CYP2B6 983T→C (β:-0.26[(-0.50 to -0.02, P= 3.91 x 10-2]), 516G→T (-0.16[-0.31 
to -0.01, P= 4.15 x 10-2]), and rs7250597 (β:0.17[0.01-0.33, P= 4.20 x 10-2]) , CYP3A5 rs185690 
(β:-0.18[-0.34 to -0.01, P= 4.35 x 10-2])  and rs15524 (β:-0.18[-0.34 to -0.01, P= 4.35 x 10-2]), 
respectively. After adjusting for CYP2B6 516G→T, we found significant nominal associations 
between NVP CL/F and ABCB1 rs1002204 (β:-0.14[-0.28 to 0.01, P= 4.93 x 10-2]), CYP2B6 983 
T→C (β:-0.19[-0.33 to -0.04, P= 1.38 x 10-2]) and CYP2B6 15582C→T (β:-0.16[-0.31 to 0.01, P= 
4.84 x 10-2]). After adjusting for the CYP2B6 516/983 haplotype, we found a significant 
associations between NVP CL/F and all genotypes in the first model including CYP2B6 





CYP2B6 15582/516/983 haplotype, we found significant associations between NVP CL/F and 
above polymorphisms. Table 3 presents associations between genetic polymorphisms and 
NVP CL/F  
Regarding NVP Cmin (Table 4), we found a Bonferroni-adjusted (P≤0.001) significant 
association by using a linear regression  with CYP2B6 983 T→C (β:6.07(95%CI:3.14-9.01, P= 
1.65 x 10-4]), and nominal associations with CYP2A6 -48T→G (β:7.14[95%CI:1.92-12.37, P= 
9.83 x 10-3]), CYP2B7 rs4124633 (β:2.98[95%CI:0.30-5.65, P= 3.38 x 10-2]),  CYP3A5 rs10211 
(β:2.74[95%CI:0.54-4.94, P= 1.80 x 10-2]),  rs1859690 (β:2.70[95%CI:0.49-4.91, P= 2.03 x 10-2 
]),  rs15524(2.70[95%CI:0.49-4.91,P= 2.03 x 10-2]), and rs113539362 (β:4.44[0.51-8.36, P= 
3.09 x 10-2]). After adjusting for CYP2B6 516G→T, there was a strong association with NVP 
Cmin and CYP2B6 983T→C (β:3.24[95%CI:1.53-4.94, P= 4.83 x 10-4]) and CYP2A6 -48T→G 
(β:2.16[95%CI:0.27-4.05,  P= 2.94 x 10-2) but not with CYP2B6 15582C→T (β:1.71[95%CI:-0.34 
to 3.77, P= 0.11]). Adjusting for composite CYP2B6 516/983 genotype was associated with 
increased NVP Cmin across all genotypes in the initial model including CYP2B6 15582C→T (β: 
3.31[95%CI:1.28-5.35,P= 2.36 x 10-3]). Likewise, after adjusting for the composite 
CYP2B6 15582/516/983 haplotype, there were significant associations with the 
aforementioned polymorphisms. 
Regarding NVP AUC0-12, by univariate regression, (Table 5),there was a significant Bonferroni-
adjusted association with CYP2B6 983T→C (β:59.3[95%CI:30.6-88.2, P= 1.71 x 10-4]) and 
nominal associations with CYP2A6 -48T→G (69.6[195%CI:8.3-120.8, P= 1.02 x 10-2]), CYP2B7 
rs4124633 (β:29.3[95%CI:0.30-5.65, P= 3.30 x 10-2]), CYP3A5 rs10211 (β:26.9[95%CI:5.4-48.4, 
P= 1.77 x 10-2]), CYP3A5 rs1859690 (β:26.9[95%CI:5.4-48.4, P= 2.00 x 10-2]), 





82.2, P= 2.97 x 10-2]. After adjusting for CYP2B6 516G→T, there was a significant association 
with CYP2B6 983T→C (β:21.9[95%CI:9.6-34.2, P= 9.96 x 10-4]), and nominal associations with 
CYP2B6 rs8100458  β:15.7[95%CI:1.7-29.6, P= 3.23 x 10-2) and CYP2B6 15582C→T 
(β:15.1[95%CI:1.1-29.2, P= 4.02 x 10-2]), CYP2A6 -48T→G (β:15.5[95%1.9-29, P= 2.99 x 10-2]), 
and CYP2B7 rs4124633 (β:13.9[95%CI: 0.1-27.8, P= 5.48 x 10-2]). After adjusting for composite 
CYP2B6 516/983 genotype, there were significant associations with all polymorphisms in the 
initial model including CYP2B6 15582C→T (β:32.2[95%CI:11.9-52.3,P=2.93 x 10-3]). Similarly, 
after adjusting for composite CYP2B6 15582/516/983 haplotype, there were significant 
associations with the above polymorphisms. 
 
6.5 Discussion 
NVP remains one of the most widely prescribed drugs for treating HIV in resource limited 
settings. The present study characterised relationships between NVP pharmacokinetics and 
genetic polymorphisms in South African children. Our population pharmacokinetic model 
estimated allometrically-scaled oral clearance to be 2.08L/h, which was lower reported in 
previous study by our group  (than 3.8L/h11 )and lower than other studies in children and 
adults. V/F of 19.7L was comparable to previously published data11. Our model could not 
estimate the absorption parameters (absorption rate constant [KA], number of transits [NN] 
and mean transit time [MTT]) due to limited number of samples within the absorption phase. 
However, we found largest IOV in KA and MTT similar to previous results from our group11.  
We evaluated associations with genetic polymorphisms in ABCB1, CYP2A6, CYP2B7, CYP2B6, 
CYP3A4 and CYP3A5 using a candidate gene approach. Previous studies have shown 





CYP2B6 15582C→T has also been associated with NVP PK in Cambodian and African 
adults18,35.  Our study replicated this findings in black South African children. In the present 
study, minor allele frequencies of CYP2B6 516G→T, CYP2B6 983T→C, CYP2B6 15582C→T 
were 0.39, 0.11, 0.06, respectively, similar to a previous report from our group17.  By 
univariate analysis, ABCB1 rs1002204 and CYP2B6 rs7250597 were nominally associated with 
increased NVP CL/F, whereas CYP3A5 rs1859690, CYP3A5 rs15524, CYP2B6 516G→T and 
CYP2B6 983T→C were nominally associated with decreased NVP CL/F. The effect of 
CYP2B6 516G→T and CYP2B6 983T→C on NVP CL/F are consistent with previous reports in 
African adults36. After adjusting for CYP2B6 516G→T, there were nominal associations with 
ABCB1 rs1002204, CYP2B6 983T→C and CYP2B6 15582 C→T. Adjusting for composite CYP2B6 
516/983 or CYP2B6 15582/516/983 genotype, there were significant associations with the 
aforementioned genotypes.  
In a univariate analysis, we found significant associations between NVP Cmin and 
CYP2B6 983T→C and nominal associations with CYP3A5 rs10211, CYP3A5 rs1859690, CYP3A5 
rs15524, CYP3A5 rs113539362, CYP2B6 rs8100458, CYP2A6 -48T→G, and CYP2B7 rs4124633. 
After adjusting for CYP2B6 516G→T, both CYP2B6 983T→C and CYP2A6 -48T→G remained 
significant.  Furthermore, after adjusting for the composite CYP2B6 516/983 or CYP2B6 
15582/516/983 genotypes, the above-mentioned polymorphisms were significantly 
associated with NVP Cmin. These findings are consistent with previous reports from our group 
with regards the relationship between CYP2B6 983T→C and NVP Cmin11. Similarly, in a 
univariate analysis, we found significant association with NVP AUC0-12 and CYP2B6 983T→C, 
and nominal associations with CYP3A5 rs10211, CYP3A5 rs1859690, CYP3A5 rs15524, CYP3A5 
rs113539362, CYP2A6 -48T→G, CYP2B7 rs4124633 and CYP2B6 rs8100458. After adjusting for 





Likewise, after adjusting for the composite CYP2B6 516/983 or CYP2B6 15582/516/983 
genotype, all the aforementioned polymorphisms were significantly associated with NVP 
AUC0-12.  
We found little association between CYP2B6 516G→T and NVP pharmacokinetics in our study. 
This is consistent with a previous report in African American adults9. In contrast, CYP2B6 
983T→C was consistently associated with NVP pharmacokinetics and suggesting fundamental 
differences between the two polymorphisms, consistent with previous reports37,38 . This may 
be because CYP2B6 983T→C reduces hepatic CYP2B6 expression and/or activity to a much 
greater extent than does CYP2B6 516G→T. This is reinforced by evidence that CYP2B6 
983T→C has a greater effect on efavirenz PK than does CYP2B6 516G→T16. In a univariate 
analysis, lack of association between 15582C→T and NVP pharmacokinetics may reflect this 
polymorphism’s weak effect on CYP2B6 expression and/or activity. Interestingly, we found 
associations with ABCB1 rs1002204 and NVP CL/F even after adjusting for CYP2B6 genotypes. 
Furthermore, we found significant association with several CYP3A5 polymorphisms and NVP 
PK after adjusting for composite CYP2B6 516/983 or composite CYP2B6 516/983/15582 
genotype. 
In summary, the present study extends our understanding of the influence of genetic 
polymorphisms on NVP PK. Improved knowledge of the impact of genetic variants on NVP 
pharmacokinetics may ultimately improve the clinical management of HIV infection in 
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Table 1: Summary of the data 
Characteristic Median(IQR) Range 
Age(Months) 30(24-42) 10-77 
BW(Kg) 13(11-15) 6.6-20 
Dose(mg/m2) 105(90-120)  55-165 
CD4% 32(24-39) 7.86-64 







Table 2: Final Model Parameter Estimates 
Parameter Typical Values(For 13KG Child) Bootstrap Values[Median(95%CI)] 
CLint [L/hr] 2.07 2.08(1.38-4.74) 
V/F[L] 19.7 19.70(13.73-26.86) 
Ka[hr-1] 0.84 FIX  
MTT[hr] 0.56 FIX  
NN 3 FIX  
F at Birth[%] 50.4 50.35(44.81-55.08) 










































Add, additive error; CL/F, clearance; F, bioavailability; IIV, inter-individual variability; IOV, inter-occasion 
variability; KA, absorption rate constant; PMA50, post menstrual age; Prop, proportional error; RUV, 




Figure 1: A Visual Predicative Check of Nevirapine Final Model. B Age driven effects on 
Nevirapine bioavailability in Children. 
 
 
 Figure 2: A composite 15582/516/983 haplotypes versus NVP CL/F. B composite 
15582/516/983 haplotypes versus NVP Cmin. C composite 15582/516/983 haplotypes versus 
NVP AUC.  
 
0(15582CC-516GG-983TT); 1(15582CT-516GG-983TT); 2(15582TT-516GG-983TT); 3(15582CC-516GT-983TT); 





















0.32(0.05-0.59,P=0.02) -0.14(-0.28 to 0.01,P=0.05) -0.21(-0.36 to -0.07,P=0.007) -0.09(-0.13 to -0.05,P=9.3E-0.6) 
19 983T→C  
(CYP2B6) 
-0.26(-0.50 to -0.02,P=0.04) -0.19(-0.33 to -0.04,P=0.01) N/A N/A 
19 516G→T 
(CYP2B6) 
-0.16(-0.31 to -0.01,P=0.04) N/A N/A N/A 
19 rs7250597 
(CYP2B6) 
0.17(0.01-0.33,P=0.04)  -0.11(-0.25 to 0.04,P=0.16) -0.19(-0.34 to -0.03,P=0.02) -0.08(-0.12 to -0.04,P=0.0001) 
7 rs1859690 
(CYP3A5) 
-0.18(-0.34 to -0.01,P=0.05) -0.13(-0.28 to 0.02, P=0.10) -0.17(-0.34 to 0.01,P=0.04) -0.09(-0.13 to -0.05,P=0.0002) 
7 rs15524 
(CYP3A5) 
-0.18(-0.34 to -0.01,P=0.05) -0.13(-0.28 to 0.02, P=0.10) 0.17(-0.34 to 0.01,P=0.04) -0.09(-0.13 to -0.05,P=0.0002) 
7 rs17064 
(ABCB1) 
0.18(0.01-0.37,P=0.06) -0.13(-0.28 to 0.01, P=0.07) -0.21(-0.36 to -0.06,P=0.009) -0.09(-0.14 to -0.05,P=2.3E-0.5) 
7 rs2687134 
(CYP3A5) 
-0.15(-0.31 to 0.01,P=0.06) -0.13(-0.28 to 0.02, P=0.09) -0.18(-0.34 to 0.01,P=0.04) -0.09(-0.13 to -0.05,P=0.0001) 
7 rs1922240 
(ABCB1) 
-0.19(-0.40 to 0.01,P=0.06) -0.09(-0.24 to 0.06, P=0.23) -0.18(-0.34 to -0.02,P=0.03) -0.09(-0.13 to -0.05,P=0.0002) 
7 rs10211 
(CYP3A5) 
-0.18(-0.33 to 0.01,P=0.07) -0.13(-0.28 to 0.02, P=0.09) -0.17(-0.34 to -0.03,P=0.03) -0.09(-0.13 to -0.05,P=0.0002) 
19 15582C→T 
(CYP2B6) 
0.13(-0.05 to 0.31, P=0.16) -0.16(-0.31 to 0.01,P=0.05) -0.21(-0.37 to -0.05,P=0.01) N/A 



































3.24(1.53-4.94,P=0.005) N/A N/A 
19 -48T→G 
(CYP2A6) 
7.14(1.92-12.37,P=0.009) 2.16(0.27-4.05,P=0.03) 3.29(1.41-5.18,P=0.001) 1.30(0.79-1.82,P=7.0E-06) 
7 rs10211 
(CYP3A5) 
2.74(0.54-4.94,P=0.02) 1.16(-0.90 to 3.22,P=0.27) 2.87(0.82-4.93,P=0.008 131(0.77-1.85,P=1.4E-0.5) 
7 rs1859690 
(CYP3A5) 
2.70(0.49-4.91,P=0.02) 1.24(-0.80 to 3.28,P=0.24) 2.93(0.91-4.93,P=0.006) 1.31(0.79-1.84,P=9.4E-0.6) 
7 rs15524 
(CYP3A5) 
2.70(0.49-4.91,P=0.02) 1.24(-0.80 to 3.28,P=0.24) 2.93(0.91-4.93,P=0.006) 1.31(0.79-1.84,P=9.4E-0.6) 
7 rs113539362 
(CYP3A5) 
4.44(0.51-8.36,P=0.03) 1.71(-0.24 to 3.66,P=0.09) 3.13(1.16-5.10,P=0.003) 1.33(0.81-1.85,P=6.9E-0.6) 
19 rs4124633 
(CYP2B7) 
2.98(0.30-5.65,P0.03) 1.51(-0.48 to 3.49, P=0.14) 3.12(1.15-5.10,P=0.003) 1.34(0.82-1.86,P=4.5E-0.6) 
19 rs8100458 
(CYP2B6) 
3.36(-0.14 to 6.86, P=0.07) 1.56(-0.44 to 3.57,P=0.13) 3.05(0.98-5.12,P=0.006) 1.36(0.81-1.90,P=1.0E-0.5) 
19 516G→T 
(CYP2B6) 
1.81(-0.21 to 3.82, P=0.08) N/A N/A N/A 
19 15582C→T 
(CYP2B6) 
-1.97(-3.46 to 1.41,P=0.41) 1.71(-0.34 to 3.77, P=0.11) 3.31(1.28-5.35,P=0.002) N/A 





































21.9(9.6-34.2, P=0.001) N/A N/A 
19 -48T→G 
(CYP2A6) 
69.6(18.3-120.8, P=0.01) 15.5(1.9-29, P=0.03) 32.3(13.6-50.6,P=0.001) 12.7(7.7-17.7,P=8.4E-0.06) 
7 rs10211 
(CYP3A5) 
26.9(5.4-48.4, P=0.02) 13.7(-0.70 to 28.10, P=0.07 27.9(7.8-48.1,P=0.009) 12.7(7.5-17.9,P=1.6E-0.5) 
7 rs1859690 
(CYP3A5) 
26.5(4.8-48.2, P=0.02) 13.8(-0.50 to 28, P=0.06) 28.6(8.7-48.4,P=0.007) 12.8(7.6-17.9,P=1.1E-0.5) 
7 rs15524 
(CYP3A5) 
26.5(4.8-48.2, P=0.02) 13.8(-0.50 to 28, P=0.06) 28.6(8.7-48.4,P=0.007) 12.8(7.6-17.9,P=1.1E-0.5) 
7 rs113539362 
(CYP3A5) 
43.8(5.4-82.2, P=0.03) 13.6(-0.1 to 27.2, P=0.06) 30.5(11.2-49.7,P=0.003) 12.9(7.8-18.1,P=8.3E-0.6) 
19 rs4124633 
(CYP2B7) 
29.3(0.30-5.65, P0.03) 13.9(0.1-27.8, P=0.05) 30.5(11.1-49.8, P=0.003) 13.6(8.0-18.1,P=5.4E-0.6) 
19 rs8100458 
(CYP2B6) 
33.35(3.1 to 55.5, P=0.06) 15.7(1.7-29.6, P=0.03) 29.6(9.3-49.9, P=0.006) 13.5(7.8-18.5,P=1.3E-05) 
19 516G→T 
(CYP2B6) 
17.4 (-2.3 to 37.2, P=0.09) N/A N/A N/A 
19 15582C→T 
(CYP2B6) 
-19.2 (-59.0 to 20.7, P=0.35) 15.1(1.1-29.2, P=0.04) 32.2(11.9-52.3,P=0.003) N/A 

















Supplemental Table S1: Minor allele frequencies, Genotype Frequencies, HWE P Values of 
the 66 polymorphisms in 60 South African Children 





ABCB1 rs1002204 7 T G 0.12 1/40/135 0.4744 
ABCB1 rs10225473 7 G A 0.14 7/36/133 0.05431 
ABCB1 rs10248420 7 A G 0.34 19/83/74 0.6183 
ABCB1 rs10260862 7 C G 0.33 21/74/79 0.6089 
ABCB1 rs10267099 7 G A 0.09 0/30/146 0.6167 
ABCB1 rs10276036 7 C T 0.15 4/46/126 1 
ABCB1 rs1045642 7 T C 0.09 3/26/147 0.1544 
ABCB1 rs11760837 7 C T 0.20 9/52/115 0.3439 
ABCB1 rs17064 7 T A 0.16 4/50/122 1 
ABCB1 rs17209837 7 C T 0.27 11/73/92 0.5691 
ABCB1 rs1858923 7 C T 0.07 0/23/153 1 
ABCB1 rs1882478 7 C T 0.31 22/66/88 0.1129 
ABCB1 rs1922240 7 C T 0.24 7/69/100 0.2999 
ABCB1 rs1989830 7 T C 0.27 12/71/93 0.8496 
ABCB1 rs2229107 7 T A 0.12 0/42/134 0.1386 
ABCB1 rs2235023 7 A G 0.31 18/73/85 0.7246 
ABCB1 rs2235033 7 T C 0.46 35/93/48 0.4511 
ABCB1 rs28364275 7 C T 0.10 1/32/143 1 
ABCB1 rs28364277 7 T C 0.12 2/39/135 1 
ABCB1 rs28364278 7 I D 0.13 2/41/133 0.7434 
ABCB1 rs3747806 7 C T 0.27 17/62/97 0.1324 
ABCB1 rs3789243 7 A G 0.35 16/88/69 0.1319 
ABCB1 rs3842 7 C T 0.18 4/57/115 0.4527 
ABCB1 rs4148751 7 G A 0.26 10/70/96 0.6923 
ABCB1 rs6465118 7 A G 0.23 4/73/99 0.03157 
ABCB1 rs651430 7 T C 0.48 3/38/135 0.7366 
ABCB1 rs6961419 7 C T 0.05 35/98/43 0.1732 
ABCB1 rs8187789 7 A G 0.21 0/19/157 1 
CYP2A6 rs28399433 19 C A 0.11 2/23/151 0.2627 
CYP2B7 rs4124633 19 G A 0.13 4/40/132 0.5351 
CYP2B6 rs1042389 19 C T 0.15 6/62/108 0.5027 
CYP2B6 rs11666982 19 T G 0.27 7/39/130 0.07895 
CYP2B6 rs11672085 19 T C 0.17 11/73/92 0.5691 
CYP2B6 rs11672352 19 G A 0.30 8/43/125 0.1046 
CYP2B6 rs16974794 19 G A 0.05 18/71/87 0.5926 
CYP2B6 rs2279341 19 C G 0.08 0/19/157 1 
CYP2B6 rs28399499 19 C T 0.05 3/33/140 0.4482 
CYP2B6 rs28399502 19 A C 0.39 1/17/158 0.4013 
CYP2B6 rs3745274 19 T G 0.42 31/75/70 0.2037 
CYP2B6 rs3745275 19 A G 0.14 36/75/65 0.1204 




CYP2B6 rs4803419 19 T C 0.18 0/20/156 1 
CYP2B6 rs6508965 19 T C 0.18 6/52/118 1 
CYP2B6 rs707265 19 A G 0.22 0/65/111 0.000874 
CYP2B6 rs7246465 19 T C 0.22 12/55/109 0.1925 
CYP2B6 rs7250597 19 T C 0.48 10/56/110 0.3823 
CYP2B6 rs7255149 19 A C 0.10 38/93/45 0.5455 
CYP2B6 rs7260329 19 A G 0.13 0/36/140 0.2223 
CYP2B6 rs8100458 19 C T 0.39 1/43/132 0.3158 
CYP2B6 rs8109818 19 G A 0.25 27/82/66 0.874 
CYP3A4 rs17161886 7 C A 0.15 9/69/97 0.5476 
CYP3A4 rs28451617 7 T C 0.13 8/38/130 0.03657 
CYP3A4 rs3735451 7 A G 0.25 3/40/133 1 
CYP3A4 rs473706 7 T C 0.13 14/58/103 0.1571 
CYP3A4 rs667660 7 A C 0.24 10/66/100 1 
CYP3A4 rs7801671 7 A C 0.22 7/62/107 0.8232 
CYP3A5 rs10211 7 A G 0.32 21/70/85 0.2968 
CYP3A5 rs10256106 7 G C 0.18 8/47/121 0.2071 
CYP3A5 rs10264272 7 T C 0.20 9/51/116 0.3353 
CYP3A5 rs113539362 7 A G 0.09 0/30/146 0.6167 
CYP3A5 rs15524 7 T C 0.32 21/71/84 0.3051 
CYP3A5 rs1859690 7 A G 0.32 20/72/84 0.4869 
CYP3A5 rs2687134 7 C A 0.37 25/79/71 0.7452 
CYP3A5 rs6977165 7 C T 0.16 3/51/122 0.5768 
CYP3A5 rs773049150 7 I D 0.10 2/32/142 0.6961 

















Supplementary Figure 1: Goodness of fit plots of the final model 
 
 






Supplementary Figure 3: Presents linkage disequilibrium plot for ABCB1 
 











𝑪𝑪𝑪𝑪 𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭⁄ = 𝑪𝑪𝑪𝑪 𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭⁄ ∗ (𝑻𝑻𝑻𝑻𝑻𝑻𝑻𝑻
𝟏𝟏𝟏𝟏.𝟓𝟓 )𝟎𝟎.𝟕𝟕𝟓𝟓                           (1.1) 
𝑽𝑽 𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭⁄ = 𝑽𝑽 𝑭𝑭𝑭𝑭𝑭𝑭𝑭𝑭⁄ ∗ (𝑻𝑻𝑻𝑻𝑻𝑻𝑻𝑻
𝟏𝟏𝟏𝟏.𝟓𝟓 )𝟏𝟏                                     (1.2) 
Equation 2 








HIV in children continues to be a large health burden globally and in Sub-Saharan Africa, 
particularly in South Africa where high proportion of infections and deaths occur1. Majority 
of HIV infections in children result from transmission of the virus from the mother during 
pregnancy, during the birth process, or from breastfeeding1,2. Antiretroviral therapy greatly 
reduces HIV associated morbidity and mortality in children3,4. Therefore, greater 
understanding of the pharmacology of antiretroviral drugs in children is of paramount 
importance so as to optimize treatment in high burden environments, particularly in South 
African and Sub-Saharan Africa. Optimal use of currently available drugs is imperative 
considering that sub-therapeutic exposures can lead to resistance and treatment failure.   
This thesis, adds to the body knowledge on the pharmacokinetics, pharmacogenetics and 
pharmacodynamics of antiretroviral drugs based on clinical data and retrospective 
measurement of antiretroviral drugs measurement (in single scheduled and unscheduled 
samples collected during clinic visits) as part a clinical trial conducted in a programmatic 
setting in South Africa. The patients received drug regimens and combinations based on 
standard regimens used in most parts of the world, hence the findings maybe applicable 
beyond South Africa. The work involved describing the relationship between serial clinic visit 
lopinavir concentrations and other pre-treatment clinical variables and virological outcomes 
in children during the induction phase of the NEVEREST2 trail. Another aim was to describe 
the relationship between maintenance of virological suppression and longitudinal drug 
concentrations in children on 2 different antiretroviral regimens (lopinavir or nevirapine) and 
other important clinical variables during the post randomization phase. For both aims, Cox 
proportional hazard multiple failure events were employed to describe a time to treatment 
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failure. Another aim pharmacokinetics. Before this could be done, population 
pharmacokinetic models were developed in order to describe antiretroviral drugs 
pharmacokinetics and from the final models three pharmacokinetic indices, namely; 
clearance (CL/F), minimum concentration (Cmin) and area under the concentration time curve 
(AUC0-12), were obtained for each individual. These were then used to assess their 
associations with genetic polymorphisms in pre-selected genes. 
In paper 1, plasma lopinavir concentrations in 237 children collected at the same time as viral 
load tests at serial clinic visits were used to determine relationship concentrations and 
virological response in children. Furthermore, other pre-determined relevant pre-treatment 
variables were used to predict virological response. Children with lopinavir concentrations 
<1.0 mg/L had a (HR 2.3[95% CI 1.63, 3.26]) fold risk of virological failure (viral load>400 
copies/mL). A cut-off value of 4.0 mg/L (HR 1.74[95% CI 1.36, 2.23]) was also associated with 
an increased risk of virological failure. Furthermore, a non-linear effect of lopinavir was shown 
graphically on the hazard of viral load>400 copies/mL. It demonstrated that lower 
concentration predicted virological failure across a full range of lopinavir concentrations. This 
finding indicates that in addition to adherence-related changes in drug exposure, individual 
variability in lopinavir concentrations might play a vital role in therapeutic outcomes.  This 
finding suggests that low lopinavir concentrations (especially <1.0 mg/L) measured at 0.42-9 
hours post dose reflect poor medication adherence and this can be used an objective for 
adherence to antiretroviral therapy as well as therapeutic drug monitoring. This finding 
confirms that a 1.0 mg/L trough concentrations derived from adults5 is also applicable to 
children in predicting virological response. The lopinavir concentrations described in this 
thesis confirms findings in our settings, similar to those found in children of comparable age 
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reported elsewhere6,7. There was also significant increase in the hazard of viral load>400 
copies/mL with pre-treatment moderate (HAZ -2 to -3sd) and severe stunting (HAZ> -3 sd) but 
not with other pre-treatment characteristics. This finding is consistent with a report in 
another study in children8. This suggests appropriated interventions may be required in 
children who are stunted in order to improve their virological outcomes. 
For paper 2, 195 children who achieved virological suppression (viral load<400 copies/mL) for 
2 consecutive visits after induction phase of antiretroviral therapy were randomized, of which 
99 to remained on a lopinavir-based regimen and 95 were switched to a nevirapine-based 
regimen for the post-randomization phase.  Viral loads and lopinavir or nevirapine 
concentrations were measured at serial clinic visits.  The hazard of viremia (viral load>50 
copies/mL) were determined for lopinavir or nevirapine and clinical relevant variables at 
baseline.  In the 99 children remaining on lopinavir, the hazard of viremia was increased by 
40% in children with concentrations <1.0 mg/L versus >1.0 mg/L. Furthermore, several 
lopinavir concentrations cut-offs (0.5-6.0 mg/L) were compared using generalized cross 
validation and the method found the 1.0 mg/L the most predictive. This suggests that 1.0 
mg/L could be used as a target concentration for lopinavir concentrations taken 2-4 post dose 
during a routine clinical visit and could be used as a measure for therapeutic drug monitoring 
in children established on antiretroviral therapy. There was also an increased hazard of 
viremia in children with low level viremia (viral load 51-400 copies/mL) at baseline suggesting 
the risk of future viremia was not modified by lopinavir exposure post-randomization. In the 
95 children switched to nevirapine-based regimen, there was no association between 
nevirapine concentrations taken 2-3.9 hours post dose and the hazard of viremia. 
Nonetheless, a cut-off 5.0 mg/L was shown to reduce the hazard of viremia by 36% though 
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the association was not statistically significant. These findings were consistent with previous 
reports whereby it shown that nevirapine concentrations do not predict virological response 
in children established on antiretroviral treatment9.  
In paper 3, a population model was developed to describe the pharmacokinetics of lopinavir 
in children and a one compartment model best described the data.  Allometric scaling using 
total body weight was applied on CL/F and volume and thus improved the model fit. Both 
lopinavir estimates of oral CL/F and volume were comparable to previous studies10,11. There 
was an age-driven effect on lopinavir relative bioavailability and an effect of concomitant 
tuberculosis therapy on lopinavir clearance, similar to other reports in the literature10,12. 
 From the final model, individual CL/F, Cmin, and AUC0-12 were obtained and this were used to 
examine for associations with genetic polymorphisms in the ABCB1, CYP3A4, CYP3A5 and 
SLCO1B1.  Lopinavir is a substrate for SLCO1B1 and reports have shown that a genetic variant 
SLCO1B1 521T→C (rs4149056) is associated with lopinavir pharmacokinetics13–16. When 
adjusting for multiple comparisons, there were no significant associations between 56 
SLCO1B1 polymorphisms and lopinavir CL/F, Cmin or AUC0-12, specifically 521→C due low 
frequency of the 521CC allele. There was nominally significant association with rs4149032 
(MAF 21%) and reduced lopinavir CL/F, contrasting previous reports13. There were significant 
nominal associations between SLCO1B1 463C→A (rs11045819) and decreased lopinavir CL/F 
or increased Cmin and AUC0-12, however the results are in contrast with previous reports13.  
Furthermore, there were nominally significant associations with SLCO1B1 388A→G 
(rs2306283) and increased lopinavir Cmin or AUC0-12, contrasting previous reports14,17. 
Additionally, there were trends of increased Cmin and AUC0-12 with SLCO1B1 rs112403792 and 
rs4149057, however this have not been reported previously.  
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Similarly, when adjusting for multiple comparisons, there were no significant associations 
between ABCB1 polymorphisms and lopinavir CL/F, Cmin or AUC0-12. Nonetheless, there was a 
trend of reduced in lopinavir CL/F for rs10267099, which has not been reported previously. 
Neither polymorphisms in CYP3A4 and CYP3A5 were associated with lopinavir 
pharmacokinetics.  
For paper 4, a one compartment population model with transit compartment and a well 
stirred liver model satisfactorily described nevirapine pharmacokinetics of 96 children. The 
application of allometric scaling for total body weight on oral CL/F and volume of distribution 
accounted for the effect of size.  The estimate oral CL/F was lower than that from a previous 
study whereas volume was comparable18. There was no maturation effect on CL/F, however 
there was an age-driven effect on relative bioavailability, similar to previous reports18. From 
the final model, individual CL/F, Cmin and AUC0-12 were obtained and were used to evaluate 
for associations with genetic polymorphisms in ABCB1, CYP2A6, CYP2B7, CYP2B6, CYP3A4 and 
CYP3A5.   
Nevirapine is substrate of CYP2B6, previous studies have shown associations between 
516G→T18–20 and 983T→C21–23 variants and nevirapine pharmacokinetics. When adjusting for 
multiple comparisons in a univariate analysis, there were nominal associations between 
nevirapine CL/F and ABCB1 rs1002204 and CYP2B6 rs7250597, CYP3A5 rs1859690, CYP3A5 
rs15524, CYP2B6 516G→T and 983T→C. Adjusting for CYP2B6 516G→T genotype resulted in 
nominal associations with ABCB1 rs1002204, CYP2B6 983T→C and CYP2B6 15582 C→T. When 
adjusting for CYP2B6 516/983 haplotype and the composite CYP2B6 516/983/15582 
haplotype, there were significant associations with the above-mentioned polymorphisms.  
Chapter 7 
Overall Discussions and Conclusions  
173 
 
Regarding nevirapine Cmin, when adjusting for multiple comparison by univariate analysis, 
there was a significant association with CYP2B6 983T→C and nominal associations with 
CYP3A5 rs10211, CYP3A5 rs1859690, CYP3A5 rs15524, CYP3A5 rs113539362, CYP2B6 
rs8100458, CYP2A6 -48T→G, and CYP2B7 rs4124633. When adjusting CYP2B6 516G→T, there 
were nominal associations with only CYP2B6 983T→C and CYP2A6 -48T→G.  After adjusting 
for CYP2B6 516/983 haplotype there were nominal association between the aforementioned 
genotypes in the first model and nevirapine Cmin, whereas adjusting composite CYP2B6 
516/983/15582 haplotype, they were significantly associated with nevirapine Cmin. 
For nevirapine AUC0-12, in a univariate analysis, when adjusting for multiple comparisons, 
there was a significant association between nevirapine AUC0-12 and CYP2B6 983T→C and 
associations nominally with CYP3A5 rs10211, CYP3A5 rs1859690, CYP3A5 rs15524, CYP3A5 
rs113539362, CYP2A6 -48T→G, CYP2B7 rs4124633 and CYP2B6 rs8100458. After adjusting for 
CYP2B6 516G→T, there were nominal associations between nevirapine AUC and 
CYP2B6 983T→C, rs8100458 and 15582C→T and/or CYP2A6 -48T→G.  After adjusting for 
CYP2B6 516/983 haplotype, there nominal associations with polymorphisms mentioned in 
the first model including 15582C→T. Adjusting for the composite 516/983/15582 haplotype 
resulted in significant associations with polymorphisms aforementioned in the first and third 
models, respectively. 
 
7.2 Limitations  
The findings from these studies need to be interpreted within the context of their limitations. 
For the studies investigating associations between drug concentration and virological 
response (paper 1 and 2) the limitations are as follows: First, there was missing data which 
Chapter 7 
Overall Discussions and Conclusions  
174 
 
was accounted by multiple imputation, as this approach has be shown to be superior to 
complete case analysis in which subjects who do not have missing values are analysed24; 
Second, the timing of dosing of lopinavir or nevirapine was not  directly observed by the study 
team and the analysis did not include adjustment for the time after dose. Nonetheless, to 
minimize recall bias, caregivers were requested to record the time of last dose on the morning 
before pharmacokinetic sampling; Third, adherence was self-reported and therefore, 
incomplete adherence cannot be excluded, which could have important effects on the 
observed concentrations; Fourth, lopinavir or nevirapine concentrations were used and not 
the area under the curve, the pharmacokinetic parameter that better describes the drug 
exposure.  
Many children on ART for treating HIV experience undetectable levels of viral load (<50 
copies/mL). However, some patients experience transient viremia24,25. Viral blips might result 
from release of drug-sensitive virions from the latent reservoir or might signal viral replication 
that occurs as a result of lack of adherence to drug treatment or increases in target cells 
secondary to infection26. The clinical significance of this phenomenon remains controversial 
in the literature. Nonetheless, in this thesis, the impact of viral blips on virological outcomes 
was not assessed and this could have led to biased in the relationship between clinic visit 
concentrations and the hazard of viremia especially that of lopinavir. 
For paper 3, there were 176 out of a total   of 237 patients with genotype data.  Furthermore, 
131 patients had both genotype and phenotype limiting the sample size.  This could have 
resulted in decreased statistical power in investigating the associations between genotype 
and phenotype. 
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Similarly, in paper 4, there were 60 out of a total of 96 patients with genotype data.  
Furthermore, 55 patients had both genotype and phenotype further limiting the sample size. 
Sample size might have limited the ability to extensively identify novel genetic associations 
with nevirapine pharmacokinetics.  
 
7.3 Conclusions  
In conclusion all the aims of this work were achieved. Cox proportional hazard models were 
used to investigate the relationship between serial visits viral loads and lopinavir 
concentrations and other clinical relevant variables. The findings showed that children with 
lopinavir concentrations <1.0 mg/L taken 0.42-9 hours post dose had a higher hazard of viral 
load>400 copies/mL. This can be used as proxy for treatment non-adherence and can be used 
as target concentration for therapeutic drug monitoring in optimizing antiretroviral treatment 
in children initiating lopinavir-based regimen.  This finding was subsequently confirmed 
children established on a lopinavir-based regimen when using a threshold of viral load>50 
copies/mL. Furthermore, it was confirmed that nevirapine concentrations do not predict the 
hazard of viremia (viral load>50 copies) in children established on antiretroviral treatment.      
Pharmacometric models were developed for lopinavir and nevirapine and associations 
between both drugs pharmacokinetics and genetic polymorphisms relevant to both drugs 
were explored.  There were nominal associations between lopinavir pharmacokinetics and 
genetic polymorphisms in SLCO1B1 and ABCB1. This thesis confirmed significant associations 
between nevirapine pharmacokinetics and CYP2B6 polymorphisms. 
Based on the work from this thesis, further larger studies are needed to confirm the proposed 
target concentrations for lopinavir and their usefulness for therapeutic drug monitoring. 
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Moreover, more pharmacogenetic studies are needed to confirm the influence of genetic 
polymorphisms in SLCO1B1 and ABCB1 in children especially those of African descent. 
Furthermore, analysis gene-gene interaction are crucial for better understanding of lopinavir 
pharmacokinetics. Regarding nevirapine, more studies are needed in order to elucidate 
clinical relevancy of the contribution of genetic variants to nevirapine pharmacokinetics.  
Datasets from more recent studies could be used to build models incorporating genetic 
effects which can then be used for clinical trial simulation to confirm the most efficient 
designs for optimizing therapy of nevirapine-based regimen. 
 
7.4 Implication for Clinical Care and Practice  
The findings in this thesis improves our understanding on relationship between longitudinal 
lopinavir or nevirapine concentrations and virological failure. Furthermore, this thesis also 
adds to the knowledge on the genetic determinants of lopinavir or nevirapine 
pharmacokinetics in African children, providing insights into the host factors associated with 
drug exposure. Some of the findings potential public health implications. 
Currently therapeutic drug monitoring is not routinely used in low and middle-income 
countries. Moreover, it has been shown that measuring drug concentrations can be used as 
an effective tool in ensuring that therapeutic targets of ART targets are met. Interestingly, 
there is also insufficient knowledge on target concentrations in children. The findings in this 
study suggests that a single sample taken 0.42-9(in children initiating LPV/r regimen) or 2-4 
hours (in children established on LPV/r regimen ) after the dose is useful predictor of lopinavir 
concentrations and can used for therapeutic drug monitoring, and therefore assist in 
adherence support.  
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The track record of randomized clinical trials that incorporate clinical phenotypes and 
genotypes in children on ART remains fraught. Furthermore, the use of pharmacogenetic 
features could be a useful tool in clinical practice. Moreover, the study of genetic profiles of 
patients could help in optimizations of therapeutic management of HIV-infected children 
through test introduced into clinical practice. LPV is recommended as first-line therapy in 
children and is likely to remain so due to its high barrier for developing drug resistance and 
tolerability. LPV is a substrate of SLCO1B1 and the clinical utility of genotyping or sequencing 
of SLCO1B1 still needs further work and cannot be recommended based on our findings. 
Nevirapine is prescribed as the 2nd preferred drug in children due to its affordability, 
availability in fixed dose combinations, and safety and efficacy profile. NVP is a substrate of 
CYP2B6 and CYP2B6 is highly polymorphic, especially in patients of African ancestry. Slow 
metabolizer genotypes are prevalent in Sub-Saharan African populations and therefore the 
clinical utility and cost-effectiveness of monitoring the effect CYP2B6 slow genotypes on NVP 
pharmacokinetics could be useful and remains to be determined. 
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### Descriptives #### 
################## 
# percentage Missingness 
round(apply(apply(cbind(lpv,adhstatus,baselinecd4pc,agestartarv,whostage2,baselinewfa,vlsupp,hfacat),c(1,2)
,is.na),2,mean),digits=3) 
surv.vl1 <- Surv(X_t0,X_t,vlsupp)       # setting survival time from Stata 
summary(surv.vl1) 
################# 






M=10 #Set Number of Impuations to Be Done 
impdat <-  
LPVPRE[,c("id","X_t0","X_t","vlsupp","lpv","adhstatus","baselinecd4pc","logbaselinevl","agestartarv","whostag
e2","baselinewfa","baselinehfa")] 
round(apply(apply(impdat,c(1,2),is.na),2,mean),digits=3)   # percentage of missing values 


















suppressWarnings(disperse(myimp, dims=1, m=10)) 





overimpute(myimp, var = "baselinecd4pc") 
overimpute(myimp, var = "whostage2") 
overimpute(myimp, var = "baselinewfa") 
overimpute(myimp, var = "baselinehfa") 
overimpute(myimp, var = "lpv") 
summary(myimp) 
 
# Categorization of relevant variables 






































## Table 3: Cox Regression   # 
## (crude, adj, selected)    # 
############################## 
 
# Adjusted analysis 
#Using Lopinavir as continous variable 
m2_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv  + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[1]]$X_t,method="breslow") 
m2_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv  + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[2]],method="breslow") 
m2_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv  + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[3]],method="breslow") 
m2_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv  + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 






m2_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv  + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[5]],method="breslow") 
m2_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv  + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[6]],method="breslow") 
m2_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv  + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[7]],method="breslow") 
m2_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv  + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[8]],method="breslow") 
m2_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv  + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[9]],method="breslow") 
m2_10<-coxph(Surv(X_t0,X_t,vlsupp) ~ lpv  + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 









my2a <- mi.inference(myest, mystd, confidence=0.95) 
my_2 <- round(cbind(exp(my2a$est),exp(my2a$lower),exp(my2a$upper),my2a$signif),digits=3) 
my_2     # overall results with Hazard ratios, CI, and p-values 
 
#Using Lopinavir with a cut-off of 1mg/L 
m3_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1  + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[1]],method="breslow") 
m3_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1  + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[2]],method="breslow") 
m3_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1  + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[3]],method="breslow") 
m3_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1  + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 






m3_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1  + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[5]],method="breslow") 
m3_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1  + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[6]],method="breslow") 
m3_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1  + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[7]],method="breslow") 
m3_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1  + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[8]],method="breslow") 
m3_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1  + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[9]],method="breslow") 
m3_10<-coxph(Surv(X_t0,X_t,vlsupp) ~ lpvcat1  + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 









my3a <- mi.inference(myest, mystd, confidence=0.95) 
my_3 <- round(cbind(exp(my3a$est),exp(my3a$lower),exp(my3a$upper),my3a$signif),digits=2) 
my_3     # overall results with Hazard ratios, CI, and p-values 
 
#Using Lopinavir with a cut-off of 4mg/L 
m4_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4  + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[1]],method="breslow") 
m4_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4  + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[2]],method="breslow") 
m4_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4  + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[3]],method="breslow") 
m4_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4  + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 






m4_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4  + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[5]],method="breslow") 
m4_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4  + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[6]],method="breslow") 
m4_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4  + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[7]],method="breslow") 
m4_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4  + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[8]],method="breslow") 
m4_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4  + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[9]],method="breslow") 
m4_10<-coxph(Surv(X_t0,X_t,vlsupp) ~ lpvcat4  + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 









my4a <- mi.inference(myest, mystd, confidence=0.95) 
my_4 <- round(cbind(exp(my4a$est),exp(my4a$lower),exp(my4a$upper),my2a$signif),digits=3) 
my_4     # overall results with Hazard ratios, CI, and p-values 
 
# Crude analysis 
m2_11<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv + cluster(id),data=myimp$imputations[[1]],method="breslow") 
m2_21<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv + cluster(id),data=myimp$imputations[[2]],method="breslow") 
m2_31<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv + cluster(id),data=myimp$imputations[[3]],method="breslow") 
m2_41<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv + cluster(id),data=myimp$imputations[[4]],method="breslow") 
m2_51<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv + cluster(id),data=myimp$imputations[[5]],method="breslow") 
m2_61<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv + cluster(id),data=myimp$imputations[[6]],method="breslow") 
m2_71<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv + cluster(id),data=myimp$imputations[[7]],method="breslow") 
m2_81<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv + cluster(id),data=myimp$imputations[[8]],method="breslow") 













my2a1 <- mi.inference(myest1, mystd1, confidence=0.95) 
my_21 <- round(cbind(exp(my2a1$est),exp(my2a1$lower),exp(my2a1$upper),my2a1$signif),digits=3) 
my_21    
 
m2_13<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(cd4pccat)+ 
cluster(id),data=myimp$imputations[[1]],method="breslow") 
m2_23<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(cd4pccat)+ 
cluster(id),data=myimp$imputations[[2]],method="breslow") 
m2_33<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(cd4pccat)+ 
cluster(id),data=myimp$imputations[[3]],method="breslow") 
m2_43<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(cd4pccat)+ 
cluster(id),data=myimp$imputations[[4]],method="breslow") 
m2_53<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(cd4pccat)+ 
cluster(id),data=myimp$imputations[[5]],method="breslow") 
m2_63<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(cd4pccat)+ 
cluster(id),data=myimp$imputations[[6]],method="breslow") 
m2_73<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(cd4pccat)+ 
cluster(id),data=myimp$imputations[[7]],method="breslow") 
m2_83<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(cd4pccat)+ 
cluster(id),data=myimp$imputations[[8]],method="breslow") 
m2_93<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(cd4pccat)+ 
cluster(id),data=myimp$imputations[[9]],method="breslow") 














my2a3 <- mi.inference(myest3, mystd3, confidence=0.95) 
my_23 <- round(cbind(exp(my2a3$est),exp(my2a3$lower),exp(my2a3$upper),my2a3$signif),digits=3) 
my_23    
 
m2_14<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(logvlcat) + 
cluster(id),data=myimp$imputations[[1]],method="breslow") 
m2_24<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(logvlcat) + 
cluster(id),data=myimp$imputations[[2]],method="breslow") 
m2_34<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(logvlcat) + 
cluster(id),data=myimp$imputations[[3]],method="breslow") 
m2_44<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(logvlcat) + 
cluster(id),data=myimp$imputations[[4]],method="breslow") 
m2_54<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(logvlcat) + 
cluster(id),data=myimp$imputations[[5]],method="breslow") 
m2_64<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(logvlcat) + 
cluster(id),data=myimp$imputations[[6]],method="breslow") 
m2_74<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(logvlcat) + 
cluster(id),data=myimp$imputations[[7]],method="breslow") 
m2_84<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(logvlcat) + 
cluster(id),data=myimp$imputations[[8]],method="breslow") 
m2_94<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(logvlcat) + 
cluster(id),data=myimp$imputations[[9]],method="breslow") 









my2a4 <- mi.inference(myest4, mystd4, confidence=0.95) 
my_24 <- round(cbind(exp(my2a4$est),exp(my2a4$lower),exp(my2a4$upper),my2a4$signif),digits=3) 
my_24    
 
m2_15<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(agecat) + 
cluster(id),data=myimp$imputations[[1]],method="breslow") 






m2_35<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(agecat) + 
cluster(id),data=myimp$imputations[[3]],method="breslow") 
m2_45<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(agecat) + 
cluster(id),data=myimp$imputations[[4]],method="breslow") 
m2_55<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(agecat) + 
cluster(id),data=myimp$imputations[[5]],method="breslow") 
m2_65<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(agecat) + 
cluster(id),data=myimp$imputations[[6]],method="breslow") 
m2_75<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(agecat) + 
cluster(id),data=myimp$imputations[[7]],method="breslow") 
m2_85<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(agecat) + 
cluster(id),data=myimp$imputations[[8]],method="breslow") 
m2_95<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(agecat) + 
cluster(id),data=myimp$imputations[[9]],method="breslow") 









my2a5 <- mi.inference(myest5, mystd5, confidence=0.95) 
my_25 <- round(cbind(exp(my2a5$est),exp(my2a5$lower),exp(my2a5$upper),my2a5$signif),digits=3) 
my_25    
 
m2_16<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(whostage2)+ 
cluster(id),data=myimp$imputations[[1]],method="breslow") 
m2_26<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(whostage2)+ 
cluster(id),data=myimp$imputations[[2]],method="breslow") 
m2_36<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(whostage2)+ 
cluster(id),data=myimp$imputations[[3]],method="breslow") 
m2_46<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(whostage2)+ 
cluster(id),data=myimp$imputations[[4]],method="breslow") 
m2_56<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(whostage2)+ 
cluster(id),data=myimp$imputations[[5]],method="breslow") 






m2_76<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(whostage2)+ 
cluster(id),data=myimp$imputations[[7]],method="breslow") 
m2_86<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(whostage2)+ 
cluster(id),data=myimp$imputations[[8]],method="breslow") 
m2_96<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(whostage2)+ 
cluster(id),data=myimp$imputations[[9]],method="breslow") 









my2a6<- mi.inference(myest6, mystd6, confidence=0.95) 
my_26 <- round(cbind(exp(my2a6$est),exp(my2a6$lower),exp(my2a6$upper),my2a6$signif),digits=3) 
my_26    
 
m2_17<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(wfacat)+ 
cluster(id),data=myimp$imputations[[1]],method="breslow") 
m2_27<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(wfacat)+ 
cluster(id),data=myimp$imputations[[2]],method="breslow") 
m2_37<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(wfacat)+ 
cluster(id),data=myimp$imputations[[3]],method="breslow") 
m2_47<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(wfacat)+ 
cluster(id),data=myimp$imputations[[4]],method="breslow") 
m2_57<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(wfacat)+ 
cluster(id),data=myimp$imputations[[5]],method="breslow") 
m2_67<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(wfacat)+ 
cluster(id),data=myimp$imputations[[6]],method="breslow") 
m2_77<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(wfacat)+ 
cluster(id),data=myimp$imputations[[7]],method="breslow") 
m2_87<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(wfacat)+ 
cluster(id),data=myimp$imputations[[8]],method="breslow") 
m2_97<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(wfacat)+ 
cluster(id),data=myimp$imputations[[9]],method="breslow") 













my2a7 <- mi.inference(myest7, mystd7, confidence=0.95) 
my_27 <- round(cbind(exp(my2a7$est),exp(my2a7$lower),exp(my2a7$upper),my2a7$signif),digits=3) 
my_27    
 
m2_18<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(hfacat) + 
cluster(id),data=myimp$imputations[[1]],method="breslow") 
m2_28<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(hfacat) + 
cluster(id),data=myimp$imputations[[2]],method="breslow") 
m2_38<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(hfacat) + 
cluster(id),data=myimp$imputations[[3]],method="breslow") 
m2_48<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(hfacat) + 
cluster(id),data=myimp$imputations[[4]],method="breslow") 
m2_58<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(hfacat) + 
cluster(id),data=myimp$imputations[[5]],method="breslow") 
m2_68<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(hfacat) + 
cluster(id),data=myimp$imputations[[6]],method="breslow") 
m2_78<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(hfacat) + 
cluster(id),data=myimp$imputations[[7]],method="breslow") 
m2_88<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(hfacat) + 
cluster(id),data=myimp$imputations[[8]],method="breslow") 
m2_98<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(hfacat) + 
cluster(id),data=myimp$imputations[[9]],method="breslow") 









my2a8 <- mi.inference(myest8, mystd8, confidence=0.95) 





my_28    
 
m2_19<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(lpvcat1) + 
cluster(id),data=myimp$imputations[[1]],method="breslow") 
m2_29<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(lpvcat1) + 
cluster(id),data=myimp$imputations[[2]],method="breslow") 
m2_39<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(lpvcat1) + 
cluster(id),data=myimp$imputations[[3]],method="breslow") 
m2_49<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(lpvcat1) + 
cluster(id),data=myimp$imputations[[4]],method="breslow") 
m2_59<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(lpvcat1) + 
cluster(id),data=myimp$imputations[[5]],method="breslow") 
m2_69<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(lpvcat1) + 
cluster(id),data=myimp$imputations[[6]],method="breslow") 
m2_79<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(lpvcat1) + 
cluster(id),data=myimp$imputations[[7]],method="breslow") 
m2_89<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(lpvcat1) + 
cluster(id),data=myimp$imputations[[8]],method="breslow") 
m2_99<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(lpvcat1) + 
cluster(id),data=myimp$imputations[[9]],method="breslow") 









my2a9 <- mi.inference(myest9, mystd9, confidence=0.95) 
my_29 <- round(cbind(exp(my2a9$est),exp(my2a9$lower),exp(my2a9$upper),my2a9$signif),digits=2) 
my_29 
 
m2_21<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(lpvcat4) + 
cluster(id),data=myimp$imputations[[1]],method="breslow") 
m2_31<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(lpvcat4) + 
cluster(id),data=myimp$imputations[[2]],method="breslow") 






m2_51<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(lpvcat4) + 
cluster(id),data=myimp$imputations[[4]],method="breslow") 
m2_61<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(lpvcat4) + 
cluster(id),data=myimp$imputations[[5]],method="breslow") 
m2_71<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(lpvcat4) + 
cluster(id),data=myimp$imputations[[6]],method="breslow") 
m2_81<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(lpvcat4) + 
cluster(id),data=myimp$imputations[[7]],method="breslow") 
m2_91<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(lpvcat4) + 
cluster(id),data=myimp$imputations[[8]],method="breslow") 
m2_101<-coxph(Surv(X_t0,X_t, vlsupp)~ as.factor(lpvcat4) + 
cluster(id),data=myimp$imputations[[9]],method="breslow") 









my2a11 <- mi.inference(myest9, mystd9, confidence=0.95) 
my_31 <- round(cbind(exp(my2a11$est),exp(my2a11$lower),exp(my2a11$upper),my2a11$signif),digits=2) 
my_31 
# Model selection based on AICw 
library(mgcv) 
 
seldat <- impdat 
seldat <- cbind(seldat,cut(seldat$logbaselinevl,breaks=c(-1,5,1000000000))) 
colnames(seldat)[13]<-c("logvlcat") 
seldat <- cbind(seldat,cut(seldat$baselinecd4pc,breaks=c(-1,25,1000000000))) 
colnames(seldat)[14]<-c("cd4pccat") 
seldat <- cbind(seldat,cut(seldat$agestartarv,breaks=c(-1,26,1000000000))) 
colnames(seldat)[15]<-c("agecat") 
seldat <- cbind(seldat,cut(seldat$baselinewfa,breaks=c(-1000,-3,-2,10))) 
colnames(seldat)[16]<-c("wfacat") 






seldat <- cbind(seldat,cut(seldat$lpv,breaks=c(-1,1,1000000000))) 
colnames(seldat)[18]<-c("lpvcat1") 
seldat <- cbind(seldat,cut(seldat$lpv,breaks=c(-1,4,1000000000))) 
colnames(seldat)[19]<-c("lpvcat4") 
#Model Selection Using lopinar Concentration 
mymissing<-as.numeric(apply(is.na(seldat),1,any)) 
probmod1 <-gam(mymissing~1 + vlsupp + whostage2 + s(baselinecd4pc) + s(agestartarv) + s(baselinewfa) + 
s(baselinehfa) + s(lpv)  ,family=binomial,data=seldat) 
summary(probmod1) 
probmod <-gam(mymissing~1 + vlsupp + whostage2  + s(baselinewfa) + s(baselinehfa) + s(lpv)  
,family=binomial,data=seldat) 
summary(probmod) 




myweights <- 1/myprob   




# First get an idea on what is happening 
library(MASS) 
stepAIC(m2_1,direction = c("both"))   # LPV, VL, stage, HFA 
stepAIC(m2_2,direction = c("both"))   # LPV, VL,      , HFA 
stepAIC(m2_3,direction = c("both"))   # LPV,   , stage, HFA 
stepAIC(m2_4,direction = c("both"))   # LPV,   ,      , HFA 
stepAIC(m2_5,direction = c("both"))   # LPV,          , HFA 
stepAIC(m2_6,direction = c("both"))   # LPV,   , stage, HFA 
stepAIC(m2_7,direction = c("both"))   # LPV, VL,      , HFA 
stepAIC(m2_8,direction = c("both"))   # LPV, VL, stage, HFA 
stepAIC(m2_9,direction = c("both"))   # LPV, VL, stage, HFA 






# Candidate models: LPV for sure, VL forced (but explore anyway), stage and hfa to check  
 
m5_1 <- coxph(Surv(X_t0,X_t, vlsupp)~ lpv + as.factor(logvlcat) + as.factor(whostage2) + as.factor(hfacat)+ 
cluster(id),data=seldat,weights=myweights+1e-08,method="breslow") 
m5_2 <- coxph(Surv(X_t0,X_t, vlsupp)~ lpv + as.factor(logvlcat)                        + as.factor(hfacat)+ 
cluster(id),data=seldat,weights=myweights+1e-08,method="breslow") 
m5_3 <- coxph(Surv(X_t0,X_t, vlsupp)~ lpv + as.factor(logvlcat) + as.factor(whostage2)                    + 
cluster(id),data=seldat,weights=myweights+1e-08,method="breslow") 
m5_4 <- coxph(Surv(X_t0,X_t, vlsupp)~ lpv + as.factor(logvlcat) +                                           
cluster(id),data=seldat,weights=myweights+1e-08,method="breslow") 
m5_5 <- coxph(Surv(X_t0,X_t, vlsupp)~         + as.factor(logvlcat)                        + as.factor(hfacat)+ 
cluster(id),data=seldat,weights=myweights+1e-08,method="breslow") 
 
m5_6 <- coxph(Surv(X_t0,X_t, vlsupp)~ lpv +                                              as.factor(hfacat)+ 
cluster(id),data=seldat,weights=myweights+1e-08,method="breslow") 
 
m5_10 <- coxph(Surv(X_t0,X_t, vlsupp)~ lpv + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ cluster(id),data=seldat,weights=myweights+1e-
08,method="breslow") 










extractAIC(m5_6)     # without VL (not considered)  
 
extractAIC(m5_10)    # Full model 
extractAIC(m5_11)    # Null model 
 





# Adjusted analysis 
m3_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv  + as.factor(logvlcat)  + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[1]],method="breslow") 
m3_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv  + as.factor(logvlcat)  + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[2]],method="breslow") 
m3_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv  + as.factor(logvlcat)  + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[3]],method="breslow") 
m3_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv  + as.factor(logvlcat)  + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[4]],method="breslow") 
m3_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv  + as.factor(logvlcat)  + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[5]],method="breslow") 
m3_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv  + as.factor(logvlcat)  + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[6]],method="breslow") 
m3_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv  + as.factor(logvlcat)  + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[7]],method="breslow") 
m3_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv  + as.factor(logvlcat)  + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[8]],method="breslow") 
m3_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv  + as.factor(logvlcat)  + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[9]],method="breslow") 










my3a <- mi.inference(myest, mystd, confidence=0.95) 
my_3 <- round(cbind(exp(my3a$est),exp(my3a$lower),exp(my3a$upper),my3a$signif),digits=3) 
my_3     # overall results with Hazard ratios, CI, and p-values 
 
############## 
#  Summary   # 
############## 
MIsummary <- matrix(rep(NA,12*9),nrow=9,ncol=12) 
MIsummary[,1:4] <- my_2 





MIsummary[2,5:8]     <- my_23 
MIsummary[3,5:8]     <- my_24 
MIsummary[4,5:8]     <- my_25 
MIsummary[5,5:8]     <- my_26 
MIsummary[6:7,5:8]   <- my_27 
MIsummary[8:9,5:8]   <- my_28 
MIsummary[c(1,3,8:9),9:12] <- my_3 
 
rownames(MIsummary) <- c("LPV conc.","CD4% (high)","logVL (5+)","Age (>1/2 yr.)","Stage (adv.)","WFA (-2 to 
-3sd.)","WFA (> -2sd.)","HFA (-2 to -3sd.)","HFA (> -2sd.)") 





# Using LPV with a cut-off of 1mg/L# 
#################################### 
m4_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1  + as.factor(logvlcat)  + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[1]],method="breslow") 
m4_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1  + as.factor(logvlcat)  + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[2]],method="breslow") 
m4_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1  + as.factor(logvlcat)  + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[3]],method="breslow") 
m4_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1  + as.factor(logvlcat)  + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[4]],method="breslow") 
m4_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1  + as.factor(logvlcat)  + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[5]],method="breslow") 
m4_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1  + as.factor(logvlcat)  + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[6]],method="breslow") 
m4_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1  + as.factor(logvlcat)  + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[7]],method="breslow") 
m4_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1  + as.factor(logvlcat)  + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[8]],method="breslow") 
m4_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1  + as.factor(logvlcat)  + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[9]],method="breslow") 














my4a <- mi.inference(myest, mystd, confidence=0.95) 
my_4 <- round(cbind(exp(my4a$est),exp(my4a$lower),exp(my4a$upper),my4a$signif),digits=3) 
my_4     # overall results with Hazard ratios, CI, and p-values 
 
MIsummary <- matrix(rep(NA,12*9),nrow=9,ncol=12) 
MIsummary[,1:4] <- my_2 
MIsummary[1,5:8]     <- my_21 
MIsummary[2,5:8]     <- my_23 
MIsummary[3,5:8]     <- my_24 
MIsummary[4,5:8]     <- my_25 
MIsummary[5,5:8]     <- my_26 
MIsummary[6:7,5:8]   <- my_27 
MIsummary[8:9,5:8]   <- my_28 
MIsummary[c(1,3,8:9),9:12] <- my_4 
 
rownames(MIsummary) <- c("LPVCAT1","CD4% (high)","logVL (5+)","Age (>1/2 yr.)","Stage (adv.)","WFA (-2 to 
-3sd.)","WFA (> -2sd.)","HFA (-2 to -3sd.)","HFA (> -2sd.)") 





# Using LPV with a cut-off of 4mg/L# 
#################################### 
m5_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4  + as.factor(logvlcat)  + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[1]],method="breslow") 






m5_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4  + as.factor(logvlcat)  + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[3]],method="breslow") 
m5_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4  + as.factor(logvlcat)  + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[4]],method="breslow") 
m5_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4  + as.factor(logvlcat)  + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[5]],method="breslow") 
m5_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4  + as.factor(logvlcat)  + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[6]],method="breslow") 
m5_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4  + as.factor(logvlcat)  + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[7]],method="breslow") 
m5_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4  + as.factor(logvlcat)  + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[8]],method="breslow") 
m5_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4  + as.factor(logvlcat)  + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[9]],method="breslow") 










my5a <- mi.inference(myest, mystd, confidence=0.95) 
my_5 <- round(cbind(exp(my5a$est),exp(my5a$lower),exp(my5a$upper),my5a$signif),digits=3) 
my_5     # overall results with Hazard ratios, CI, and p-values 
 
MIsummary <- matrix(rep(NA,12*9),nrow=9,ncol=12) 
MIsummary[,1:4] <- my_2 
MIsummary[1,5:8]     <- my_21 
MIsummary[2,5:8]     <- my_23 
MIsummary[3,5:8]     <- my_24 
MIsummary[4,5:8]     <- my_25 
MIsummary[5,5:8]     <- my_26 
MIsummary[6:7,5:8]   <- my_27 
MIsummary[8:9,5:8]   <- my_28 






rownames(MIsummary) <- c("LPVCAT4","CD4% (high)","logVL (5+)","Age (>1/2 yr.)","Stage (adv.)","WFA (-2 to 
-3sd.)","WFA (> -2sd.)","HFA (-2 to -3sd.)","HFA (> -2sd.)") 




# Figure 1 # 
############ 
 
# Spline representation   
# Imputation based approach 
library(pspline) 
Lpvm31 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpv, df=4) + as.factor(logvlcat) + as.factor(whostage2)+ 
as.factor(cd4pccat)+ as.factor(hfacat) + as.factor(agecat)+ as.factor(wfacat)+ cluster(id), 
data=myimp$imputations[[1]], robust=TRUE, method="breslow") 
Lpvm32 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpv, df=4) + as.factor(logvlcat) + as.factor(whostage2)+ 
as.factor(cd4pccat)+ as.factor(hfacat) + as.factor(agecat)+ as.factor(wfacat)+ cluster(id), 
data=myimp$imputations[[2]], robust=TRUE, method="breslow") 
Lpvm33 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpv, df=4) + as.factor(logvlcat) + as.factor(whostage2)+ 
as.factor(cd4pccat)+ as.factor(hfacat) + as.factor(agecat)+ as.factor(wfacat)+ cluster(id), 
data=myimp$imputations[[3]], robust=TRUE, method="breslow") 
Lpvm34 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpv, df=4) + as.factor(logvlcat) + as.factor(whostage2)+ 
as.factor(cd4pccat)+ as.factor(hfacat) + as.factor(agecat)+ as.factor(wfacat)+ cluster(id), 
data=myimp$imputations[[4]], robust=TRUE, method="breslow") 
Lpvm35 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpv, df=4) + as.factor(logvlcat) + as.factor(whostage2)+ 
as.factor(cd4pccat)+ as.factor(hfacat) + as.factor(agecat)+ as.factor(wfacat)+ cluster(id), 
data=myimp$imputations[[5]], robust=TRUE, method="breslow") 
Lpvm36 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpv, df=4) + as.factor(logvlcat) + as.factor(whostage2)+ 
as.factor(cd4pccat)+ as.factor(hfacat) + as.factor(agecat)+ as.factor(wfacat)+ cluster(id), 
data=myimp$imputations[[6]], robust=TRUE, method="breslow") 
Lpvm37 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpv, df=4) + as.factor(logvlcat) + as.factor(whostage2)+ 
as.factor(cd4pccat)+ as.factor(hfacat) + as.factor(agecat)+ as.factor(wfacat)+ cluster(id), 
data=myimp$imputations[[7]], robust=TRUE, method="breslow") 
Lpvm38 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpv, df=4) + as.factor(logvlcat) + as.factor(whostage2)+ 
as.factor(cd4pccat)+ as.factor(hfacat) + as.factor(agecat)+ as.factor(wfacat)+ cluster(id), 
data=myimp$imputations[[8]], robust=TRUE, method="breslow") 
Lpvm39 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpv, df=4) + as.factor(logvlcat) + as.factor(whostage2)+ 
as.factor(cd4pccat)+ as.factor(hfacat) + as.factor(agecat)+ as.factor(wfacat)+ cluster(id), 





Lpvm310 <- coxph(Surv(X_t0,X_t,vlsupp) ~ pspline(lpv, df=4)+ as.factor(logvlcat) + as.factor(whostage2)+ 
as.factor(cd4pccat)+ as.factor(hfacat) + as.factor(agecat)+ as.factor(wfacat)+ cluster(id), 
data=myimp$imputations[[10]], robust=TRUE, method="breslow") 
Lpvm311 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpv, df=4) + as.factor(logvlcat) + as.factor(whostage2)+ 
as.factor(cd4pccat)+ as.factor(hfacat) + as.factor(agecat)+ as.factor(wfacat)+ cluster(id), 
data=myimp$imputations[[11]], robust=TRUE, method="breslow") 
Lpvm312 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpv, df=4) + as.factor(logvlcat) + as.factor(whostage2)+ 
as.factor(cd4pccat)+ as.factor(hfacat) + as.factor(agecat)+ as.factor(wfacat)+ cluster(id), 
data=myimp$imputations[[12]], robust=TRUE, method="breslow") 
Lpvm313 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpv, df=4) + as.factor(logvlcat) + as.factor(whostage2)+ 
as.factor(cd4pccat)+ as.factor(hfacat) + as.factor(agecat)+ as.factor(wfacat)+ cluster(id), 
data=myimp$imputations[[13]], robust=TRUE, method="breslow") 
Lpvm314 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpv, df=4) + as.factor(logvlcat) + as.factor(whostage2)+ 
as.factor(cd4pccat)+ as.factor(hfacat) + as.factor(agecat)+ as.factor(wfacat)+ cluster(id), 
data=myimp$imputations[[14]], robust=TRUE, method="breslow") 
Lpvm315 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpv, df=4) + as.factor(logvlcat) + as.factor(whostage2)+ 
as.factor(cd4pccat)+ as.factor(hfacat) + as.factor(agecat)+ as.factor(wfacat)+ cluster(id), 
data=myimp$imputations[[15]], robust=TRUE, method="breslow") 
Lpvm316 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpv, df=4) + as.factor(logvlcat) + as.factor(whostage2)+ 
as.factor(cd4pccat)+ as.factor(hfacat) + as.factor(agecat)+ as.factor(wfacat)+ cluster(id), 
data=myimp$imputations[[16]], robust=TRUE, method="breslow") 
Lpvm317 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpv, df=4) + as.factor(logvlcat) + as.factor(whostage2)+ 
as.factor(cd4pccat)+ as.factor(hfacat) + as.factor(agecat)+ as.factor(wfacat)+ cluster(id), 
data=myimp$imputations[[17]], robust=TRUE, method="breslow") 
Lpvm318 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpv, df=4) + as.factor(logvlcat) + as.factor(whostage2)+ 
as.factor(cd4pccat)+ as.factor(hfacat) + as.factor(agecat)+ as.factor(wfacat)+ cluster(id), 
data=myimp$imputations[[18]], robust=TRUE, method="breslow") 
Lpvm319 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpv, df=4) + as.factor(logvlcat) + as.factor(whostage2)+ 
as.factor(cd4pccat)+ as.factor(hfacat) + as.factor(agecat)+ as.factor(wfacat)+ cluster(id), 
data=myimp$imputations[[19]], robust=TRUE, method="breslow") 
Lpvm320 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpv, df=4)+ as.factor(logvlcat) + as.factor(whostage2)+ 
as.factor(cd4pccat)+ as.factor(hfacat) + as.factor(agecat)+ as.factor(wfacat)+ cluster(id), 
data=myimp$imputations[[20]], robust=TRUE, method="breslow") 
Lpvm321 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpv, df=4) + as.factor(logvlcat) + as.factor(whostage2)+ 
as.factor(cd4pccat)+ as.factor(hfacat) + as.factor(agecat)+ as.factor(wfacat)+ cluster(id), 
data=myimp$imputations[[21]], robust=TRUE, method="breslow") 
Lpvm322 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpv, df=4) + as.factor(logvlcat) + as.factor(whostage2)+ 
as.factor(cd4pccat)+ as.factor(hfacat) + as.factor(agecat)+ as.factor(wfacat)+ cluster(id), 
data=myimp$imputations[[22]], robust=TRUE, method="breslow") 
Lpvm323 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpv, df=4) + as.factor(logvlcat) + as.factor(whostage2)+ 
as.factor(cd4pccat)+ as.factor(hfacat) + as.factor(agecat)+ as.factor(wfacat)+ cluster(id), 





Lpvm324 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpv, df=4) + as.factor(logvlcat) + as.factor(whostage2)+ 
as.factor(cd4pccat)+ as.factor(hfacat) + as.factor(agecat)+ as.factor(wfacat)+ cluster(id), 
data=myimp$imputations[[24]], robust=TRUE, method="breslow") 
Lpvm325 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpv, df=4) + as.factor(logvlcat) + as.factor(whostage2)+ 
as.factor(cd4pccat)+ as.factor(hfacat) + as.factor(agecat)+ as.factor(wfacat)+ cluster(id), 
data=myimp$imputations[[25]], robust=TRUE, method="breslow") 
 
predicted31 <- predict(Lpvm31, type = "terms" , se.fit = TRUE , terms = 1) 
predicted32 <- predict(Lpvm32, type = "terms" , se.fit = TRUE , terms = 1) 
predicted33 <- predict(Lpvm33, type = "terms" , se.fit = TRUE , terms = 1) 
predicted34 <- predict(Lpvm34, type = "terms" , se.fit = TRUE , terms = 1) 
predicted35 <- predict(Lpvm35, type = "terms" , se.fit = TRUE , terms = 1) 
predicted36 <- predict(Lpvm36, type = "terms" , se.fit = TRUE , terms = 1) 
predicted37 <- predict(Lpvm37, type = "terms" , se.fit = TRUE , terms = 1) 
predicted38 <- predict(Lpvm38, type = "terms" , se.fit = TRUE , terms = 1) 
predicted39 <- predict(Lpvm39, type = "terms" , se.fit = TRUE , terms = 1) 
predicted310 <- predict(Lpvm310, type = "terms" , se.fit = TRUE , terms = 1) 
predicted311 <- predict(Lpvm311, type = "terms" , se.fit = TRUE , terms = 1) 
predicted312 <- predict(Lpvm312, type = "terms" , se.fit = TRUE , terms = 1) 
predicted313 <- predict(Lpvm313, type = "terms" , se.fit = TRUE , terms = 1) 
predicted314 <- predict(Lpvm314, type = "terms" , se.fit = TRUE , terms = 1) 
predicted315 <- predict(Lpvm315, type = "terms" , se.fit = TRUE , terms = 1) 
predicted316 <- predict(Lpvm316, type = "terms" , se.fit = TRUE , terms = 1) 
predicted317 <- predict(Lpvm317, type = "terms" , se.fit = TRUE , terms = 1) 
predicted318 <- predict(Lpvm318, type = "terms" , se.fit = TRUE , terms = 1) 
predicted319 <- predict(Lpvm319, type = "terms" , se.fit = TRUE , terms = 1) 
predicted320 <- predict(Lpvm320, type = "terms" , se.fit = TRUE , terms = 1) 
predicted321 <- predict(Lpvm321, type = "terms" , se.fit = TRUE , terms = 1) 
predicted322 <- predict(Lpvm322, type = "terms" , se.fit = TRUE , terms = 1) 
predicted323 <- predict(Lpvm323, type = "terms" , se.fit = TRUE , terms = 1) 
predicted324 <- predict(Lpvm324, type = "terms" , se.fit = TRUE , terms = 1) 



































mycoeff <- apply(mycoefflist,1,mean) 
coeffdiff<-(matrix(cbind(rep(mycoeff,M)),ncol=M,nrow=length(mycoeff))-mycoefflist)^2 
between <-  apply(coeffdiff,1,sum) 
variance <- within + ((M+1)/(M*(M-1)))*between 




plot(0 , xlab=" Lopinavir concentration (mg/L)" , ylab = "Hazard of virological failure" , axes=T, main = "" , type 
= "n" , xlim=c(0,15) , las=1,ylim=c(0.5,1.75)) 





lines(sm.spline(myimp$imputations[[1]]$lpv[is.na(seldat$lpv)==F], exp(lp + 1.96 * sqrt(variance))) , col = 
"orange" , lty = 2 , lwd = 0.4) 
lines(sm.spline(myimp$imputations[[1]]$lpv[is.na(seldat$lpv)==F], exp(lp - 1.96 * sqrt(variance))) , col = 
"orange" , lty = 2 , lwd = 0.4) 
axis(side = 1 , at = c(seq(0,17.5,2.5)), labels = F , tick = T , tcl = 0.4 , lwd.ticks = 0.1) 
#axis(2,at=c(seq(0.5,1.75,0.25)),las=1) 
#legend("top",col=c("red","blue","blue"),legend=c("Multiple Imputation (n=524)","Complete cases (adj., 
n=213)","Complete cases (crude, n=452)"), lty=c(1,1,2),lwd=1.5, cex=1.25, bty="n",ncol=1) 




# Model Selection ###################### 
##################################### 
 
m4_0a<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1 + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ cluster(id),data=seldat,weights=myweights+1e-
08,method="breslow") 
m4_0b<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4 + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ cluster(id),data=seldat,weights=myweights+1e-
08,method="breslow") 
m4_0c<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ cluster(id),data=seldat,weights=myweights+1e-
08,method="breslow") 
m4_0d<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpv) + as.factor(cd4pccat) + as.factor(logvlcat) + 







m4_1a<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1 + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[1]],method="breslow") 
m4_1b<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4 + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 






m4_1c<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[1]],method="breslow") 
m4_1d<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpv) + as.factor(cd4pccat) + as.factor(logvlcat) + 







m4_2a<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1 + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[2]],method="breslow") 
m4_2b<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4 + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[2]],method="breslow") 
m4_2c<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[2]],method="breslow") 
m4_2d<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpv) + as.factor(cd4pccat) + as.factor(logvlcat) + 







m4_3a<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1 + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[3]],method="breslow") 
m4_3b<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4 + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[3]],method="breslow") 
m4_3c<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[3]],method="breslow") 
m4_3d<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpv) + as.factor(cd4pccat) + as.factor(logvlcat) + 











m4_4a<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1 + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[4]],method="breslow") 
m4_4b<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4 + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[4]],method="breslow") 
m4_4c<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[4]],method="breslow") 
m4_4d<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpv) + as.factor(cd4pccat) + as.factor(logvlcat) + 







m4_5a<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1 + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[5]],method="breslow") 
m4_5b<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4 + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[5]],method="breslow") 
m4_5c<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[5]],method="breslow") 
m4_5d<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpv) + as.factor(cd4pccat) + as.factor(logvlcat) + 











m4_6a<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1 + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[6]],method="breslow") 
m4_6b<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4 + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[6]],method="breslow") 
m4_6c<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[6]],method="breslow") 
m4_6d<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpv) + as.factor(cd4pccat) + as.factor(logvlcat) + 







m4_7a<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1 + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[7]],method="breslow") 
m4_7b<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4 + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[7]],method="breslow") 
m4_7c<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[7]],method="breslow") 
m4_7d<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpv) + as.factor(cd4pccat) + as.factor(logvlcat) + 







m4_8a<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1 + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[8]],method="breslow") 
m4_8b<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4 + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 






m4_8c<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[8]],method="breslow") 
m4_8d<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpv) + as.factor(cd4pccat) + as.factor(logvlcat) + 







m4_9a<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1 + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),,data=myimp$imputations[[9]],method="breslow") 
m4_9b<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4 + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),,data=myimp$imputations[[9]],method="breslow") 
m4_9c<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),,data=myimp$imputations[[9]],method="breslow") 
m4_9d<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpv) + as.factor(cd4pccat) + as.factor(logvlcat) + 







m4_10a<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1 + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) 
+ as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[10]],method="breslow") 
m4_10b<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4 + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) 
+ as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[10]],method="breslow") 
m4_10c<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[10]],method="breslow") 
m4_10d<-coxph(Surv(X_t0,X_t, vlsupp) ~pspline(lpv) + as.factor(cd4pccat) + as.factor(logvlcat) + 












# Adherence vs. Concentration ##### 
############################### 
m5_0 <- coxph(Surv(X_t0,X_t, vlsupp)~ lpvcat1   + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ cluster(id),data=seldat,weights=myweights+1e-
08,method="breslow") 
m5_1 <- coxph(Surv(X_t0,X_t, vlsupp)~ lpv   + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ cluster(id),data=seldat,weights=myweights+1e-
08,method="breslow") 
m5_2 <- coxph(Surv(X_t0,X_t, vlsupp)~ adhstatus + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) 
+ as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ cluster(id),data=seldat,weights=myweights+1e-
08,method="breslow") 
m5_3 <- coxph(Surv(X_t0,X_t, vlsupp)~ pspline(lpv) + as.factor(cd4pccat) + as.factor(logvlcat) + 








m5_31<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv   + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[1]],method="breslow") 
m5_32<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv   + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[2]],method="breslow") 
m5_33<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv   + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[3]],method="breslow") 
m5_34<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv   + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 






m5_35<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv   + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[5]],method="breslow") 
m5_36<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv   + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[6]],method="breslow") 
m5_37<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv   + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[7]],method="breslow") 
m5_38<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv   + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[8]],method="breslow") 
m5_39<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv   + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[9]],method="breslow") 
m5_310<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpv   + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) + 
as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[10]],method="breslow") 
 
m5_41<-coxph(Surv(X_t0,X_t, vlsupp) ~ adhstatus + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) 
+ as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[1]],method="breslow") 
m5_42<-coxph(Surv(X_t0,X_t, vlsupp) ~ adhstatus + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) 
+ as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[2]],method="breslow") 
m5_43<-coxph(Surv(X_t0,X_t, vlsupp) ~ adhstatus + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) 
+ as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[3]],method="breslow") 
m5_44<-coxph(Surv(X_t0,X_t, vlsupp) ~ adhstatus + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) 
+ as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[4]],method="breslow") 
m5_45<-coxph(Surv(X_t0,X_t, vlsupp) ~ adhstatus + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) 
+ as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[5]],method="breslow") 
m5_46<-coxph(Surv(X_t0,X_t, vlsupp) ~ adhstatus + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) 
+ as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[6]],method="breslow") 
m5_47<-coxph(Surv(X_t0,X_t, vlsupp) ~ adhstatus + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) 
+ as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[7]],method="breslow") 
m5_48<-coxph(Surv(X_t0,X_t, vlsupp) ~ adhstatus + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) 






m5_49<-coxph(Surv(X_t0,X_t, vlsupp) ~ adhstatus + as.factor(cd4pccat) + as.factor(logvlcat) + as.factor(agecat) 
+ as.factor(whostage2) + as.factor(wfacat) + as.factor(hfacat)+ 
cluster(id),data=myimp$imputations[[9]],method="breslow") 
m5_410<-coxph(Surv(X_t0,X_t, vlsupp) ~ adhstatus+ as.factor(cd4pccat) + as.factor(logvlcat) + 





























### Descriptives #### 
##################### 




surv.vl1 <- Surv(X_t0,X_t,vlsupp)       # setting survival time from Stata 
summary(surv.vl1) 
################# 










round(apply(apply(impdat,c(1,2),is.na),2,mean),digits=3)   # percentage of missing values 
# Michael 1: Made changes here 
myimp <- amelia(impdat, m=M, 

















compare.density(myimp,var="X_t")   
dev.off() 
par(mfrow=c(1,1)) 
suppressWarnings(disperse(myimp, dims=1, m=10)) 




par(mfrow=c(1,1))                        
overimpute(myimp,var="lpvcorr")          
















































write.amelia(obj=myimp , file.stem = "lpv3imp") 
 
 
# function to create lags 
shift.1<-function(x,shift_by=-1){ 
    stopifnot(is.numeric(shift_by)) 
    stopifnot(is.numeric(x)) 
    if (length(shift_by)>1) 
        return(sapply(shift_by,shift, x=x)) 
    out<-NULL 





    if (shift_by > 0 ) 
        out<-c(tail(x,-abs_shift_by),rep(NA,abs_shift_by)) 
    else if (shift_by < 0 ) 
        out<-c(rep(NA,abs_shift_by), head(x,-abs_shift_by)) 
    else 
        out<-x 
    out 
} 
# ...use this function for longitudinal data, means apply them by patient 
shift.l <- function(x,splitby){ 
unsplit(lapply(split(x,splitby),shift.1),splitby) 
} 













## Table 3: Cox Regression   # 
## (crude, adj, selected)    # 
############################## 
# Crude analysis 
m1_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m1_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 






m1_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m1_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m1_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m1_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m1_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m1_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 









my1a <- mi.inference(myest1, mystd1, confidence=0.95) 
my_1 <- round(cbind(exp(my1a$est),exp(my1a$lower),exp(my1a$upper),my1a$signif),digits=3) 
my_1     # significant 
 
 
m1b_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m1b_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr + 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m1b_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m1b_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m1b_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m1b_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 






m1b_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m1b_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr + 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 









my1b <- mi.inference(myest1b, mystd1b, confidence=0.95) 
my_1b <- round(cbind(exp(my1b$est),exp(my1b$lower),exp(my1b$upper),my1b$signif),digits=3) 
my_1b     # significant 
 
m1c_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvre + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m1c_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvre + 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m1c_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvre + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m1c_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvre + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m1c_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvre + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m1c_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvre + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m1c_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvre + 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m1c_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvre + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m1c_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvre + 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 













my1c <- mi.inference(myest1c, mystd1c, confidence=0.95) 
my_1c <- round(cbind(exp(my1c$est),exp(my1c$lower),exp(my1c$upper),my1c$signif),digits=3) 
my_1c     # significant 
 
m1d_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpave + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m1d_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpave + 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m1d_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpave + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m1d_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpave + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m1d_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpave + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m1d_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpave + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m1d_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpave + 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m1d_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpave + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m1d_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpave + 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 









my1d <- mi.inference(myest1d, mystd1d, confidence=0.95) 
my_1d <- round(cbind(exp(my1d$est),exp(my1d$lower),exp(my1d$upper),my1d$signif),digits=3) 






m1e_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1 + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m1e_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1 + 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m1e_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1 + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m1e_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1 + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m1e_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1 + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m1e_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1 + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m1e_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1 + 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m1e_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1 + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m1e_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1 + 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 









my1e <- mi.inference(myest1e, mystd1e, confidence=0.95) 
my_1e <- round(cbind(exp(my1e$est),exp(my1e$lower),exp(my1e$upper),my1e$signif),digits=3) 
my_1e  
 
m1f_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m1f_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m1f_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 






m1f_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m1f_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m1f_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m1f_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m1f_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 









my1f <- mi.inference(myest1f, mystd1f, confidence=0.95) 
my_1f <- round(cbind(exp(my1f$est),exp(my1f$lower),exp(my1f$upper),my1f$signif),digits=3) 
my_1f     # significant 
 
m2_1<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(vlcat) + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m2_2<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(vlcat) + 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m2_3<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(vlcat) + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m2_4<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(vlcat) + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m2_5<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(vlcat) + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m2_6<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(vlcat) + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m2_7<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(vlcat) + 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 






m2_9<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(vlcat) + 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 









my2a <- mi.inference(myest2, mystd2, confidence=0.95) 
my_2 <- round(cbind(exp(my2a$est),exp(my2a$lower),exp(my2a$upper),my2a$signif),digits=3) 
my_2   
 
m3_1<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(cd4pccat)+ 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m3_2<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(cd4pccat)+ 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m3_3<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(cd4pccat)+ 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m3_4<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(cd4pccat)+ 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m3_5<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(cd4pccat)+ 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m3_6<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(cd4pccat)+ 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m3_7<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(cd4pccat)+ 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m3_8<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(cd4pccat)+ 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m3_9<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(cd4pccat)+ 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 













my3a <- mi.inference(myest3, mystd3, confidence=0.95) 
my_3 <- round(cbind(exp(my3a$est),exp(my3a$lower),exp(my3a$upper),my3a$signif),digits=3) 
my_3 
 
m4_1<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(agecat) + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m4_2<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(agecat) + 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m4_3<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(agecat) + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m4_4<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(agecat) + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m4_5<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(agecat) + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m4_6<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(agecat) + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m4_7<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(agecat) + 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m4_8<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(agecat) + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m4_9<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(agecat) + 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 









my4a <- mi.inference(myest4, mystd4, confidence=0.95) 









m6_1<-coxph(Surv(X_t0,X_t, vlsupp) ~as.factor (wfacat)+ 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m6_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (wfacat)+ 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m6_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (wfacat)+ 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m6_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (wfacat)+ 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m6_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (wfacat)+ 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m6_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (wfacat)+ 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m6_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (wfacat)+ 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m6_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (wfacat)+ 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m6_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (wfacat)+ 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 









my6a <- mi.inference(myest6, mystd6, confidence=0.95) 
my_6 <- round(cbind(exp(my6a$est),exp(my6a$lower),exp(my6a$upper),my6a$signif),digits=3) 
my_6    
 
m7_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (hfacat) + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m7_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (hfacat) + 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m7_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (hfacat) + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 






m7_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (hfacat) + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m7_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (hfacat) + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m7_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (hfacat) + 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m7_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (hfacat) + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m7_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (hfacat) + 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 









my7a <- mi.inference(myest7, mystd7, confidence=0.95) 
my_7 <- round(cbind(exp(my7a$est),exp(my7a$lower),exp(my7a$upper),my7a$signif),digits=3) 




m9_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m9_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m9_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m9_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m9_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m9_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 






m9_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m9_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 









my9a <- mi.inference(myest9, mystd9, confidence=0.95) 
my_9 <- round(cbind(exp(my9a$est),exp(my9a$lower),exp(my9a$upper),my9a$signif),digits=3) 
my_9 
 
# Adjusted analysis 
# Using Lopinavir as continous variable 
m11_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m11_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m11_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m11_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m11_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m11_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m11_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 






m11_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m11_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 
m11_10<-coxph(Surv(X_t0,X_t,vlsupp) ~ lpvcorr  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 









my11a <- mi.inference(myest, mystd, confidence=0.95) 
my_11 <- round(cbind(exp(my11a$est),exp(my11a$lower),exp(my11a$upper),my11a$signif),digits=3) 
my_11     # overall results with Hazard ratios, CI, and p-values 
 
m14_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvre  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m14_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvre  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m14_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvre  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m14_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvre  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m14_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvre  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m14_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvre  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m14_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvre  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 






m14_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvre  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m14_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvre  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 
m14_10<-coxph(Surv(X_t0,X_t,vlsupp) ~ lpvre  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 









my14a <- mi.inference(myest, mystd, confidence=0.95) 
my_14 <- round(cbind(exp(my14a$est),exp(my14a$lower),exp(my14a$upper),my14a$signif),digits=3) 
my_14     # overall results with Hazard ratios, CI, and p-values 
 
m15_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpave  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m15_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpave  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m15_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpave  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m15_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpave  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m15_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpave  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m15_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpave  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m15_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpave  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 






m15_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpave  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m15_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpave  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 
m15_10<-coxph(Surv(X_t0,X_t,vlsupp) ~ lpave  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 









my15a <- mi.inference(myest, mystd, confidence=0.95) 
my_15 <- round(cbind(exp(my15a$est),exp(my15a$lower),exp(my15a$upper),my15a$signif),digits=3) 




# Cut-off Selection Using Cox Regression Approach vs Mixed Addative Logistic Regression Approach  # 
##########################################################################################
######### 
LPV2 <- LPV[,c("X_t","vlsupp","lpvcorr","id")] 
 
# Approach 1: Cox regression 
m2_0 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ cut(lpvcorr, breaks=c(0,0.25,100))    + cluster(id), data=LPV, 
robust=TRUE, method="breslow") 
m2_1 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ cut(lpvcorr, breaks=c(0,0.5,100))     + cluster(id), data=LPV, 
robust=TRUE, method="breslow") 
m2_2 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ cut(lpvcorr, breaks=c(0,0.75,100))    + cluster(id), data=LPV, 
robust=TRUE, method="breslow") 
m2_3 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ cut(lpvcorr, breaks=c(0,1,100))       + cluster(id), data=LPV, 
robust=TRUE, method="breslow") 
m2_4 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ cut(lpvcorr, breaks=c(0,2,100))       + cluster(id), data=LPV, 
robust=TRUE, method="breslow") 






m2_6 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ cut(lpvcorr, breaks=c(0,4,100))       + cluster(id), data=LPV, 
robust=TRUE, method="breslow") 
m2_7 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ cut(lpvcorr, breaks=c(0,5,100))       + cluster(id), data=LPV, 
robust=TRUE, method="breslow") 
m2_8 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ cut(lpvcorr, breaks=c(0,6,100))       + cluster(id), data=LPV, 
robust=TRUE, method="breslow") 
 











# Michael 6: add this library 
library(gamm4) 
# Approach 2: mixed additive logistic regression    (not working so well) 
m0_1a <- gamm4(vlsupp ~ cut(lpvcorr, 
breaks=c(0,0.25,100))+s(X_t),random=~(1|id),data=na.omit(LPV2),family=binomial)    
m0_2a <- gamm4(vlsupp ~ cut(lpvcorr, 
breaks=c(0,0.5,100))+s(X_t),random=~(1|id),data=na.omit(LPV2),family=binomial)  
m0_3a <- gamm4(vlsupp ~ cut(lpvcorr, 
breaks=c(0,0.75,100))+s(X_t),random=~(1|id),data=na.omit(LPV2),family=binomial)  
m0_4a <- gamm4(vlsupp ~ cut(lpvcorr, 
breaks=c(0,1,100))+s(X_t),random=~(1|id),data=na.omit(LPV2),family=binomial)  
m0_5a <- gamm4(vlsupp ~ cut(lpvcorr, 
breaks=c(0,2,100))+s(X_t),random=~(1|id),data=na.omit(LPV2),family=binomial)  
m0_6a <- gamm4(vlsupp ~ cut(lpvcorr, 
breaks=c(0,3,100))+s(X_t),random=~(1|id),data=na.omit(LPV2),family=binomial)  
m0_7a <- gamm4(vlsupp ~ cut(lpvcorr, 
breaks=c(0,4,100))+s(X_t),random=~(1|id),data=na.omit(LPV2),family=binomial)  
m0_8a <- gamm4(vlsupp ~ cut(lpvcorr, 

















# Approach 3 just additive logistic 
library(mgcv) 
m0_1b <- gam(vlsupp ~ cut(lpvcorr, breaks=c(0,0.25,100))+s(X_t),data=na.omit(LPV2),family=binomial,scale=-
1)    
m0_2b <- gam(vlsupp ~ cut(lpvcorr, breaks=c(0,0.5,100))+s(X_t) ,data=na.omit(LPV2),family=binomial,scale=-1)  
m0_3b <- gam(vlsupp ~ cut(lpvcorr, breaks=c(0,0.75,100))+s(X_t),data=na.omit(LPV2),family=binomial,scale=-
1)  
m0_4b <- gam(vlsupp ~ cut(lpvcorr, breaks=c(0,1,100))+s(X_t)   ,data=na.omit(LPV2),family=binomial,scale=-1)  
m0_5b <- gam(vlsupp ~ cut(lpvcorr, breaks=c(0,2,100))+s(X_t)   ,data=na.omit(LPV2),family=binomial,scale=-1)  
m0_6b <- gam(vlsupp ~ cut(lpvcorr, breaks=c(0,3,100))+s(X_t)   ,data=na.omit(LPV2),family=binomial,scale=-1)  
m0_7b <- gam(vlsupp ~ cut(lpvcorr, breaks=c(0,4,100))+s(X_t)   ,data=na.omit(LPV2),family=binomial,scale=-1)  
m0_8b <- gam(vlsupp ~ cut(lpvcorr, breaks=c(0,5,100))+s(X_t)   ,data=na.omit(LPV2),family=binomial,scale=-1)   














# Michael 2: Let's discuss if multivariate or not 
# Note: I neglected longitudinal structure, but Helen wanted predictive criterion and results make sense, we 
likely have to be pragmatic here 
 
# Also, for figure: What is better: average or current? 
 
m_current1 <- gam(vlsupp ~ s(lpvcorr)+s(X_t),data=myimp$imputations[[1]],family=binomial)    
m_average1 <- gam(vlsupp ~ s(lpave)+s(X_t),data=myimp$imputations[[1]],family=binomial) 
m_current2 <- gam(vlsupp ~ s(lpvcorr)+s(X_t),data=myimp$imputations[[2]],family=binomial)    
m_average2 <- gam(vlsupp ~ s(lpave)+s(X_t),data=myimp$imputations[[2]],family=binomial) 
m_current3 <- gam(vlsupp ~ s(lpvcorr)+s(X_t),data=myimp$imputations[[3]],family=binomial)    
m_average3 <- gam(vlsupp ~ s(lpave)+s(X_t),data=myimp$imputations[[3]],family=binomial) 
m_current4 <- gam(vlsupp ~ s(lpvcorr)+s(X_t),data=myimp$imputations[[4]],family=binomial)    
m_average4 <- gam(vlsupp ~ s(lpave)+s(X_t),data=myimp$imputations[[4]],family=binomial) 
m_current5 <- gam(vlsupp ~ s(lpvcorr)+s(X_t),data=myimp$imputations[[5]],family=binomial)    
m_average5 <- gam(vlsupp ~ s(lpave)+s(X_t),data=myimp$imputations[[5]],family=binomial) 
    






# Figure  # 
############ 
 
# Spline representation   
# Imputation based approach Using Current Visit LPV Conc's 
Lpvm31 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpvcorr, df=4) + as.factor(vlcat) + as.factor(cd4pccat) + 
as.factor (hfacat) + as.factor(agecat)+ as.factor (wfacat)  + as.factor(postrantb) + cluster(id), 
data=myimp$imputations[[1]], robust=TRUE, method="breslow") 
Lpvm32 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpvcorr, df=4) + as.factor(vlcat) + as.factor(cd4pccat) + 
as.factor (hfacat) + as.factor(agecat)+ as.factor (wfacat)  + as.factor(postrantb) + cluster(id), 





Lpvm33 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpvcorr, df=4) + as.factor(vlcat) + as.factor(cd4pccat) + 
as.factor (hfacat) + as.factor(agecat)+ as.factor (wfacat)  + as.factor(postrantb) + cluster(id), 
data=myimp$imputations[[3]], robust=TRUE, method="breslow") 
Lpvm34 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpvcorr, df=4) + as.factor(vlcat) + as.factor(cd4pccat) + 
as.factor (hfacat) + as.factor(agecat)+ as.factor (wfacat)  + as.factor(postrantb) + cluster(id), 
data=myimp$imputations[[4]], robust=TRUE, method="breslow") 
Lpvm35 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpvcorr, df=4) + as.factor(vlcat) + as.factor(cd4pccat) + 
as.factor (hfacat) + as.factor(agecat)+ as.factor (wfacat)  + as.factor(postrantb) + cluster(id), 
data=myimp$imputations[[5]], robust=TRUE, method="breslow") 
Lpvm36 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpvcorr, df=4) + as.factor(vlcat) + as.factor(cd4pccat) + 
as.factor (hfacat) + as.factor(agecat)+ as.factor (wfacat)  + as.factor(postrantb) + cluster(id), 
data=myimp$imputations[[6]], robust=TRUE, method="breslow") 
Lpvm37 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpvcorr, df=4) + as.factor(vlcat) + as.factor(cd4pccat) + 
as.factor (hfacat) + as.factor(agecat)+ as.factor (wfacat)  + as.factor(postrantb) + cluster(id), 
data=myimp$imputations[[7]], robust=TRUE, method="breslow") 
Lpvm38 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpvcorr, df=4) + as.factor(vlcat) + as.factor(cd4pccat) + 
as.factor (hfacat) + as.factor(agecat)+ as.factor (wfacat)  + as.factor(postrantb) + cluster(id), 
data=myimp$imputations[[8]], robust=TRUE, method="breslow") 
Lpvm39 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpvcorr, df=4) + as.factor(vlcat) + as.factor(cd4pccat) + 
as.factor (hfacat) + as.factor(agecat)+ as.factor (wfacat)  + as.factor(postrantb) + cluster(id), 
data=myimp$imputations[[9]], robust=TRUE, method="breslow") 
Lpvm40 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(lpvcorr, df=4) + as.factor(vlcat) + as.factor(cd4pccat) + 
as.factor (hfacat) + as.factor(agecat)+ as.factor (wfacat)  + as.factor(postrantb) + cluster(id), 
data=myimp$imputations[[10]], robust=TRUE, method="breslow") 
 
 
predicted31 <- predict(Lpvm31, type = "terms" , se.fit = TRUE , terms = 1) 
predicted32 <- predict(Lpvm32, type = "terms" , se.fit = TRUE , terms = 1) 
predicted33 <- predict(Lpvm33, type = "terms" , se.fit = TRUE , terms = 1) 
predicted34 <- predict(Lpvm34, type = "terms" , se.fit = TRUE , terms = 1) 
predicted35 <- predict(Lpvm35, type = "terms" , se.fit = TRUE , terms = 1) 
predicted36 <- predict(Lpvm36, type = "terms" , se.fit = TRUE , terms = 1) 
predicted37 <- predict(Lpvm37, type = "terms" , se.fit = TRUE , terms = 1) 
predicted38 <- predict(Lpvm38, type = "terms" , se.fit = TRUE , terms = 1) 
predicted39 <- predict(Lpvm39, type = "terms" , se.fit = TRUE , terms = 1) 



















# Michael 9: have defined "seldat" now and adapted 
seldat <- impdat 










mycoeff <- apply(mycoefflist,1,mean) 
coeffdiff<-(matrix(cbind(rep(mycoeff,M)),ncol=M,nrow=length(mycoeff))-mycoefflist)^2 
between <-  apply(coeffdiff,1,sum) 
variance <- within + ((M+1)/(M*(M-1)))*between 
se <- round(sqrt(variance),digits=5) 
 
# Main Figure: Nice  
# Michael 3: changed 
dev.off() 
par(mfrow=c(1,1)) 
plot(0 , xlab=" Lopinavir Concentration (mg/L)" , ylab = "Hazard of  failure" , axes=T  ,main = "Non-Linear Effect 
of Lopinavir Concentration" ,type = "n" , xlim=c(0,15) , las=1,ylim=c(0.5,1.75)) 





lines(sm.spline(myimp$imputations[[5]]$lpvcorr[is.na(seldat$lpvcorr)==F], exp(lp + 1.96 * sqrt(variance))) , col 
= "orange" , lty = 6 , lwd = 0.8) 
lines(sm.spline(myimp$imputations[[5]]$lpvcorr[is.na(seldat$lpvcorr)==F], exp(lp - 1.96 * sqrt(variance))) , col 
= "orange" , lty = 6 , lwd = 0.8) 





tiff("LPV.tif", res=600, compression = "lzw", height=5, width=5, units="in") 
 
tiff("outfile.tif", compression = "lzw") 
 
dev.print(tiff, "image.tiff2", res=600, height=4, width=4, units="p") 
 
 
tiff(file = "temp.tiff", width =672, height = 672, units = "px", res = 800,type = c("windows", "cairo"),family = "", 
restoreConsole = TRUE,antialias="cleartype") 
 







png(filename = "LPV15mg.png", width = 3200, height = 3200, units = "px", pointsize = 12, 
     bg = "white", res = 400, family = "", restoreConsole = TRUE,type = c("windows", "cairo"), 
antialias="cleartype") 
      
 
#Average LPV 











# Adjusted analysis 
# Using Lopinavir 1 mg/L Cut off 
m12_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m12_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m12_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m12_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m12_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m12_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m12_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m12_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m12_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 
m12_10<-coxph(Surv(X_t0,X_t,vlsupp) ~ lpvcorr  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 













my12a <- mi.inference(myest, mystd, confidence=0.95) 
my_12 <- round(cbind(exp(my12a$est),exp(my12a$lower),exp(my12a$upper),my12a$signif),digits=3) 
my_12    
   
# Adjusted analysis 
#Using Lopinavir 4 mg/L Cut off 
m13_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m13_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m13_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m13_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m13_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m13_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m13_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m13_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m13_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 
m13_10<-coxph(Surv(X_t0,X_t,vlsupp) ~ lpvcat4  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 













my13a <- mi.inference(myest, mystd, confidence=0.95) 
my_13 <- round(cbind(exp(my13a$est),exp(my13a$lower),exp(my13a$upper),my13a$signif),digits=3) 




#Using Lopinavir 2 mg/L Cut off 
m14_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat2  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m14_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat2  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m14_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat2  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m14_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat2  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m14_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat2  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m14_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat2  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m14_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat2  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m14_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat2  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m14_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat2  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 
m14_10<-coxph(Surv(X_t0,X_t,vlsupp) ~ lpvcat2  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 













my14a <- mi.inference(myest, mystd, confidence=0.95) 
my_14 <- round(cbind(exp(my14a$est),exp(my14a$lower),exp(my14a$upper),my14a$signif),digits=3) 
my_14     # overall results with Hazard ratios, CI, and p-values    # overall results with Hazard ratios, CI, and p-
valuess 
 
#Using Lopinavir 3 mg/L Cut off 
m15_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat3  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m15_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat3  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m15_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat3  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m15_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat3  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m15_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat3  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m15_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat3  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m15_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat3  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m15_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat3  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m15_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat3  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 
m15_10<-coxph(Surv(X_t0,X_t,vlsupp) ~ lpvcat3  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 













my15a <- mi.inference(myest, mystd, confidence=0.95) 
my_15 <- round(cbind(exp(my15a$est),exp(my15a$lower),exp(my15a$upper),my15a$signif),digits=3) 




#Using Lopinavir 5 mg/L Cut off 
m16_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat5  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m16_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat5  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m16_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat5  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m16_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat5  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m16_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat5  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m16_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat5  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m16_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat5  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m16_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat5  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m16_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat5  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 






m16_10<-coxph(Surv(X_t0,X_t,vlsupp) ~ lpvcat5  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 









my16a <- mi.inference(myest, mystd, confidence=0.95) 
my_16 <- round(cbind(exp(my16a$est),exp(my16a$lower),exp(my16a$upper),my16a$signif),digits=3) 
my_16     # overall results with Hazard ratios, CI, and p-values    # overall results with Hazard ratios, CI, and p-
valuess 
 
#Using Lopinavir 5 mg/L Cut off 
m17_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat3.5  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m17_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat3.5  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m17_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat3.5  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m17_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat3.5  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m17_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat3.5  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m17_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat3.5  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m17_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat3.5  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m17_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat3.5  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m17_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat3.5  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 






m17_10<-coxph(Surv(X_t0,X_t,vlsupp) ~ lpvcat3.5  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 









my17a <- mi.inference(myest, mystd, confidence=0.95) 
my_17 <- round(cbind(exp(my17a$est),exp(my17a$lower),exp(my17a$upper),my17a$signif),digits=3) 




my_12    













#  Summary   # 
############## 
 
# Michael 17: I chose LPV cat1 
 





MIsummary[1,1:4] <- my_1 
MIsummary[2,1:4] <- my_2 
MIsummary[3,1:4] <- my_3 
MIsummary[4,1:4] <- my_4 
MIsummary[6,1:4] <- my_6 
MIsummary[7,1:4] <- my_7 
MIsummary[8,1:4] <- my_9 
#MIsummary[9:8,1:4] <- my_12 
 
 






MIsummary <- matrix(rep(NA,8*10),nrow=10,ncol=8) 
MIsummary[1,1:4] <- my_1b 
MIsummary[2,1:4] <- my_2 
MIsummary[3,1:4] <- my_3 
MIsummary[4,1:4] <- my_4 
MIsummary[6,1:4] <- my_6 
MIsummary[7,1:4] <- my_7 
MIsummary[8,1:4] <- my_9 
MIsummary[9:10,1:4] <- my_10 
 






MIsummary <- matrix(rep(NA,8*10),nrow=10,ncol=8) 





MIsummary[2,1:4] <- my_2 
MIsummary[3,1:4] <- my_3 
MIsummary[4,1:4] <- my_4 
MIsummary[5,1:4] <- my_5 
MIsummary[6,1:4] <- my_6 
MIsummary[7,1:4] <- my_7 
MIsummary[8,1:4] <- my_9 
MIsummary[9:10,1:4] <- my_10 
MIsummary[,5:8]     <- my_12 
 






MIsummary <- matrix(rep(NA,8*10),nrow=10,ncol=8) 
MIsummary[1,1:4] <- my_1d 
MIsummary[2,1:4] <- my_2 
MIsummary[3,1:4] <- my_3 
MIsummary[4,1:4] <- my_4 
MIsummary[5,1:4] <- my_5 
MIsummary[6,1:4] <- my_6 
MIsummary[7,1:4] <- my_7 
MIsummary[8,1:4] <- my_9 
#MIsummary[9:10,1:4] <- my_10 
MIsummary[,5:8]     <- my_12 
 










MIsummary <- matrix(rep(NA,8*10),nrow=10,ncol=8) 
MIsummary[1,1:4] <- my_1e 
MIsummary[2,1:4] <- my_2 
MIsummary[3,1:4] <- my_3 
MIsummary[4,1:4] <- my_4 
MIsummary[5,1:4] <- my_5 
MIsummary[6,1:4] <- my_6 
MIsummary[7,1:4] <- my_7 
MIsummary[8,1:4] <- my_9 
MIsummary[9:10,1:4] <- my_10 
MIsummary[,5:8]     <- my_12 
 









# Analysis with "interaction of time"## 
####################################### 
# Michael 18: is not interaction but rather conditioned on a certain time period 
 




# First 6 months = 6*4 =24weeks 
# Michael 19: I replaced "<-" with "<=". Works now. You can summarize as above. 
hist(impdat$lpvcorr[impdat$time1<=24]) # not much data above 20/30 
m4_1a<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr)  + as.factor(cd4pccat)    + as.factor(wfacat) + 







m4_2a<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr)  + as.factor(cd4pccat)    + as.factor(wfacat) + 
as.factor(hfacat)  +as.factor(postrantb)+ 
cluster(id),data=(myimp$imputations[[2]])[myimp$imputations[[2]]$time1<=24,], 
robust=TRUE,method="breslow") 
m4_3a<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr)  + as.factor(cd4pccat)    + as.factor(wfacat) + 
as.factor(hfacat)  +as.factor(postrantb)+ 
cluster(id),data=(myimp$imputations[[3]])[myimp$imputations[[3]]$time1<=24,], 
robust=TRUE,method="breslow") 
m4_4a<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr)  + as.factor(cd4pccat)    + as.factor(wfacat) + 
as.factor(hfacat)  +as.factor(postrantb)+ 
cluster(id),data=(myimp$imputations[[4]])[myimp$imputations[[4]]$time1<=24,], 
robust=TRUE,method="breslow") 
m4_5a<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr)  + as.factor(cd4pccat)    + as.factor(wfacat) + 
as.factor(hfacat)  +as.factor(postrantb) + 
cluster(id),data=(myimp$imputations[[5]])[myimp$imputations[[5]]$time1<=24,], 
robust=TRUE,method="breslow") 
m4_6a<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr)  + as.factor(cd4pccat)    + as.factor(wfacat) + 
as.factor(hfacat)  +as.factor(postrantb) + 
cluster(id),data=(myimp$imputations[[6]])[myimp$imputations[[6]]$time1<=24,], 
robust=TRUE,method="breslow") 
m4_7a<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr)  + as.factor(cd4pccat)    + as.factor(wfacat) + 
as.factor(hfacat)  +as.factor(postrantb) + 
cluster(id),data=(myimp$imputations[[7]])[myimp$imputations[[7]]$time1<=24,], 
robust=TRUE,method="breslow") 
m4_8a<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr)  + as.factor(cd4pccat)    + as.factor(wfacat) + 
as.factor(hfacat)  +as.factor(postrantb) + 
cluster(id),data=(myimp$imputations[[8]])[myimp$imputations[[8]]$time1<=24,], 
robust=TRUE,method="breslow") 
m4_9a<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr)  + as.factor(cd4pccat)    + as.factor(wfacat) + 
as.factor(hfacat)  +as.factor(postrantb) + 
cluster(id),data=(myimp$imputations[[9]])[myimp$imputations[[9]]$time1<=24,], 
robust=TRUE,method="breslow") 
m4_10a<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr)  + as.factor(cd4pccat)    + as.factor(wfacat) + 




# 6 months - 12 months 
hist(impdat$lpvcorr[impdat$X_t<24]) # not much data above 20/30 
m4_1b<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr)  + as.factor(cd4pccat)    + as.factor(wfacat) + 







m4_2b<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr)  + as.factor(cd4pccat)    + as.factor(wfacat) + 
as.factor(hfacat)  +as.factor(postrantb) + 
cluster(id),data=(myimp$imputations[[2]])[myimp$imputations[[2]]$X_t>24 & 
myimp$imputations[[1]]$X_t<53,], robust=TRUE,method="breslow") 
m4_3b<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr)  + as.factor(cd4pccat)    + as.factor(wfacat) + 
as.factor(hfacat)  +as.factor(postrantb) + 
cluster(id),data=(myimp$imputations[[3]])[myimp$imputations[[3]]$X_t>24 & 
myimp$imputations[[1]]$X_t<53,], robust=TRUE,method="breslow") 
m4_4b<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr)  + as.factor(cd4pccat)    + as.factor(wfacat) + 
as.factor(hfacat)  +as.factor(postrantb) + 
cluster(id),data=(myimp$imputations[[4]])[myimp$imputations[[4]]$X_t>24 & 
myimp$imputations[[1]]$X_t<53,], robust=TRUE,method="breslow") 
m4_5b<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr)  + as.factor(cd4pccat)    + as.factor(wfacat) + 
as.factor(hfacat)  +as.factor(postrantb) + 
cluster(id),data=(myimp$imputations[[5]])[myimp$imputations[[5]]$X_t>24 & 
myimp$imputations[[1]]$X_t<53,], robust=TRUE,method="breslow") 
m4_6b<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr)  + as.factor(cd4pccat)    + as.factor(wfacat) + 
as.factor(hfacat)  +as.factor(postrantb) + 
cluster(id),data=(myimp$imputations[[6]])[myimp$imputations[[6]]$X_t>24 & 
myimp$imputations[[1]]$X_t<53,], robust=TRUE,method="breslow") 
m4_7b<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr)  + as.factor(cd4pccat)    + as.factor(wfacat) + 
as.factor(hfacat)  +as.factor(postrantb) + 
cluster(id),data=(myimp$imputations[[7]])[myimp$imputations[[7]]$X_t>24 & 
myimp$imputations[[1]]$X_t<53,], robust=TRUE,method="breslow") 
m4_8b<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr)  + as.factor(cd4pccat)    + as.factor(wfacat) + 
as.factor(hfacat)  +as.factor(postrantb) + 
cluster(id),data=(myimp$imputations[[8]])[myimp$imputations[[8]]$X_t>24 & 
myimp$imputations[[1]]$X_t<53,], robust=TRUE,method="breslow") 
m4_9b<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr)  + as.factor(cd4pccat)    + as.factor(wfacat) + 
as.factor(hfacat)  +as.factor(postrantb) + 
cluster(id),data=(myimp$imputations[[9]])[myimp$imputations[[9]]$X_t>24 & 
myimp$imputations[[1]]$X_t<53,], robust=TRUE,method="breslow") 
m4_10b<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr)  + as.factor(cd4pccat)    + as.factor(wfacat) + 




# after 1 year 
hist(impdat$lpvcorr[impdat$X_t>53]) # not much data above 30 
m4_1c<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr,df=2)  + as.factor(cd4pccat)    + as.factor(wfacat) + 
as.factor(hfacat)   +as.factor(postrantb)+ 
cluster(id),data=(myimp$imputations[[1]])[myimp$imputations[[1]]$X_t>=53,], 
robust=TRUE,method="breslow") 
m4_2c<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr,df=2)  + as.factor(cd4pccat)    + as.factor(wfacat) + 







m4_3c<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr,df=2)  + as.factor(cd4pccat)    + as.factor(wfacat) + 
as.factor(hfacat)   +as.factor(postrantb)+ 
cluster(id),data=(myimp$imputations[[3]])[myimp$imputations[[3]]$X_t>=53,], 
robust=TRUE,method="breslow") 
m4_4c<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr,df=2)  + as.factor(cd4pccat)    + as.factor(wfacat) + 
as.factor(hfacat)   +as.factor(postrantb)+ 
cluster(id),data=(myimp$imputations[[4]])[myimp$imputations[[4]]$X_t>=53,], 
robust=TRUE,method="breslow") 
m4_5c<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr,df=2)  + as.factor(cd4pccat)    + as.factor(wfacat) + 
as.factor(hfacat)   +as.factor(postrantb)+ 
cluster(id),data=(myimp$imputations[[5]])[myimp$imputations[[5]]$X_t>=53,], 
robust=TRUE,method="breslow") 
m4_6c<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr,df=2)  + as.factor(cd4pccat)    + as.factor(wfacat) + 
as.factor(hfacat)   +as.factor(postrantb)+ 
cluster(id),data=(myimp$imputations[[6]])[myimp$imputations[[6]]$X_t>=53,], 
robust=TRUE,method="breslow") 
m4_7c<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr,df=2)  + as.factor(cd4pccat)    + as.factor(wfacat) + 
as.factor(hfacat)   +as.factor(postrantb)+ 
cluster(id),data=(myimp$imputations[[7]])[myimp$imputations[[7]]$X_t>=53,], 
robust=TRUE,method="breslow") 
m4_8c<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr,df=2)  + as.factor(cd4pccat)    + as.factor(wfacat) + 
as.factor(hfacat)   +as.factor(postrantb)+ 
cluster(id),data=(myimp$imputations[[8]])[myimp$imputations[[8]]$X_t>=53,], 
robust=TRUE,method="breslow") 
m4_9c<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr,df=2)  + as.factor(cd4pccat)    + as.factor(wfacat) + 
as.factor(hfacat)   +as.factor(postrantb)+ 
cluster(id),data=(myimp$imputations[[9]])[myimp$imputations[[9]]$X_t>=53,], 
robust=TRUE,method="breslow") 
m4_10c<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr,df=2)  + as.factor(cd4pccat)    + as.factor(wfacat) + 

















m5_0a<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr          + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[1]],method="breslow") 
m5_0b<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvre           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[1]],method="breslow") 
m5_0c<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpave           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[1]],method="breslow") 
m5_0d<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr)  + as.factor(vlcat)+ as.factor(cd4pccat)  + 







m5_1a<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr          + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[2]],method="breslow")                              
m5_1b<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvre           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[2]],method="breslow")                              
m5_1c<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpave           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[2]],method="breslow")                              
m5_1d<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr)  + as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 





      
m5_2a<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 





m5_2b<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvre             + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[3]],method="breslow")                              
m5_2c<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpave             + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[3]],method="breslow")                              
m5_2d<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr)  + as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 





      
m5_3a<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[4]],method="breslow")                              
m5_3b<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvre             + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[4]],method="breslow")                              
m5_3c<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpave             + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[4]],method="breslow")                              
m5_3d<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr)  + as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 





      
m5_4a<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[5]],method="breslow")                              
m5_4b<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvre             + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[5]],method="breslow")                              
m5_4c<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpave             + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 





m5_4d<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr)  + as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 





      
m5_5a<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[6]],method="breslow")                              
m5_5b<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvre             + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[6]],method="breslow")                              
m5_5c<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpave             + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[6]],method="breslow")                              
m5_5d<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr)  + as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 





      
m5_6a<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[7]],method="breslow")                              
m5_6b<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvre             + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[7]],method="breslow")                              
m5_6c<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpave             + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[7]],method="breslow")                              
m5_6d<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr)  + as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 









      
m5_7a<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[8]],method="breslow")                              
m5_7b<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvre             + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[8]],method="breslow")                              
m5_7c<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpave             + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[8]],method="breslow")                              
m5_7d<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr)  + as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 





      
m5_8a<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[9]],method="breslow")                              
m5_8b<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvre             + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[9]],method="breslow")                              
m5_8c<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpave             + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[9]],method="breslow")                              
m5_8d<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr)  + as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 





      
m5_9a<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 





m5_9b<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvre             + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[10]],method="breslow")                              
m5_9c<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpave             + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[10]],method="breslow")                              
m5_9d<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(lpvcorr)  + as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
















m4_0a<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[1]],method="breslow") 
m4_0b<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  





      
m4_1a<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[2]],method="breslow")                              
m4_1b<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 







      
m4_2a<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[3]],method="breslow")                              
m4_2b<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[3]],method="breslow")                              
extractAIC(m4_2a)[2] 
extractAIC(m4_2b)[2] 
      
m4_3a<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[4]],method="breslow")                              
m4_3b<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[4]],method="breslow")                              
extractAIC(m4_3a)[2] 
extractAIC(m4_3b)[2] 
      
m4_4a<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[5]],method="breslow")                              
m4_4b<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[5]],method="breslow")                              
extractAIC(m4_4a)[2] 
extractAIC(m4_4b)[2] 
      
m4_5a<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[6]],method="breslow")                              
m4_5b<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[6]],method="breslow")                              
extractAIC(m4_5a)[2] 
extractAIC(m4_5b)[2] 





m4_6a<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[7]],method="breslow")                              
m4_6b<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[7]],method="breslow")                              
extractAIC(m4_6a)[2] 
extractAIC(m4_6b)[2] 
      
m4_7a<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[8]],method="breslow")                              
m4_7b<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[8]],method="breslow")                              
extractAIC(m4_7a)[2] 
extractAIC(m4_7b)[2] 
      
m4_8a<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[9]],method="breslow")                              
m4_8b<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[9]],method="breslow")                              
extractAIC(m4_8a)[2] 
extractAIC(m4_8b)[2] 
      
m4_9a<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat1           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[10]],method="breslow")                              
m4_9b<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcat4           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 














m5_31<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr   + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[1]],method="breslow") 
m5_32<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr   + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[2]],method="breslow") 
m5_33<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr   + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[3]],method="breslow") 
m5_34<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr   + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[4]],method="breslow") 
m5_35<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr   + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[5]],method="breslow") 
m5_36<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr   + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[6]],method="breslow") 
m5_37<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr   + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[7]],method="breslow") 
m5_38<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr   + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[8]],method="breslow") 
m5_39<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr   + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[9]],method="breslow") 
m5_310<-coxph(Surv(X_t0,X_t, vlsupp) ~ lpvcorr  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 




m5_41<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[1]],method="breslow") 
m5_42<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 






m5_43<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[3]],method="breslow") 
m5_44<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[4]],method="breslow") 
m5_45<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[5]],method="breslow") 
m5_46<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[6]],method="breslow") 
m5_47<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[7]],method="breslow") 
m5_48<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[8]],method="breslow") 
m5_49<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[9]],method="breslow") 
m5_410<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus+ as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 









my541a <- mi.inference(myest, mystd, confidence=0.95) 

























Cox Proportional Hazards Mutliple failure Event Model of Nevirapine During The Post-randomization Phase 
library(splines) 
library(survival) 





### Descriptives ####### 
##################### 
















impdat <-  
NVP[,c("id","nvp","adstatus","t0rvl","t0rcd4pc","ageatran","t0rwfa","t0rhfa","postrantb","X_t0","X_t","vlsupp
","vlsupp1")] 
round(apply(apply(impdat,c(1,2),is.na),2,mean),digits=3)   # percentage of missing values 
myimp <- amelia(impdat, m=M, p2s=1, 























suppressWarnings(disperse(myimp, dims=1, m=10)) 




par(mfrow=c(1,1))                        
overimpute(myimp,var="nvp")         # Not perfect, but only small amount imputed 
































# function to create lags 
shift.1<-function(x,shift_by=-1){ 
  stopifnot(is.numeric(shift_by)) 
  stopifnot(is.numeric(x)) 
  if (length(shift_by)>1) 
    return(sapply(shift_by,shift, x=x)) 
  out<-NULL 
  abs_shift_by=abs(shift_by) 
  if (shift_by > 0 ) 
    out<-c(tail(x,-abs_shift_by),rep(NA,abs_shift_by)) 
  else if (shift_by < 0 ) 
    out<-c(rep(NA,abs_shift_by), head(x,-abs_shift_by)) 
  else 
    out<-x 
  out 
} 
# use this function for longitudinal data, means apply them by patient 
shift.l <- function(x,splitby){ 







for(m in 1:M){ 
  myimp$imputations[[m]]<-
transform(myimp$imputations[[m]],nvpre=shift.l(myimp$imputations[[m]]$nvp,myimp$imputations[[m]]$id)) 
  myimp$imputations[[m]]$nvpre <- 
replace((myimp$imputations[[m]])$nvpre,is.na((myimp$imputations[[m]])$nvpre),0)  




## Table 3: Cox Regression   # 
## (crude, adj, selected)    # 
############################## 
# Crude analysis 
m1_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp  + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m1_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp  + 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m1_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp  + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m1_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp  + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m1_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp  + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m1_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp  + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m1_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp  + 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m1_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp  + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m1_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp  + 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 













my1a <- mi.inference(myest1, mystd1, confidence=0.95) 
my_1 <- round(cbind(exp(my1a$est),exp(my1a$lower),exp(my1a$upper),my1a$signif),digits=3) 
my_1     # significant 
 
m1b_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat5 + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m1b_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat5 + 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m1b_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat5 + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m1b_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat5 + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m1b_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat5 + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m1b_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat5 + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m1b_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat5 + 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m1b_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat5 + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m1b_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat5 + 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 









my1b <- mi.inference(myest1b, mystd1b, confidence=0.95) 
my_1b <- round(cbind(exp(my1b$est),exp(my1b$lower),exp(my1b$upper),my1b$signif),digits=3) 
my_1b     # significant 
 






m1c_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpre + 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m1c_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpre + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m1c_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpre + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m1c_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpre + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m1c_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpre + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m1c_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpre + 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m1c_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpre + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m1c_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpre + 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 









my1c <- mi.inference(myest1c, mystd1c, confidence=0.95) 
my_1c <- round(cbind(exp(my1c$est),exp(my1c$lower),exp(my1c$upper),my1c$signif),digits=3) 
my_1c     # significant 
 
m1d_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpave + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m1d_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpave + 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m1d_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpave + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m1d_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpave + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 






m1d_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpave + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m1d_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpave + 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m1d_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpave + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m1d_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpave + 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 









my1d <- mi.inference(myest1d, mystd1d, confidence=0.95) 
my_1d <- round(cbind(exp(my1d$est),exp(my1d$lower),exp(my1d$upper),my1d$signif),digits=3) 
my_1d     # significant 
 
m1e_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat10 + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m1e_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat10 + 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m1e_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat10 + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m1e_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat10 + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m1e_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat10 + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m1e_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat10 + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m1e_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat10 + 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m1e_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat10 + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 















my1e <- mi.inference(myest1e, mystd1e, confidence=0.95) 
my_1e <- round(cbind(exp(my1e$est),exp(my1e$lower),exp(my1e$upper),my1e$signif),digits=3) 
my_1e  
 
m1f_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ ageatran + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m1f_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ ageatran + 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m1f_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ ageatran + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m1f_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ ageatran + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m1f_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ ageatran + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m1f_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ ageatran + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m1f_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ ageatran + 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m1f_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ ageatran + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m1f_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ ageatran + 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 


















m1g_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m1g_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m1g_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m1g_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m1g_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m1g_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m1g_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m1g_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m1g_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 









my1f <- mi.inference(myestf, mystdf, confidence=0.95) 
my_1f <- round(cbind(exp(my1f$est),exp(my1f$lower),exp(my1f$upper),my1f$signif),digits=3) 










m2_2<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(vlcat) + 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m2_3<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(vlcat) + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m2_4<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(vlcat) + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m2_5<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(vlcat) + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m2_6<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(vlcat) + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m2_7<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(vlcat) + 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m2_8<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(vlcat) + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m2_9<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(vlcat) + 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 









my2a <- mi.inference(myest2, mystd2, confidence=0.95) 
my_2 <- round(cbind(exp(my2a$est),exp(my2a$lower),exp(my2a$upper),my2a$signif),digits=3) 
my_2   
 
m3_1<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(cd4pccat)+ 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m3_2<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(cd4pccat)+ 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m3_3<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(cd4pccat)+ 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m3_4<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(cd4pccat)+ 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 






m3_6<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(cd4pccat)+ 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m3_7<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(cd4pccat)+ 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m3_8<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(cd4pccat)+ 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m3_9<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(cd4pccat)+ 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 









my3a <- mi.inference(myest3, mystd3, confidence=0.95) 
my_3 <- round(cbind(exp(my3a$est),exp(my3a$lower),exp(my3a$upper),my3a$signif),digits=3) 
my_3 
 
m4_1<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(agecat) + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m4_2<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(agecat) + 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m4_3<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(agecat) + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m4_4<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(agecat) + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m4_5<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(agecat) + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m4_6<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(agecat) + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m4_7<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(agecat) + 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m4_8<-coxph(Surv(X_t0,X_t, vlsupp) ~  as.factor(agecat) + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 















my4a <- mi.inference(myest4, mystd4, confidence=0.95) 





m6_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (wfacat) + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m6_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (wfacat) + 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m6_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (wfacat) + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m6_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (wfacat) + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m6_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (wfacat) + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m6_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (wfacat) + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m6_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (wfacat) + 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m6_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (wfacat) + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m6_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (wfacat) + 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 













my6a <- mi.inference(myest6, mystd6, confidence=0.95) 
my_6 <- round(cbind(exp(my6a$est),exp(my6a$lower),exp(my6a$upper),my6a$signif),digits=3) 
my_6    
 
m7_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (hfacat) + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m7_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (hfacat) + 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m7_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (hfacat) + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m7_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (hfacat) + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m7_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (hfacat) + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m7_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (hfacat) + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m7_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (hfacat) + 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m7_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (hfacat) + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m7_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor (hfacat) + 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 









my7a <- mi.inference(myest7, mystd7, confidence=0.95) 
my_7 <- round(cbind(exp(my7a$est),exp(my7a$lower),exp(my7a$upper),my7a$signif),digits=3) 








m9_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m9_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[2]],robust=TRUE,method="breslow") 
m9_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m9_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m9_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m9_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m9_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m9_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m9_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 









my9a <- mi.inference(myest9, mystd9, confidence=0.95) 




# Adjusted analysis## 
##################### 
m11_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m11_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 






m11_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m11_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m11_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m11_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m11_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m11_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m11_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 
m11_10<-coxph(Surv(X_t0,X_t,vlsupp) ~ nvp  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 









my11a <- mi.inference(myest, mystd, confidence=0.95) 
my_11 <- round(cbind(exp(my11a$est),exp(my11a$lower),exp(my11a$upper),my11a$signif),digits=3) 
my_11     # overall results with Hazard ratios, CI, and p-values 
 
m14_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpre  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m14_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpre  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 






m14_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpre  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m14_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpre  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m14_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpre  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m14_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpre  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m14_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpre  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m14_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpre  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m14_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpre  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 
m14_10<-coxph(Surv(X_t0,X_t,vlsupp) ~ nvpre  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 









my14a <- mi.inference(myest, mystd, confidence=0.95) 
my_14 <- round(cbind(exp(my14a$est),exp(my14a$lower),exp(my14a$upper),my14a$signif),digits=3) 
my_14     # overall results with Hazard ratios, CI, and p-values 
 
m15_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpave  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m15_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpave  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 






m15_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpave  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m15_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpave  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m15_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpave  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m15_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpave  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m15_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpave  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m15_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpave  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m15_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpave  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 
m15_10<-coxph(Surv(X_t0,X_t,vlsupp) ~ nvpave  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 









my15a <- mi.inference(myest, mystd, confidence=0.95) 
my_15 <- round(cbind(exp(my15a$est),exp(my15a$lower),exp(my15a$upper),my15a$signif),digits=3) 
my_15     # overall results with Hazard ratios, CI, and p-values 
 
m16_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat5  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m16_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat5  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 






m16_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat5  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m16_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat5  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m16_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat5  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m16_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat5  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m16_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat5  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m16_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat5  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m16_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat5  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 
m16_10<-coxph(Surv(X_t0,X_t,vlsupp) ~ nvpcat5  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 









my16a <- mi.inference(myest, mystd, confidence=0.95) 
my_16 <- round(cbind(exp(my16a$est),exp(my16a$lower),exp(my16a$upper),my16a$signif),digits=3) 
my_16     # overall results with Hazard ratios, CI, and p-values 
 
m17_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat10  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m17_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat10  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 






m17_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat10  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m17_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat10  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m17_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat10  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m17_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat10  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m17_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat10  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m17_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat10  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m17_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat10  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 
m17_10<-coxph(Surv(X_t0,X_t,vlsupp) ~ nvpcat10  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 









my17a <- mi.inference(myest, mystd, confidence=0.95) 
my_17 <- round(cbind(exp(my17a$est),exp(my17a$lower),exp(my17a$upper),my17a$signif),digits=3) 
my_17     # overall results with Hazard ratios, CI, and p-values 
 
m18_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat15  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m18_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat15  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 






m18_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat15  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m18_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat15  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m18_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat15  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m18_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat15  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m18_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat15  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m18_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat15  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m18_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat15  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 
m18_10<-coxph(Surv(X_t0,X_t,vlsupp) ~ nvpcat15  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 









my18a <- mi.inference(myest, mystd, confidence=0.95) 
my_18 <- round(cbind(exp(my18a$est),exp(my18a$lower),exp(my18a$upper),my18a$signif),digits=3) 
my_18  
 
m19_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat20  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m19_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat20  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 






m19_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat20  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m19_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat20  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m19_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat20  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m19_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat20  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m19_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat20  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m19_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat20  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m19_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat20  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 
m19_10<-coxph(Surv(X_t0,X_t,vlsupp) ~ nvpcat20  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 









my19a <- mi.inference(myest, mystd, confidence=0.95) 
my_19 <- round(cbind(exp(my19a$est),exp(my19a$lower),exp(my19a$upper),my19a$signif),digits=3) 
my_19  
 
m20_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat25  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m20_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat25  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 






m20_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat25  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m20_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat25  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m20_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat25  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m20_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat25  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m20_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat25  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m20_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat25  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m20_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat25  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 
m20_10<-coxph(Surv(X_t0,X_t,vlsupp) ~ nvpcat25  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 









my20a <- mi.inference(myest, mystd, confidence=0.95) 
my_20 <- round(cbind(exp(my20a$est),exp(my20a$lower),exp(my20a$upper),my20a$signif),digits=3) 
my_20  
 
m21_1<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[1]],robust=TRUE,method="breslow") 
m21_2<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 






m21_3<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[3]],robust=TRUE,method="breslow") 
m21_4<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[4]],robust=TRUE,method="breslow") 
m21_5<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[5]],robust=TRUE,method="breslow") 
m21_6<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[6]],robust=TRUE,method="breslow") 
m21_7<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[7]],robust=TRUE,method="breslow") 
m21_8<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[8]],robust=TRUE,method="breslow") 
m21_9<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb)+ 
cluster(id),data=myimp$imputations[[9]],robust=TRUE,method="breslow") 
m21_10<-coxph(Surv(X_t0,X_t,vlsupp) ~ adstatus  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 









my21a <- mi.inference(myest, mystd, confidence=0.95) 




# Cut-off Selection Using Cox Regression Approach vs Mixed Addative Logistic Regression Approach  ######## 
########################################################################################## 
NVP<-read.csv("NVP_22_07_2014.csv",header=T,sep=",",stringsAsFactors=FALSE) 










# Table 1 (Cutoffs) 
# Approach 1: Cox regression 
m0 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ cut(nvp, breaks=c(0,0.25,100))    + cluster(id), data=NVP, robust=TRUE, 
method="breslow") 
m1 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ cut(nvp, breaks=c(0,0.5,100))     + cluster(id), data=NVP, robust=TRUE, 
method="breslow") 
m2 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ cut(nvp, breaks=c(0,0.75,100))    + cluster(id), data=NVP, robust=TRUE, 
method="breslow") 
m3 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ cut(nvp, breaks=c(0,1,100))       + cluster(id), data=NVP, robust=TRUE, 
method="breslow") 
m4 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ cut(nvp, breaks=c(0,1.5,100))     + cluster(id), data=NVP, robust=TRUE, 
method="breslow") 
m5 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ cut(nvp, breaks=c(0,3,100))       + cluster(id), data=NVP, robust=TRUE, 
method="breslow") 
m6 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ cut(nvp, breaks=c(0,6,100))       + cluster(id), data=NVP, robust=TRUE, 
method="breslow") 
m7 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ cut(nvp, breaks=c(0,9,100))       + cluster(id), data=NVP, robust=TRUE, 
method="breslow") 
m8 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ cut(nvp, breaks=c(0,12,100))      + cluster(id), data=NVP, robust=TRUE, 
method="breslow") 
 















# add this library 
library(gamm4) 
# Approach 2: mixed additive logistic regression     
m0_1 <- gamm4(vlsupp ~ cut(nvp, 
breaks=c(0,0.25,100))+s(X_t),random=~(1|id),data=na.omit(NVP2),family=binomial)    
m0_2 <- gamm4(vlsupp ~ cut(nvp, 
breaks=c(0,0.5,100))+s(X_t),random=~(1|id),data=na.omit(NVP2),family=binomial)  
m0_3 <- gamm4(vlsupp ~ cut(nvp, 
breaks=c(0,0.75,100))+s(X_t),random=~(1|id),data=na.omit(NVP2),family=binomial)  
m0_4 <- gamm4(vlsupp ~ cut(nvp, 
breaks=c(0,1,100))+s(X_t),random=~(1|id),data=na.omit(NVP2),family=binomial)  
m0_5 <- gamm4(vlsupp ~ cut(nvp, 
breaks=c(0,2,100))+s(X_t),random=~(1|id),data=na.omit(NVP2),family=binomial)  
m0_6 <- gamm4(vlsupp ~ cut(nvp, 
breaks=c(0,3,100))+s(X_t),random=~(1|id),data=na.omit(NVP2),family=binomial)  
m0_7 <- gamm4(vlsupp ~ cut(nvp, 
breaks=c(0,6,100))+s(X_t),random=~(1|id),data=na.omit(NVP2),family=binomial)  
m0_8 <- gamm4(vlsupp ~ cut(nvp, 
breaks=c(0,9,100))+s(X_t),random=~(1|id),data=na.omit(NVP2),family=binomial)  












#add library  
library(mgcv) 
# Approach 3: additive logistic regression     
m0_11 <- gam(vlsupp ~ cut(nvp, 





m0_12 <- gam(vlsupp ~ cut(nvp, 
breaks=c(0,3,100))+s(X_t),random=~(1|id),data=na.omit(NVP2),family=binomial,scale=-1)  
m0_13 <- gam(vlsupp ~ cut(nvp, 
breaks=c(0,4,100))+s(X_t),random=~(1|id),data=na.omit(NVP2),family=binomial,scale=-1)  
m0_14 <- gam(vlsupp ~ cut(nvp, 
breaks=c(0,5,100))+s(X_t),random=~(1|id),data=na.omit(NVP2),family=binomial,scale=-1)  
m0_15 <- gam(vlsupp ~ cut(nvp, 
breaks=c(0,6,100))+s(X_t),random=~(1|id),data=na.omit(NVP2),family=binomial,scale=-1)  
m0_16 <- gam(vlsupp ~ cut(nvp, 
breaks=c(0,7,100))+s(X_t),random=~(1|id),data=na.omit(NVP2),family=binomial,scale=-1)  
m0_17 <- gam(vlsupp ~ cut(nvp, 
breaks=c(0,9,100))+s(X_t),random=~(1|id),data=na.omit(NVP2),family=binomial,scale=-1)  
m0_18 <- gam(vlsupp ~ cut(nvp, 
breaks=c(0,10,100))+s(X_t),random=~(1|id),data=na.omit(NVP2),family=binomial,scale=-1)  
m0_19 <- gam(vlsupp ~ cut(nvp, 
breaks=c(0,11,100))+s(X_t),random=~(1|id),data=na.omit(NVP2),family=binomial,scale=-1) 




m0_12$gcv      
m0_13$gcv      
m0_14$gcv      
m0_15$gcv      
m0_16$gcv      
m0_17$gcv      
m0_18$gcv      
m0_19$gcv      
m0_20$gcv  
 
# Approach 4: like approach 3, but with imputed data  
mi1_1 <- gam(vlsupp ~ cut(nvp, breaks=c(0,7.5,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[1]],random=~(1|id),family=binomial)  
mi1_2 <- gam(vlsupp ~ cut(nvp, breaks=c(0,7.5,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 






mi1_3 <- gam(vlsupp ~ cut(nvp, breaks=c(0,7.5,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[3]],random=~(1|id),family=binomial)  
mi1_4 <- gam(vlsupp ~ cut(nvp, breaks=c(0,7.5,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[4]],random=~(1|id),family=binomial)  
mi1_5 <- gam(vlsupp ~ cut(nvp, breaks=c(0,7.5,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 




mi2_1 <- gam(vlsupp ~ cut(nvp, breaks=c(0,10,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[1]],random=~(1|id),family=binomial)  
mi2_2 <- gam(vlsupp ~ cut(nvp, breaks=c(0,10,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[2]],random=~(1|id),family=binomial)  
mi2_3 <- gam(vlsupp ~ cut(nvp, breaks=c(0,10,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[3]],random=~(1|id),family=binomial)  
mi2_4 <- gam(vlsupp ~ cut(nvp, breaks=c(0,10,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[4]],random=~(1|id),family=binomial)  
mi2_5 <- gam(vlsupp ~ cut(nvp, breaks=c(0,10,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 




mi3_1 <- gam(vlsupp ~ cut(nvp, breaks=c(0,12.5,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[1]],random=~(1|id),family=binomial)  
mi3_2 <- gam(vlsupp ~ cut(nvp, breaks=c(0,12.5,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[2]],random=~(1|id),family=binomial)  
mi3_3 <- gam(vlsupp ~ cut(nvp, breaks=c(0,12.5,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[3]],random=~(1|id),family=binomial)  
mi3_4 <- gam(vlsupp ~ cut(nvp, breaks=c(0,12.5,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[4]],random=~(1|id),family=binomial)  
mi3_5 <- gam(vlsupp ~ cut(nvp, breaks=c(0,12.5,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 








mi4_1 <- gam(vlsupp ~ cut(nvp, breaks=c(0,15,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[1]],random=~(1|id),family=binomial)  
mi4_2 <- gam(vlsupp ~ cut(nvp, breaks=c(0,15,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[2]],random=~(1|id),family=binomial)  
mi4_3 <- gam(vlsupp ~ cut(nvp, breaks=c(0,15,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[3]],random=~(1|id),family=binomial)  
mi4_4 <- gam(vlsupp ~ cut(nvp, breaks=c(0,15,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[4]],random=~(1|id),family=binomial)  
mi4_5 <- gam(vlsupp ~ cut(nvp, breaks=c(0,15,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 




mi5_1 <- gam(vlsupp ~ cut(nvp, breaks=c(0,17.5,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[1]],random=~(1|id),family=binomial)  
mi5_2 <- gam(vlsupp ~ cut(nvp, breaks=c(0,17.5,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[2]],random=~(1|id),family=binomial)  
mi5_3 <- gam(vlsupp ~ cut(nvp, breaks=c(0,17.5,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[3]],random=~(1|id),family=binomial)  
mi5_4 <- gam(vlsupp ~ cut(nvp, breaks=c(0,17.5,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[4]],random=~(1|id),family=binomial)  
mi5_5 <- gam(vlsupp ~ cut(nvp, breaks=c(0,17.5,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 




mi6_1 <- gam(vlsupp ~ cut(nvp, breaks=c(0,20,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[1]],random=~(1|id),family=binomial)  
mi6_2 <- gam(vlsupp ~ cut(nvp, breaks=c(0,20,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 






mi6_3 <- gam(vlsupp ~ cut(nvp, breaks=c(0,20,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[3]],random=~(1|id),family=binomial)  
mi6_4 <- gam(vlsupp ~ cut(nvp, breaks=c(0,20,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[4]],random=~(1|id),family=binomial)  
mi6_5 <- gam(vlsupp ~ cut(nvp, breaks=c(0,20,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 




mi7_1 <- gam(vlsupp ~ cut(nvp, breaks=c(0,22.5,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[1]],random=~(1|id),family=binomial)  
mi7_2 <- gam(vlsupp ~ cut(nvp, breaks=c(0,22.5,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[2]],random=~(1|id),family=binomial)  
mi7_3 <- gam(vlsupp ~ cut(nvp, breaks=c(0,22.5,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[3]],random=~(1|id),family=binomial)  
mi7_4 <- gam(vlsupp ~ cut(nvp, breaks=c(0,22.5,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[4]],random=~(1|id),family=binomial)  
mi7_5 <- gam(vlsupp ~ cut(nvp, breaks=c(0,22.5,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[5]],random=~(1|id),family=binomial)  
mi7_1$gcv+mi7_2$gcv+mi7_3$gcv+mi7_4$gcv+mi7_5$gcv     # somehwhere around here 
 
mi8_1 <- gam(vlsupp ~ cut(nvp, breaks=c(0,25,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[1]],random=~(1|id),family=binomial)  
mi8_2 <- gam(vlsupp ~ cut(nvp, breaks=c(0,25,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[2]],random=~(1|id),family=binomial)  
mi8_3 <- gam(vlsupp ~ cut(nvp, breaks=c(0,25,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[3]],random=~(1|id),family=binomial)  
mi8_4 <- gam(vlsupp ~ cut(nvp, breaks=c(0,25,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[4]],random=~(1|id),family=binomial)  
mi8_5 <- gam(vlsupp ~ cut(nvp, breaks=c(0,25,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 








mi9_1 <- gam(vlsupp ~ cut(nvp, breaks=c(0,25,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[1]],random=~(1|id),family=binomial)  
mi9_2 <- gam(vlsupp ~ cut(nvp, breaks=c(0,25,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[2]],random=~(1|id),family=binomial)  
mi9_3 <- gam(vlsupp ~ cut(nvp, breaks=c(0,25,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[3]],random=~(1|id),family=binomial)  
mi9_4 <- gam(vlsupp ~ cut(nvp, breaks=c(0,25,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + 
as.factor(postrantb),data=myimp$imputations[[4]],random=~(1|id),family=binomial)  
mi9_5 <- gam(vlsupp ~ cut(nvp, breaks=c(0,25,100))+s(X_t)+ as.factor(vlcat)+ as.factor(cd4pccat)  + 




# For figure: What is better: average or current? 
m_current <- gam(vlsupp ~ s(nvp)+s(X_t),data=myimp$imputations[[1]],family=binomial)    
m_average <- gam(vlsupp ~ s(nvpave)+s(X_t),data=myimp$imputations[[1]],family=binomial)    
m_current$gcv   # Michael 5: current NVP better, but to discuss with Ray, because method limited 
m_average$gcv   
 
############ 
# Figure  #### 
############ 
# Spline representation   
# Imputation based approach 
Lpvm31 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(nvp, df=4) + as.factor(vlcat) + as.factor(cd4pccat) + as.factor 
(hfacat) + as.factor(agecat)+ as.factor (wfacat)  + as.factor(postrantb) + cluster(id), 
data=myimp$imputations[[1]], robust=TRUE, method="breslow") 
Lpvm32 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(nvp, df=4) + as.factor(vlcat) + as.factor(cd4pccat) + as.factor 
(hfacat) + as.factor(agecat)+ as.factor (wfacat)  + as.factor(postrantb) + cluster(id), 
data=myimp$imputations[[2]], robust=TRUE, method="breslow") 
Lpvm33 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(nvp, df=4) + as.factor(vlcat) + as.factor(cd4pccat) + as.factor 
(hfacat) + as.factor(agecat)+ as.factor (wfacat)  + as.factor(postrantb) + cluster(id), 





Lpvm34 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(nvp, df=4) + as.factor(vlcat) + as.factor(cd4pccat) + as.factor 
(hfacat) + as.factor(agecat)+ as.factor (wfacat)  + as.factor(postrantb) + cluster(id), 
data=myimp$imputations[[4]], robust=TRUE, method="breslow") 
Lpvm35 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(nvp, df=4) + as.factor(vlcat) + as.factor(cd4pccat) + as.factor 
(hfacat) + as.factor(agecat)+ as.factor (wfacat)  + as.factor(postrantb) + cluster(id), 
data=myimp$imputations[[5]], robust=TRUE, method="breslow") 
Lpvm36 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(nvp, df=4) + as.factor(vlcat) + as.factor(cd4pccat) + as.factor 
(hfacat) + as.factor(agecat)+ as.factor (wfacat)  + as.factor(postrantb) + cluster(id), 
data=myimp$imputations[[6]], robust=TRUE, method="breslow") 
Lpvm37 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(nvp, df=4) + as.factor(vlcat) + as.factor(cd4pccat) + as.factor 
(hfacat) + as.factor(agecat)+ as.factor (wfacat)  + as.factor(postrantb) + cluster(id), 
data=myimp$imputations[[7]], robust=TRUE, method="breslow") 
Lpvm38 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(nvp, df=4) + as.factor(vlcat) + as.factor(cd4pccat) + as.factor 
(hfacat) + as.factor(agecat)+ as.factor (wfacat)  + as.factor(postrantb) + cluster(id), 
data=myimp$imputations[[8]], robust=TRUE, method="breslow") 
Lpvm39 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(nvp, df=4) + as.factor(vlcat) + as.factor(cd4pccat) + as.factor 
(hfacat) + as.factor(agecat)+ as.factor (wfacat)  + as.factor(postrantb) + cluster(id), 
data=myimp$imputations[[9]], robust=TRUE, method="breslow") 
Lpvm40 <- coxph(Surv(X_t0,X_t,vlsupp)  ~ pspline(nvp, df=4) + as.factor(vlcat) + as.factor(cd4pccat) + as.factor 
(hfacat) + as.factor(agecat)+ as.factor (wfacat)  + as.factor(postrantb) + cluster(id), 
data=myimp$imputations[[10]], robust=TRUE, method="breslow") 
 
predicted31 <- predict(Lpvm31, type = "terms" , se.fit = TRUE , terms = 1) 
predicted32 <- predict(Lpvm32, type = "terms" , se.fit = TRUE , terms = 1) 
predicted33 <- predict(Lpvm33, type = "terms" , se.fit = TRUE , terms = 1) 
predicted34 <- predict(Lpvm34, type = "terms" , se.fit = TRUE , terms = 1) 
predicted35 <- predict(Lpvm35, type = "terms" , se.fit = TRUE , terms = 1) 
predicted36 <- predict(Lpvm36, type = "terms" , se.fit = TRUE , terms = 1) 
predicted37 <- predict(Lpvm37, type = "terms" , se.fit = TRUE , terms = 1) 
predicted38 <- predict(Lpvm38, type = "terms" , se.fit = TRUE , terms = 1) 
predicted39 <- predict(Lpvm39, type = "terms" , se.fit = TRUE , terms = 1) 

















# defined "seldat" 
seldat <- impdat 










mycoeff <- apply(mycoefflist,1,mean) 
coeffdiff<-(matrix(cbind(rep(mycoeff,M)),ncol=M,nrow=length(mycoeff))-mycoefflist)^2 
between <-  apply(coeffdiff,1,sum) 
variance <- within + ((M+1)/(M*(M-1)))*between 
se <- round(sqrt(variance),digits=5) 
# Main Figure: 
par(mfrow=c(1,1)) 
plot(0 , xlab=" Nevirapine Concentration (mg/L)" , ylab = "Hazard of  failure" , axes=T, main = "Non-Linear 
Effect of Nevirapine Concentration" ,type = "n" , xlim=c(0,15) , las=1,ylim=c(0,2)) 
lines(sm.spline(myimp$imputations[[1]]$nvp[is.na(impdat$nvp)==F], exp(lp)), col = "red" , lwd = 1) 
lines(sm.spline(myimp$imputations[[1]]$nvp[is.na(impdat$nvp)==F], exp(lp + 1.96 * sqrt(variance))) , col = 
"orange" , lty = 6 , lwd = 0.8) 
lines(sm.spline(myimp$imputations[[1]]$nvp[is.na(impdat$nvp)==F], exp(lp - 1.96 * sqrt(variance))) , col = 
"orange" , lty = 6 , lwd = 0.8) 
axis(side = 1, at = c(seq(0,20,5)), labels = F , tick = T , tcl = 0.4 , lwd.ticks = 0.1) 
 












#tiff(file = "temp.tiff", width = 672, height = 672 units = "px", res = 800,type = c("windows", "cairo") 
#     family = "", restoreConsole = TRUE,antialias="cleartype") 
#tiff(filename = "Rplot%03d.tiff, width = 3200, height = 3200, units = "px", pointsize = 12, 
#     bg = "white", res = 400, family = "", restoreConsole = TRUE,type = c("windows", "cairo"), antialias= 
 
############## 
#  Summary   # 
############## 
MIsummary <- matrix(rep(NA,8*10),nrow=10,ncol=8) 
MIsummary[1,1:4] <- my_1 
MIsummary[2,1:4] <- my_2 
MIsummary[3,1:4] <- my_3 
MIsummary[4,1:4] <- my_4 
MIsummary[6,1:4] <- my_6 
MIsummary[7,1:4] <- my_7 
MIsummary[8,1:4] <- my_9 
MIsummary[9:10,1:4] <- my_10     





MIsummary <- matrix(rep(NA,8*10),nrow=10,ncol=8) 
MIsummary[1,1:4] <- my_1b 
MIsummary[2,1:4] <- my_2 
MIsummary[3,1:4] <- my_3 
MIsummary[4,1:4] <- my_4 
MIsummary[6,1:4] <- my_6 





MIsummary[8,1:4] <- my_9 
MIsummary[9:10,1:4] <- my_10 
 rownames(MIsummary) <- c(" NVP<3mg/L","VL (>50)","CD4% (Low)","Age (>1/2 yr.)","WFA (Advanced)","HFA 
(Advanced)","Postrantab(Yes)","(0)","(1)") 
colnames(MIsummary) <-c("Crude","","","","Adj.","","","") 
write.csv(round(MIsummary, digits=3),file="Cox_nvpcat1.csv")      
 
MIsummary <- matrix(rep(NA,8*10),nrow=10,ncol=8) 
MIsummary[1,1:4] <- my_1c 
MIsummary[2,1:4] <- my_2 
MIsummary[3,1:4] <- my_3 
MIsummary[4,1:4] <- my_4 
MIsummary[5,1:4] <- my_5 
MIsummary[6,1:4] <- my_6 
MIsummary[7,1:4] <- my_7 
MIsummary[8,1:4] <- my_9 
MIsummary[9:10,1:4] <- my_10 
MIsummary[,5:8]     <- my_12 





MIsummary <- matrix(rep(NA,8*10),nrow=10,ncol=8) 
MIsummary[1,1:4] <- my_1d 
MIsummary[2,1:4] <- my_2 
MIsummary[3,1:4] <- my_3 
MIsummary[4,1:4] <- my_4 
MIsummary[5,1:4] <- my_5 
MIsummary[6,1:4] <- my_6 
MIsummary[7,1:4] <- my_7 
MIsummary[8,1:4] <- my_9 
MIsummary[9:10,1:4] <- my_10 





      





      
MIsummary <- matrix(rep(NA,8*10),nrow=10,ncol=8) 
MIsummary[1,1:4] <- my_1e 
MIsummary[2,1:4] <- my_2 
MIsummary[3,1:4] <- my_3 
MIsummary[4,1:4] <- my_4 
MIsummary[5,1:4] <- my_5 
MIsummary[6,1:4] <- my_6 
MIsummary[7,1:4] <- my_7 
MIsummary[8,1:4] <- my_9 
MIsummary[9:10,1:4] <- my_10 
MIsummary[,5:8]     <- my_12 






#Model Selection Using AIC for Each Imputed Data ## 
############################################ 
m5_0a<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[1]],method="breslow") 
m5_0b<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpre + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[1]],method="breslow") 
m5_0c<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpave + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 






m5_0d<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(nvp)  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  







m5_1a<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[2]],method="breslow")                              
m5_1b<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpre + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[2]],method="breslow")                              
m5_1c<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpave           + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[2]],method="breslow")                              
m5_1d<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(nvp)  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 






m5_2a<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[3]],method="breslow")                              
m5_2b<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpre + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[3]],method="breslow")                              
m5_2c<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpave + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[3]],method="breslow")                              
m5_2d<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(nvp)  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 










m5_3a<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[4]],method="breslow")                              
m5_3b<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpre  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[4]],method="breslow")                              
m5_3c<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpave + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[4]],method="breslow")                              
m5_3d<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(nvp)  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 






m5_4a<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[5]],method="breslow")                              
m5_4b<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpre  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[5]],method="breslow")                              
m5_4c<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpave + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[5]],method="breslow")                              
m5_4d<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(nvp)  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 






m5_5a<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 





m5_5b<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpre + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[6]],method="breslow")                              
m5_5c<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpave + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[6]],method="breslow")                              
m5_5d<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(nvp)  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 






m5_6a<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[7]],method="breslow")                              
m5_6b<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpre + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[7]],method="breslow")                              
m5_6c<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpave + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[7]],method="breslow")                              
m5_6d<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(nvp)  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 






m5_7a<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[8]],method="breslow")                              
m5_7b<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpre + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[8]],method="breslow")                              
m5_7c<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpave + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 





m5_7d<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(nvp)  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 






m5_8a<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[9]],method="breslow")                              
m5_8b<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpre + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[9]],method="breslow")                              
m5_8c<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpave + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[9]],method="breslow")                              
m5_8d<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(nvp)  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 






m5_9a<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[10]],method="breslow")                              
m5_9b<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpre  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[10]],method="breslow")                              
m5_9c<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpave + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[10]],method="breslow")                              
m5_9d<-coxph(Surv(X_t0,X_t, vlsupp) ~ pspline(nvp)  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  
+ as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 










m4_0a<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat3   + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[1]],method="breslow") 
m4_0b<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat10  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 





m4_1a<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat3           + as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[2]],method="breslow")                              
m4_1b<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat10           + as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 




m4_2a<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat3           + as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[3]],method="breslow")                              
m4_2b<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat10           + as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 




m4_3a<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat3   + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[4]],method="breslow")                              
m4_3b<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat10           + as.factor(vlcat)+ as.factor(cd4pccat)  + 
as.factor(agecat)  + as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 








m4_4a<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat3  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[5]],method="breslow")                              
m4_4b<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat10  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 




m4_5a<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat3  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[6]],method="breslow")                              
m4_5b<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat10  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 




m4_6a<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat3  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[7]],method="breslow")                              
m4_6b<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat10 + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 




m4_7a<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat3  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[8]],method="breslow")                              
m4_7b<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat10 + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 




m4_8a<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat3  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 





m4_8b<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat10  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 




m4_9a<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat3  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[10]],method="breslow")                              
m4_9b<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvpcat10  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 




# Adherence vs. Concentration ##### 
###############################     
 m5_31<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp   + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[1]],method="breslow") 
m5_32<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp   + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[2]],method="breslow") 
m5_33<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp   + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[3]],method="breslow") 
m5_34<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp   + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[4]],method="breslow") 
m5_35<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp   + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[5]],method="breslow") 
m5_36<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp   + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[6]],method="breslow") 
m5_37<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp   + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[7]],method="breslow") 
m5_38<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp   + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 






m5_39<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp   + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[9]],method="breslow") 
m5_310<-coxph(Surv(X_t0,X_t, vlsupp) ~ nvp  + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[10]],method="breslow") 
     
m5_41<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[1]],method="breslow") 
m5_42<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[2]],method="breslow") 
m5_43<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[3]],method="breslow") 
m5_44<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[4]],method="breslow") 
m5_45<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[5]],method="breslow") 
m5_46<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[6]],method="breslow") 
m5_47<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[7]],method="breslow") 
m5_48<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[8]],method="breslow") 
m5_49<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus + as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[9]],method="breslow") 
m5_410<-coxph(Surv(X_t0,X_t, vlsupp) ~ adstatus+ as.factor(vlcat)+ as.factor(cd4pccat)  + as.factor(agecat)  + 
as.factor (wfacat) + as.factor (hfacat)  + as.factor(postrantb) + 
cluster(id),data=myimp$imputations[[10]],method="breslow") 











# Everything is indicating that it is better to use Nevirapine compared to adherence  
     
      
      
      






Population Pharmacokinetic Model of Lopinavir In Children  
;Model Desc: LPVRTV| CL vs K & V|BSV CL,V,BIO,KA,LAG| BOV KA,BIO,CL,LAG|EFFECT OF AGE on BIO|1COMP 
LPV + EFFECT OF TB TREAT|ADVAN2 TRANS1  
$SIZES      MAXIDS=300 NO=120 LTH=20 LVR=100 MAXFCN=100000000 
$PROBLEM    Effect of Clinic Visit LPVRTV in Children  
$INPUT  ID WEEKS OCC ID_OCC=DROP TIME ABLAG=DROP WHAT=DROP AMT DV OLD_DV2=DROP DV1=DROP 
DV2=DROP MDV DVID II=DROP SS=DROP EVID BLQ TBT DRUG=DROP PREPOST AGE SEX=DROP MISKAL WT HT 
HDCIRMM BSA BMI WFA HFA WFH BMIFA CD4CNT CD4PC VL VLSUPP=DROP VLSUPP1=DROP HBCNT=DROP 
PLT=DROP ALT=DROP AST=DROP BILI=DROP NEUT=DROP MONO=DROP LMPHCNT=DROP EOSIN=DROP 
BASO=DROP HDL=DROP LDL=DROP TRGLCRDS=DROP PROB COMMENT=DROP 
$DATA LPVRTV_09_06_2017.csv IGNORE=# 
           IGNORE(PROB.GT.1)IGNORE(DVID.GT.1) IGNORE(BLQ.GT.0) 
$ABBREVIATED DERIV2=NO 
$SUBROUTINE ADVAN2 TRANS1 
;-----------------------------------------------------------Initial Estimates from Chao------------ 
$THETA  (0,1.04989) ; 1 CL [L/h] 
$THETA  (0,8.03299) ; 2 V [L] 
$THETA  (0,0.74) FIX ; 3 KA [1/h] 
$THETA  (0.004,0.103454,5) ; 4 ADD [mg/L] 
$THETA  (0,0.11682) ; 5 PROP[%] 
$THETA  (0,26.6646) ; 6 PMA50 [Months] 
$THETA  (0,0.594982,1) ; 7 RIFCL 
$THETA  (0,0.37) FIX ; 9 TVLAG 
$OMEGA  BLOCK(1) 
 0.177698  ;   1 IIV_CL 
$OMEGA  BLOCK(1) 
 0.07973  ;    3 IIV_V 
$OMEGA  BLOCK(1) 
 0.0991334  ;  3  IOV KA 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 





$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) 
 0.169358  ; 22  IIV BIO 
$OMEGA  BLOCK(1) 
 0.133771  ; 23 IOV BIO 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 





$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) FIX 
 0  ; 42  IOV CL 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) FIX 
 0  ; 61  IIV_KA 
$OMEGA  BLOCK(1) 
 0.0700647  ; 62  IIV_LAG 
$OMEGA  BLOCK(1) 
 0.197  ; 63  IOV LAG 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 





$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$PK                                                                                                                           
;----------------------------------------------------------------------Variability------------------------------------------- 
BSV_CL  = ETA(1) 
BSV_V   = ETA(2) 
BOV_KA = ETA(3)  
IF (OCC.EQ.2)  BOV_KA  = ETA(4) 
IF (OCC.EQ.3)  BOV_KA  = ETA(5) 
IF (OCC.EQ.4)  BOV_KA  = ETA(6) 
IF (OCC.EQ.5)  BOV_KA  = ETA(7) 
IF (OCC.EQ.6)  BOV_KA  = ETA(8) 
IF (OCC.EQ.7)  BOV_KA  = ETA(9) 
IF (OCC.EQ.8)  BOV_KA  = ETA(10) 
IF (OCC.EQ.9)  BOV_KA  = ETA(11) 
IF (OCC.EQ.10) BOV_KA  = ETA(12) 
IF (OCC.EQ.11) BOV_KA  = ETA(13) 
IF (OCC.EQ.12) BOV_KA  = ETA(14) 
IF (OCC.EQ.13) BOV_KA  = ETA(15) 
IF (OCC.EQ.14) BOV_KA  = ETA(16) 
IF (OCC.EQ.15) BOV_KA  = ETA(17) 
IF (OCC.EQ.16) BOV_KA  = ETA(18) 





IF (OCC.EQ.18) BOV_KA  = ETA(20) 
IF (OCC.EQ.19) BOV_KA  = ETA(21) 
 
BSV_BIO = ETA(22) 
BOV_BIO = ETA(23) 
IF (OCC.EQ.2)  BOV_BIO = ETA(24) 
IF (OCC.EQ.3)  BOV_BIO = ETA(25) 
IF (OCC.EQ.4)  BOV_BIO = ETA(26) 
IF (OCC.EQ.5)  BOV_BIO = ETA(27) 
IF (OCC.EQ.6)  BOV_BIO = ETA(28) 
IF (OCC.EQ.7)  BOV_BIO = ETA(29) 
IF (OCC.EQ.8)  BOV_BIO = ETA(30) 
IF (OCC.EQ.9)  BOV_BIO = ETA(31) 
IF (OCC.EQ.10) BOV_BIO = ETA(32) 
IF (OCC.EQ.11) BOV_BIO = ETA(33) 
IF (OCC.EQ.12) BOV_BIO = ETA(34) 
IF (OCC.EQ.13) BOV_BIO = ETA(35) 
IF (OCC.EQ.14) BOV_BIO = ETA(36) 
IF (OCC.EQ.15) BOV_BIO = ETA(37) 
IF (OCC.EQ.16) BOV_BIO = ETA(38) 
IF (OCC.EQ.17) BOV_BIO = ETA(39) 
IF (OCC.EQ.18) BOV_BIO = ETA(40) 
IF (OCC.EQ.19) BOV_BIO = ETA(41) 
 
 
BOV_CL = ETA(42) 
IF (OCC.EQ.2)  BOV_CL = ETA(43) 
IF (OCC.EQ.3)  BOV_CL = ETA(44) 
IF (OCC.EQ.4)  BOV_CL = ETA(45) 
IF (OCC.EQ.5)  BOV_CL = ETA(46) 
IF (OCC.EQ.6)  BOV_CL = ETA(47) 
IF (OCC.EQ.7)  BOV_CL = ETA(48) 





IF (OCC.EQ.9)  BOV_CL = ETA(50) 
IF (OCC.EQ.10) BOV_CL = ETA(51) 
IF (OCC.EQ.11) BOV_CL = ETA(52) 
IF (OCC.EQ.12) BOV_CL = ETA(53) 
IF (OCC.EQ.13) BOV_CL = ETA(54) 
IF (OCC.EQ.14) BOV_CL = ETA(55) 
IF (OCC.EQ.15) BOV_CL = ETA(56) 
IF (OCC.EQ.16) BOV_CL = ETA(57) 
IF (OCC.EQ.17) BOV_CL = ETA(58) 
IF (OCC.EQ.18) BOV_CL = ETA(59) 
IF (OCC.EQ.19) BOV_CL = ETA(60) 
BSV_KA  = ETA(61) 
BSV_LAG  = ETA(62) 
 
BOV_LAG = ETA(63) 
IF (OCC.EQ.2)  BOV_LAG = ETA(64) 
IF (OCC.EQ.3)  BOV_LAG = ETA(65) 
IF (OCC.EQ.4)  BOV_LAG = ETA(66) 
IF (OCC.EQ.5)  BOV_LAG = ETA(67) 
IF (OCC.EQ.6)  BOV_LAG = ETA(68) 
IF (OCC.EQ.7)  BOV_LAG = ETA(69) 
IF (OCC.EQ.8)  BOV_LAG = ETA(70) 
IF (OCC.EQ.9)  BOV_LAG = ETA(71) 
IF (OCC.EQ.10) BOV_LAG = ETA(72) 
IF (OCC.EQ.11) BOV_LAG = ETA(73) 
IF (OCC.EQ.12) BOV_LAG = ETA(74) 
IF (OCC.EQ.13) BOV_LAG = ETA(75) 
IF (OCC.EQ.14) BOV_LAG = ETA(76) 
IF (OCC.EQ.15) BOV_LAG = ETA(77) 
IF (OCC.EQ.16) BOV_LAG = ETA(78) 
IF (OCC.EQ.17) BOV_LAG = ETA(79) 
IF (OCC.EQ.18) BOV_LAG = ETA(80) 






SCL = (WT/10)**0.75 
SV  = WT/10 
;--------------------------------------------------------------------------Maturation function 
MEDAGE=31 
HILL   = 1 
PMA50   = THETA(6) 
PMA    = AGE + (9/12) 
TVPMA   = MEDAGE +  (9/12) 
FMAT = 1/(1+(PMA/TVPMA+PMA50)**(-HILL)) 
 ; ------------------------------------------------------------------------LPV MODEL-------------------------------------------- 
;Effect of Concomittant TB Therapy 
RIFCL = 0 
IF (TBT.EQ.1) RIFCL = THETA(7) ;Baseline 
TVCL  = THETA(1)*SCL*(1+RIFCL) 
TVV   = THETA(2)*SV 
TVKA  = THETA(3) 
TVBIO = 1 
TVLAG = THETA(8) 
CL    = TVCL*EXP(BSV_CL + BOV_CL) 
V     = TVV*EXP(BSV_V) 
KA    = TVKA*EXP(BOV_KA + BSV_KA) 
LAG =  TVLAG*EXP(BSV_LAG + BOV_LAG) 
BIO = TVBIO*EXP(BSV_BIO + BOV_BIO)*FMAT 
 
F1    = BIO 
K     = CL/V 
ALAG1 = LAG  
S2    = V 
;Dosing Compartment Initialization  
 TAU_EQ = ALAG1+1/KA 






; DOSING IS EVERY 12H, HERE USE HF THE TOTAL DOSE 
BASELINE = (((BIO*AMT) * KA_EQ) / (KA_EQ - K))  * ( (1 / (1- EXP(-K * 12))) - (1 /( 1- EXP(-KA_EQ*12))) ) 
 A_0 (1) = 0.0001 
 A_0 (2) = BASELINE 
 ;Calculating Cmin   
CMIN= (((BIO*AMT/2) * KA_EQ) / (V*(KA_EQ - K)))*((1 / (1- EXP(-K * 12)))-(1 / (1- EXP(-KA_EQ*12)))) 
 
$ERROR    
 ;(OBSERVATIONS ONLY) 
IPRED = A(2)/V 
ADD = THETA(4)   ;Addative Error 
PROP= THETA(5)*IPRED ;Proportional Error 
W = SQRT(ADD**2+PROP**2) 
IF (W.LE.0.000001) W=0.000001 
  
IRES=DV-IPRED 
IWRES = IRES/W  
Y= (IPRED)+W*EPS(1) 
 
AA1 = A(1) 
AA2 = A(2) 
IF(AMT.EQ.0) THEN  
 TDOS = 48  
 PD   = AMT 
 TAD  = TIME - TDOS  
ENDIF 
;----------------------------------- Handling LLOQ 
LLOQ=0.08 
IMPUTED_BLQ=LLOQ/2 
; BLQ==1 are the first BLQ samples in a series 






ADD = IMPUTED_BLQ*10000000000 ; A separate error, only for the BLQ data. It could be fixed to 
IMPUTED_BLQ, which is normally LLOQ/2 
ENDIF 
; For simulation, like in case of VPC 
IF (ICALL==4.AND.Y<=LLOQ) THEN  




AUC = BIO*AMT/CL 
;Calculating Combined Variability 
VAR_CL  = BSV_CL  + BOV_CL 
VAR_BIO = BSV_BIO + BOV_BIO 
VAR_AUC = VAR_CL  - VAR_BIO  
 
$SIGMA  1  FIX 
;------------------------------------------------------------------------------------------------------------------------------------- 
$ESTIMATION MAXEVAL=0 SIGL=10 ATOL=9 SIGDIG=3 PRINT=5 METHOD=COND 
            INTER MSFO=msfo427 MCETA=100 NONINFETA=1 ETASTYPE=1 
            RANMETHOD=4P NOABORT 
$ESTIMATION MAXEVAL=9999 SIGL=10 ATOL=9 SIGDIG=3 PRINT=5 METHOD=COND 
            INTER MSFO=msfo427 MCETA=5 NONINFETA=1 ETASTYPE=1 
            RANMETHOD=4P NOABORT 
$NONPARAMETRIC MARGINALS MSFO=msfo427 UNCONDITIONAL NPSUPP=300 
;$COVARIANCE PRINT=E  MATRIX=S 
$TABLE      FILE=sdtab427.csv ID WEEKS OCC TIME TAD AMT DV IPRED IRES 
            IWRES PRED RES WRES CWRES NPDE OBJI ESAMPLE=1000 NOPRINT 
            NOAPPEND ONEHEADER FORMAT=, 
$TABLE      FILE=patab427.csv ID DVID CL V KA K ALAG1 F1 PMA50 PMA 
            FMAT PROP ADD CMIN AUC TAU_EQ KA_EQ AA1 AA2 BSV_CL BSV_V 
            BSV_KA BSV_LAG BSV_BIO BOV_KA BOV_BIO BOV_CL BOV_LAG RIFCL 
            NOPRINT NOAPPEND ONEHEADER FORMAT=, 
$TABLE      FILE=cotab427.csv AGE MISKAL WT HT HDCIRMM BSA BMI WFA HFA 





$TABLE      FILE=catab427.csv ID BLQ TBT PREPOST NOPRINT NOAPPEND 
            ONEHEADER FORMAT=, 
;$SIMULATION (123) ONLYSIM 
 
;$TABLE  ID TIME Y DV CLL VL KAL CLR KAR NOPRINT NOAPPEND ONEHEADER FILE=sim.tab214 
$TABLE      FILE=mytab427.csv ID OCC TIME TAD AMT DV IPRED IRES IWRES 
            PRED RES WRES CWRES NPDE CL V KA K ALAG1 F1 PMA50 PMA FMAT 
            PROP ADD CMIN AUC TAU_EQ KA_EQ AA1 AA2 BSV_CL BSV_V BSV_KA 
            BSV_LAG BSV_BIO BOV_KA BOV_BIO BOV_CL BOV_LAG RIFCL VAR_CL 
            VAR_BIO VAR_AUC AGE MISKAL WT HT HDCIRMM BSA BMI WFA HFA 
            WFH BMIFA CD4CNT CD4PC VL BLQ TBT PREPOST NOPRINT NOAPPEND 





Population Pharmacokinetic Model of Nevirapine In Children  
;;Model Desc: NEVIRAPINE| CL vs K & V|BSV CL, V,KA,BIO|BOV CL,KA,MTT,BIO 
BIO,MTT|1COMP+ALLOMETRY+TRANSIT+HEPATIC EXTRACTION+EXP ON BIO|ADVAN6 TRANS1 
$SIZES  MAXIDS=100 LVR=90 LTH=20 
$PROBLEM STEADY STATE NVP PK IN CHILDREN 
$ABBREVIATED DERIV2=NO COMRES=2 
$INPUT ID WEEKS OCC ID_OCC=DROP WHAT=DROP AMT TIME DV MDV EVID II=DROP SS=DROP BLQ 
SEX=DROP BASEAGE=DROP VISAGE RANAGE TB RESISTANCE WT HT HDCIRMM BSA BMI WFA HFA WFH BMIFA 
CD4CNT CD4PC VIRALOAD PROB COMMENT=DROP 
$DATA NVP_20_06_17.csv IGNORE=# IGNORE=(PROB.GT.1) 
$SUBROUTINE ADVAN=6 TRANS1 TOL=6 
$MODEL NCOMPARTMENTS=3 COMP=(ABS DEFDOSE) COMP=(LIVER)  
COMP=(CENTRAL DEFOBSERVATION) 
$PK                                                        
;--------------------------------------------------------------------------Allometric Scaling 
SCL = (WT/13)**0.75 
SV  = WT/13 
;---------------------------------------------------------------------------Variability 
BSV_CL = ETA(1) 
BSV_V  = ETA(2)   
BOV_CL = ETA(3) 
IF (OCC.EQ.2)  BOV_CL = ETA(4) 
IF (OCC.EQ.3)  BOV_CL = ETA(5) 
IF (OCC.EQ.4)  BOV_CL = ETA(6) 
IF (OCC.EQ.5)  BOV_CL = ETA(7) 
IF (OCC.EQ.6)  BOV_CL = ETA(8) 
IF (OCC.EQ.7)  BOV_CL = ETA(9) 
IF (OCC.EQ.8)  BOV_CL = ETA(10) 
IF (OCC.EQ.9)  BOV_CL = ETA(11) 
IF (OCC.EQ.10) BOV_CL = ETA(12) 
IF (OCC.EQ.11) BOV_CL = ETA(13) 
IF (OCC.EQ.12) BOV_CL = ETA(14) 
IF (OCC.EQ.13) BOV_CL = ETA(15) 





IF (OCC.EQ.15) BOV_CL = ETA(17) 
IF (OCC.EQ.16) BOV_CL = ETA(18) 
IF (OCC.EQ.17) BOV_CL = ETA(19) 
IF (OCC.EQ.18) BOV_CL = ETA(20) 
 
BSV_KA = ETA(21) 
BOV_KA = ETA(22) 
IF (OCC.EQ.2)  BOV_KA = ETA(23) 
IF (OCC.EQ.3)  BOV_KA = ETA(24) 
IF (OCC.EQ.4)  BOV_KA = ETA(25) 
IF (OCC.EQ.5)  BOV_KA = ETA(26) 
IF (OCC.EQ.6)  BOV_KA = ETA(27) 
IF (OCC.EQ.7)  BOV_KA = ETA(28) 
IF (OCC.EQ.8)  BOV_KA = ETA(29) 
IF (OCC.EQ.9)  BOV_KA = ETA(30) 
IF (OCC.EQ.10) BOV_KA = ETA(31) 
IF (OCC.EQ.11) BOV_KA = ETA(32) 
IF (OCC.EQ.12) BOV_KA = ETA(33) 
IF (OCC.EQ.13) BOV_KA = ETA(34) 
IF (OCC.EQ.14) BOV_KA = ETA(35) 
IF (OCC.EQ.15) BOV_KA = ETA(36) 
IF (OCC.EQ.16) BOV_KA = ETA(37) 
IF (OCC.EQ.17) BOV_KA = ETA(38) 
IF (OCC.EQ.18) BOV_KA = ETA(39) 
 
BSV_BIO = ETA(40) 
BOV_BIO = ETA(41) 
IF (OCC.EQ.2)  BOV_BIO = ETA(42) 
IF (OCC.EQ.3)  BOV_BIO = ETA(43) 
IF (OCC.EQ.4)  BOV_BIO = ETA(44) 
IF (OCC.EQ.5)  BOV_BIO = ETA(45) 
IF (OCC.EQ.6)  BOV_BIO = ETA(46) 





IF (OCC.EQ.8)  BOV_BIO = ETA(48) 
IF (OCC.EQ.9)  BOV_BIO = ETA(49) 
IF (OCC.EQ.10) BOV_BIO = ETA(50) 
IF (OCC.EQ.11) BOV_BIO = ETA(51) 
IF (OCC.EQ.12) BOV_BIO = ETA(52) 
IF (OCC.EQ.13) BOV_BIO = ETA(53) 
IF (OCC.EQ.14) BOV_BIO = ETA(54) 
IF (OCC.EQ.15) BOV_BIO = ETA(55) 
IF (OCC.EQ.16) BOV_BIO = ETA(56) 
IF (OCC.EQ.17) BOV_BIO = ETA(57) 
IF (OCC.EQ.18) BOV_BIO = ETA(58) 
 
BSV_MTT = ETA(59) 
BOV_MTT = ETA(60) 
IF (OCC.EQ.2)  BOV_MTT = ETA(61) 
IF (OCC.EQ.3)  BOV_MTT = ETA(62) 
IF (OCC.EQ.4)  BOV_MTT = ETA(63) 
IF (OCC.EQ.5)  BOV_MTT = ETA(64) 
IF (OCC.EQ.6)  BOV_MTT = ETA(65) 
IF (OCC.EQ.7)  BOV_MTT = ETA(66) 
IF (OCC.EQ.8)  BOV_MTT = ETA(67) 
IF (OCC.EQ.9)  BOV_MTT = ETA(68) 
IF (OCC.EQ.10) BOV_MTT = ETA(69) 
IF (OCC.EQ.11) BOV_MTT = ETA(70) 
IF (OCC.EQ.12) BOV_MTT = ETA(71) 
IF (OCC.EQ.13) BOV_MTT = ETA(72) 
IF (OCC.EQ.14) BOV_MTT = ETA(73) 
IF (OCC.EQ.15) BOV_MTT = ETA(74) 
IF (OCC.EQ.16) BOV_MTT = ETA(75) 
IF (OCC.EQ.17) BOV_MTT = ETA(76) 







      
 
;------------------------------------------------------------------------------Typical Parameters  
TVCL  = THETA(1) 
TVV   = THETA(2) 
TVKA  = THETA(3) 
TVNN  = THETA(6) 
TVMTT = THETA(7) 
     
CL   = TVCL*EXP (BSV_CL + BOV_CL)*SCL ;*MATCL  
V3   = TVV*EXP(BSV_V)*SV 
KA   = TVKA*EXP(BSV_KA + BOV_KA) 
NN   = TVNN 
MTT  = TVMTT*EXP(BSV_MTT + BOV_MTT) 
 
; HEPATIC EXTRACTION 
CLINT = CL 
FU    = 0.4 ; fraction unbound in plasma 
QH    = 50 *(WT/70)**0.75 ; hepatic plasma flow - adult = 50L/h  
EH    = (FU * CLINT) / (QH +(FU *CLINT))  ; hepatic extraction ratio 
FH    = 1 - EH ; bioavailibility after first pass metabolism 
VH = 1 *(WT/70) 
CLH= QH *EH      ; part metabolised 
K   =(QH*EH)/VH  ; Metabolic rate constant from liver - ELIMINATION 
K23 =(QH*FH)/VH  ; part that goes back to cent CMT - 
;------------------ TRANFER RATE CONSTANTS --------------------------------------------- 
K32 = QH/V3 ; FROM CENTRAL BACK TO LIVER 
     ; THE ONES FROM LIVER TO CENTRAL AND EXTRACTION RATE COST DEFINED IN 
$DES 
  
 ; AGE EFFECT ON BIO 
TVBIO     = FH ; bioavailibility after first pass 





KBIO      = THETA(9)  ; AGE EFFECT CONSTANT 
AGEBIO    = 1 - ((1-BIO_BIRTH)*(EXP(-(VISAGE*KBIO)))) ; AGE EFF ON F1 AS INVERSE EXP WITH INTERCEPT; AGE 
IN YEARS FROM BIRTH 
BIO       = TVBIO *EXP(BSV_BIO + BOV_BIO)*AGEBIO  ;  PRE-HEPATIC BIO 
    
S3 = V3 
;---------------------------------------------------------------------------Transit Compartment 
F1  = 0  
KTR =(NN+1)/MTT 
 
IF (NEWIND/=2.OR.EVID>=3) THEN ; new individual, or reset event 
    ; The values read here will be stored in TDOS and PD in this very PK call. 
 TNXD = TIME ; Time of the dose 
 PNXD = AMT ; Amount. If it's zero, the DE is deactivated. 
ENDIF 
 
TDOS = TNXD ; This will either save here the temporary values if it's a new individual... 
PD   = PNXD ; ...or the values which were read one record ahead during the execution of the previous record. 
 
IF(AMT.GT.0) THEN ; This reads one record ahead and stores the data to be used when running the following 
record 
; IF(AMT.GT.0.AND.ALAG1.EQ.0) THEN ; Use this instead if there is ALAG, as it will also checks if the ALAG is not 
0 
 TNXD = TIME 
 PNXD = AMT 
ENDIF 
 
LNGAM = NN*LOG(NN)-NN+LOG(NN*(1+4*NN*(1+2*NN)))/6+0.572364942 ; approximation of log of 
gamma(n), 0.572364942 is LOG(PI)/2 
; To speed up the computation, I calculate here all the non-time-varying quantities used in $DES 
PIZZA = LOG(BIO*PD*KTR+0.00001)-LNGAM ; without +0.00001, it won't work with ETAs in bioavailability 
 
;Dosing Compartment Initialization  





 KA_EQ  = 1/TAU_EQ 
  
; DOSING IS EVERY 12H, HERE USE HF THE TOTAL DOSE 
BASELINE = (((BIO*AMT) * KA_EQ) / (KA_EQ - K))  * ( (1 / (1- EXP(-K * 12))) - (1 /( 1- EXP(-KA_EQ*12))) ) 
 A_0(1)= 0.0001  
 A_0(2)= BASELINE *VH 
 A_0(3)= BASELINE *V3 
  
;Calculating Cmin   
CMIN= (((BIO*PNXD/2) * KA_EQ) / (V3*(KA_EQ - K)))*((1 / (1- EXP(-K * 12)))-(1 / (1- EXP(-KA_EQ*12)))) 
 
IF (NEWIND.NE.2.OR.EVID.GE.3) THEN ; Each time I have a new subject, or a reset 
 COM(1)=0 
 COM(2)=0 
 TDOS = 0 
ENDIF 
 
$DES                                                                      
TEMPO=T-TDOS ; this is time after dose, it should always be >= 0 
KTT=0 
CP = A(3)/V3  
IF (CP.GE.COM(1)) THEN 
 COM(1) = CP              ; CMAX 
 COM(2) = T - TDOS        ; TIME OF CMAX 
ENDIF   
 
DADT(1)=0 










DADT(3)= K23*A(2)-K32*A(3)  
 
;-----------------------------------------------------------------------------Error 
$ERROR                                                       
 ;(ONLY OBSERVATIONS) 
IPRED = A(3)/V3 
IRES  = DV - IPRED 
PROP=THETA(4)*IPRED                 ;proportional error 
ADD=THETA(5) ;+ THETA(11)            ;additive error 
W = SQRT(ADD**2 + PROP**2)   
IF (W<0.0001) W = 0.0001 
IWRES = IRES/W 
Y = IPRED + W*ERR(1) 
AA1 = A(1) 
AA2 = A(2) 
IF(AMT.EQ.0) THEN  
 TDOS = 48  
 PD   = AMT 





 ;BLQ==1 are the first BLQ samples in a series 
IF (ICALL/=4.AND.BLQ==1) THEN 
PROP=0 
ADD_BLQ = IMPUTED_BLQ*10000000000 ; A separate error, only for the BLQ data. It could be fixed to 
IMPUTED_BLQ, which is normally LLOQ/2 
ENDIF 
 
 AA1=A(1) ; abs comp 
 AA2=A(2) ; LIVER 





; For simulation, like in case of VPC 
IF (ICALL==4.AND.Y<=LLOQ) THEN  
 Y=IMPUTED_BLQ ; All BLQ values in simulation get imputed to LLOQ/2. This also prevents negative 
values 
ENDIF 
CMAX = COM(1) ; CMAX 
TMAX = COM(2) ; TIME OF CMAX 
;Calculate AUC 
AUC = AMT*BIO / CL  
; Reset CMAX code when a new dose is given  
 COM(1)=0 
 COM(2)=0 
IF (ICALL==4.AND.Y.LE.0.1) Y=0.05 ; prevents negative simulated values 
;------------------------------------------------------------------------------------Parameter Estimates  
 
$THETA  (0,2.8833,10) ; 1 CL [L/h] 
$THETA  (0,21.7866,40) ; 2 V [L]  
$THETA  (0,0.84,10) FIX ; 3 KA [1/h] 
$THETA  (0,0.115378,1) ; 4 PROP [%] 
$THETA  (0.01,1.18234,10) ; 5 ADD [mg/L] 
$THETA  3 FIX ; 6 NN [] 
$THETA  (0,0.56,8) FIX ; 7 MTT[h] 
$THETA  (0,0.503515,1) ; 8 BIO_BIRTH[%] 
$THETA  (0.05,0.843688,10) ; 9 KBIO[Years] 
$OMEGA  BLOCK(1) 
 0.253145  ;   1 BSV_CL 
$OMEGA  BLOCK(1) 
 0.220806  ;    2 BSV_V 
$OMEGA  BLOCK(1) 
 0.113794  ;             ;   3 BOV_CL 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 





$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) 
 0.23842  ;  21 BSV_KA 
$OMEGA  BLOCK(1) 
 0.173174  ;  22 BOV_KA 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 





$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) 
 0.0285655  ; 40 BSV_BIO 
$OMEGA  BLOCK(1) 
 0.1995301  ; 41 BOV_BIO 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) FIX 
 0  ; 59 BSV_MTT 
$OMEGA  BLOCK(1) 
 1.16439  ; 60 B0V_MTT 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 





$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$SIGMA  1  FIX 
$ESTIMATION MAXEVAL=0 SIGDIG=3 PRINT=1 NOABORT METHOD=COND INTER MSFO=msfo190 MCETA=100 
RANMETHOD=4P ATOL=9 
$ESTIMATION MAXEVAL=9999 SIGDIG=3 PRINT=1 NOABORT METHOD=COND INTER MSFO=msfo190 MCETA=5 
ETASTYPE=1 RANMETHOD=4P ATOL=9 
$NONPARAMETRIC MARGINALS MSFO=msfo190 UNCONDITIONAL NPSUPP=100 
 
$TABLE FILE=sdtab190.csv ID WEEKS OCC TIME TAD DV IPRED IRES WRES PRED RES WRES CWRES NPDE OBJI 
ESAMPLE=300 WRESCHOL NOPRINT NOAPPEND ONEHEADER FORMAT=, 
$TABLE FILE=patab190.csv ID WEEKS OCC TIME CL KA V3 K K23 K32 N MTT QH EH FH CLH VH BSV_V BIO_BIRTH 
KBIO AGEBIO BSV_CL BSV_KA BSV_BIO BSV_MTT BOV_CL BOV_KA BOV_BIO BOV_MTT NOPRINT NOAPPEND 
ONEHEADER FORMAT=, 
$TABLE FILE=cotab190.csv ID RANAGE VISAGE WT HT HDCIRMM BSA BMI WFA HFA WFH BMIFA CD4CNT 
CD4PC VIRALOAD NOPRINT NOAPPEND ONEHEADER FORMAT=, 
$TABLE FILE=catab190.csv ID TB RESISTANCE NOPRINT NOAPPEND ONEHEADER FORMAT=, 
$TABLE FILE=mytab190.csv ID WEEKS OCC TIME TAD AMT DV AA1 AA2 IPRED IRES IWRES PRED RES WRES 
CWRES NPDE CL KA V3 K K23 K32 BIO_BIRTH KBIO AGEBIO CMIN AUC NN MTT TAU_EQ KA_EQ BASELINE QH 
EH FH CLH VH BSV_V BSV_CL BSV_KA BSV_MT BSV_BIO BOV_CL BOV_KA BOV_BIO BOV_MTT RANAGE VISAGE 
WT HT HDCIRMM BSA BMI WFA HFA WFH BMIFA CD4CNT CD4PC VIRALOAD TB RESISTANCE NOPRINT 
NOAPPEND ONEHEADER FORMAT=, 
